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Abstract
Treatmentofextravasationinjuriesininfantsandyoung
children:ascopingreviewandsurvey
MarkCorbett,1*DavidMarshall,1MelissaHarden,1SamOddie,2
RobertPhillips1andWilliamMcGuire1
1CentreforReviewsandDissemination,UniversityofYork,York,UK
2BradfordTeachingHospitalsNHSFoundationTrust,Bradford,UK
*Correspondingauthor mark.corbett@york.ac.uk
Background:Extravasation injuriesarecausedbyunintended leakagesoffluidsormedicinesfrom
intravenous lines,butthere isnoconsensusonthebesttreatmentapproaches.
Objectives:To identifywhichtreatmentsmaybebestfortreatingextravasation injuries in infantsand
youngchildren.
Design:Scopingreviewandsurveyofpractice.
Population:Childrenaged<18yearswithextravasation injuriesandNHSstaffwhotreatchildrenwith
extravasation injuries.
Interventions:Anytreatmentforextravasation injury.
Mainoutcomemeasures:Woundhealingtime, infection,pain,scarring,functional impairment,
requirementforsurgery.
Datasources:Twelvedatabasesearcheswerecarriedout inFebruary2017withoutdaterestrictions,
includingMEDLINE,CINAHL(Cumulative IndextoNursingandAlliedHealthLiterature)PlusandEMBASE
(ExcerptaMedicadataBASE).
Methods:Scopingreview–studieswerescreened induplicate.Datawereextractedbyoneresearcher
andcheckedbyanother.Studiesweregroupedbydesign,andthenby intervention,withdetails
summarisednarrativelyand intables.ThesurveyquestionnairewasdistributedtoNHSstaffatneonatal
units,paediatric intensivecareunitsandprincipaloncology/haematologyunits.Summaryresultswere
presentednarrativelyand intablesandfigures.
Results:Theevidence identified inthescopingreviewmostlycomprisedsmall,retrospective,uncontrolled
groupstudiesorcasereports.Thestudiescoveredawiderangeof interventions includingconservative
managementapproaches,salineflush-outtechniques(withorwithoutpriorhyaluronidase),hyaluronidase
(withoutflush-out),artificialskintreatments,debridementandplasticsurgery.Fewstudiesgraded injury
severityandtheresultssectionsandoutcomesreported inmoststudieswere limited.Therewas
heterogeneityacrossstudypopulations inage,typesof infusate, injuryseverity, locationof injuryandthe
timegapsbetween injury identificationandsubsequenttreatment.Someofthebetterevidencerelatedto
studiesofflush-outtechniques.TheNHSsurveyyielded63responsesfromhospitalunitsacrosstheUK.
Results indicatedthat,althoughmostunitshadawrittenprotocolorguidelinefortreatingextravasation
injuries,onlyone-thirdofdocuments includedastagingsystemforgrading injuryseverity. Inneonatal
units,parenteralnutritioncausedmostextravasation injuries. Inprincipaloncology/haematologyunits,
most injurieswereduetovesicantchemotherapies.Themostfrequentlyused interventionswereelevation
©Queen’sPrinterandControllerofHMSO2018.ThisworkwasproducedbyCorbettetal.underthetermsofacommissioningcontract issuedbytheSecretaryofStatefor
HealthandSocialCare.This issuemaybefreelyreproducedforthepurposesofprivateresearchandstudyandextracts (or indeed,thefullreport)maybe included inprofessional
journalsprovidedthatsuitableacknowledgement ismadeandthereproduction isnotassociatedwithanyformofadvertising.Applicationsforcommercialreproductionshould
beaddressedto:NIHRJournalsLibrary,National InstituteforHealthResearch,Evaluation,TrialsandStudiesCoordinatingCentre,AlphaHouse,UniversityofSouthamptonScience
Park,SouthamptonSO167NS,UK.
v
of the affected area and analgesics. Warm or cold compresses were rarely used. Saline flush-out
treatments, either with or without hyaluronidase, were regularly used in about half of all neonatal units.
Most responders thought a randomised controlled trial might be a viable future research design, though
opinions varied greatly by setting.
Limitations: Paucity of good-quality studies.
Conclusions: There is uncertainty about which treatments are most promising, particularly with respect to
treating earlier-stage injuries. Saline flush-out techniques and conservative management approaches are
commonly used and may be suitable for evaluation in trials.
Future work: Conventional randomised trials may be difficult to perform, although a randomised registry
trial may be an appropriate alternative.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Extravasation injuries are skin injuries caused by accidental leakages of treatments that are givenintravenously. They can cause short-term pain and longer-term scarring that can sometimes result in
restricted movement of the affected joint. These injuries may be particularly problematic in babies because
of their fragile skin. Prompt care is usually required, but there is no agreement on the best treatment
approaches. This is mainly because much of the published research appears to have a limited value in
helping to inform treatment decisions. This project aimed to identify which treatments may be the most
promising for babies and children. The results would help to inform which treatments may be the most
appropriate to study in the future.
We identified and studied all the key data from all relevant studies and also surveyed knowledge and
opinions across relevant NHS staff. The results from examining the studies showed that, although it is
unclear which treatments are best, flushing injuries with salt solution appears to be an approach worthy of
further research. However, this treatment carries risks, so it is possible that a simpler treatment – such as a
dressing – might be better.
The survey results showed that variation exists across the NHS in terms of how extravasation injuries are
initially assessed and in terms of which treatments are used. In hospital units that care for newborns,
treatment of injuries by flushing them with salt solution was adopted in around half the units, but was
never used in around one-third of units. The survey also revealed a variation in opinion about how a future
research study should be designed. We comprehensively discussed the likely advantages and disadvantages
of adopting different types of research design when considering how to plan a new research study on
treatments for extravasation injuries.
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xv
Scientific summary
Background
Extravasation injuries are caused by unintended leakages of fluids or medicines from intravenous (i.v.) lines
in which a fluid deviates from its planned pathway – the vein – into surrounding tissue. These injuries can
cause pain, inflammation, tendon or nerve damage and predispose to local and invasive infection. Initial
treatments aim to reduce pain and prevent or minimise local tissue necrosis and associated functional and
cosmetic impairment. Injuries that result in tissue necrosis seem to be more prevalent in neonates and
younger infants. This is likely to be due to their immature skin, fragile veins, lack of subcutaneous tissue,
likelihood of needing longer periods of i.v. treatment and their limited ability to report pain.
Treatment strategies are normally driven by the type and extent of the injury and by the time interval
between injury identification and subsequent intervention. Although treatment options are many and
varied, there is no consensus on the best approach to management, with guidelines offering conflicting
recommendations. This is likely a consequence of the limited research evidence available, particularly in
newborns and infants.
Objectives
To begin the process of resolving the uncertainty surrounding which treatments are best for treating
extravasation injuries in infants and young children. Results from a systematic scoping review will
determine which treatments appear likely to be the most promising, and results from a NHS survey will
inform on which treatment approaches are currently used across the NHS and will elicit opinions regarding
which interventions are most worthy of future research.
Methods
Scoping review
A scoping review was undertaken based on the framework proposed in key methodology papers
(Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol
2005;8:19–32; Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology.
Implement Sci 2010;5:69; Daudt HML, van Mossel C, Scott SJ. Enhancing the scoping study methodology:
a large, inter-professional team’s experience with Arksy and O’Malley’s framework. BMC Med Res
Methodol 2013;13:48). In February 2017, we searched 12 electronic databases without date restrictions,
including MEDLINE, CINAHL (Cumulative Index to Nursing and Allied Health Literature) Plus and EMBASE
(Excerpta Medica dataBASE) to identify published and unpublished studies in any language. We searched
clinical trial registries for ongoing studies.
Eligible studies were of children (aged < 18 years) with an extravasation injury (of the skin, subcutaneous
tissue or muscle tissue) associated with central or peripheral i.v. access. Any interventions or comparators
were eligible. The outcomes of interest were wound healing time, scarring, infection, pain, contractures,
functional impairment, disfigurement, requirement for surgery, mortality and anaphylactic reactions to
extravasation treatments.
Two reviewers independently assessed titles and abstracts for eligibility. If deemed eligible, the full texts
were then sought and assessed independently by the same two reviewers, with disagreements resolved
through discussion or via a third reviewer. Piloted data extraction forms for comparative studies,
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non-comparative studies and case reports were used to record details of study methods, population
characteristics (such as age, type of infusate, and injury severity), interventions (type, number and
frequency of treatments), comparators, outcome measures and results. Recommendations for future
research that were relevant to the aims of this scoping review were extracted. Data were extracted by
one researcher and checked by another. Study details and findings were presented in structured
tables and described, synthesised and summarised narratively.
Survey
A systematic approach was used to develop the questionnaire content, informed mainly by initial findings
from the scoping review and peer-to-peer consultation of clinicians. The questionnaire was piloted among
colleagues at neonatal and paediatric units in York, Bradford and Leeds and was distributed to NHS staff
at neonatal units, paediatric intensive care units (PICUs) and principal oncology/haematology units
nationwide. Summary results were presented narratively with accompanying tables and figures.
Results
Scoping review
From the database searches, 3830 records were identified for title and abstract screening, from which
289 records were selected as being of interest. After screening full papers, we included 26 group studies
(of which two were comparative), six guidelines, three reviews and 106 case report studies.
The two comparative studies (which were not randomised trials) had limitations with respect to the
particular outcomes and results relevant to this review. Many types of extravasation injury treatments have
been studied in non-comparative studies; most studies were small and retrospective. Seventeen of the 24
non-comparative studies had sample sizes of < 20, and only three were reported as having a prospective
design. There was considerable heterogeneity across study populations in age, types of infusate, injury
severity, location of injury and the time gaps between injury identification and subsequent treatment.
The treatments studied were grouped into these broad categories: conservative management approaches,
saline flush-out techniques with or without prior hyaluronidase, hyaluronidase without flush-out, artificial
skin treatments, debridement and plastic surgery. Limitations inherent in non-comparative studies made it
difficult to compare results across treatments. Some results were likely to have been subject to chance
effects or biases. Few studies reported data on the grading of injury severities and the results sections of
most studies were minimal. No studies reported pain as an outcome and few studies quantified outcomes,
for example, by using measures of scarring such as scar scores. Only one study reported on whether or
not interventions resulted in adverse effects. All three of the identified reviews were in agreement that,
although immediate treatment is needed for the best outcomes, there is no consensus regarding which
treatments constitute best practice (Clifton-Koeppel R. Wound care after peripheral intravenous extravasation:
what is the evidence? Newborn Infant Nurs Rev 2006;6:202–11; Gopalakrishnan PN, Goel N, Banerjee S.
Saline irrigation for the management of skin extravasation injury in neonates. Cochrane Database Syst Rev
2012;2:CD008404; Harrold K, Gould D, Drey N. The management of cytotoxic chemotherapy extravasation:
a systematic review of the literature to evaluate the evidence underpinning contemporary practice.
Eur J Cancer Care 2015;24:771–800). All mentioned saline flush-out with or without hyaluronidase as
a frequently studied treatment, but no review could make conclusive statements on its effectiveness
compared with other treatments because of the limited quality of evidence. Overall, the results from the
reviews and guidelines, which included evidence from studies in adults, added little to the primary study
evidence in babies and children.
Survey
Sixty-three questionnaires were received from 56 different hospitals: 71% were from neonatal units,
21% were from principal oncology/haematology units and 8% were from PICUs. Most responders were
consultant neonatologists (48%), nursing staff (16%) or consultant paediatricians (13%). Of 57 responding
units, 82% said they had a written protocol or guideline for treating extravasation injuries, although a
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staging system for grading injury severity was included in only around one-third of protocols or guidelines.
Almost all responders indicated that peripheral lines were the access site most associated with extravasation
injuries. In neonatal units, parenteral nutrition was the cause of the largest proportion of extravasation
injuries. In principal oncology/haematology units, the largest proportion of injuries was due to vesicant
chemotherapies.
The most frequently used intervention approaches were elevation of the affected area and analgesics. In
most units warm or cold compresses were either rarely or never used. In neonatal units, there was notable
variation regarding the use of occlusive dressings, ranging from always being used (8% of responses)
to never being used (31% of responses). Variation in the use of saline flush-out, either with or without
hyaluronidase, was also evident; these interventions seem to be either usually used or sometimes used in
around half of neonatal units, and never used in around one-third of units. Results for principal oncology/
haematology units and PICUs were broadly similar to the neonatal unit results.
When asked about a future research study, 65% of the 57 responders thought that a randomised controlled
trial (RCT) might be viable, 21% did not think a RCT was viable and 14% did not know. However, the results
varied by setting: the proportion thinking a RCT was viable was 83% of the 40 neonatal unit responses,
33% of the 12 principal oncology/haematology unit responses and 0% of PICU responses. Almost all of the
responders who thought that a RCT was viable mentioned one or more of the following types of treatment
when asked which treatments they would most like to see studied: saline irrigation/wash-out, hyaluronidase
and conservative management. Of those who thought that a RCT was not viable, various reasons were
provided including: the presence of too many variables which could affect outcomes, timeliness of treatment
when using randomisation, low numbers of patients and unwillingness to deviate from current practice.
Conclusions
Studies exist that, together, cover a wide range of treatments for extravasation injuries. However, in
considering the study methods and designs used, small sample sizes and the variation across population
and intervention characteristics, the quality of evidence overall is very low. Consequently, there is
uncertainty about which treatments are most promising, particularly with respect to treating earlier-stage
injuries. Notwithstanding the evidence limitations, the results of studies of flush-out techniques suggest
that these treatments may be worthy of further research. This finding was echoed in the NHS survey
results, with flush-out techniques, hyaluronidase and conservative management approaches frequently
suggested as being treatments where further study would be most worthwhile.
In planning a future comparative study of extravasation injury treatments, population heterogeneity and
low rates and sporadic incidence of injuries are key issues. In the light of this, the most viable population
for any randomised trial may be preterm neonates receiving i.v. parenteral nutrition at a peripheral site (but
this is rare and not recommended). A paucity of standardised relevant outcome measures used in previous
studies in neonates is a concern. Outcome measures used in a future study would need to be clinically
practicable yet also demonstrate adequate reliability and validity. Some of the practicalities involved in
undertaking a conventional RCT are the recruitment of adequate numbers of participants, avoiding
treatment delays and selection bias. Although a prospective, observational database study would maximise
the number of patients recruited, and eliminate concerns about treatment delays, its results would
inherently be subject to uncertainty due to the likelihood of selection bias.
An alternative to a conventional RCT design is the randomised registry trial, which incorporates many of
the best aspects of both conventional RCTs and observational database studies. However, a key relevant
database {the UK National Neonatal Research Database [www.imperial.ac.uk/neonatal-data-analysis-unit/
neonatal-data (accessed 27 July 2018)]} does not currently record data on extravasation injuries. Further
issues to be considered in any randomised registry trial of neonates include the lack of a protocol or
DOI: 10.3310/hta22460 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 46
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix
guideline for treating extravasation injuries in 25% of units, and the absence of the use of a staging
system for grading injury severity in over half of the units that do have access to a protocol or guideline.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Intravenous (i.v.) access for the provision of medication and nutrition is a common, and in many casesessential, procedure used for children and infants in hospitals. Although adverse outcomes resulting from
i.v. access are rare, the procedure is not without risk. Extravasation injuries are caused by unintended
leakages from i.v. lines in which a fluid deviates from its planned pathway (the vein) into surrounding tissue.
Extravasation of fluid can cause pain, inflammation, tendon or nerve damage and predispose to local and
invasive infection. Initial treatments aim to reduce pain and prevent or minimise local tissue necrosis and
associated functional and cosmetic impairment. Longer term treatment of severe extravasation episodes may
require skin grafts and prolonged hospitalisation. The severity of injury and likelihood of long-term damage
depends on a number of factors, including the type and amount of fluid extravasated, the injury site, how
quickly treatment is administered and the treatment itself.1
The terms ‘extravasation’ and ‘infiltration’ are often used interchangeably in the literature but are sometimes
defined separately, based on the type of fluid being administered.2 A vesicant is any medication or fluid with
the potential for causing blisters, severe tissue injury, or necrosis primarily due to biochemical reactions.
Vesicants can vary in type but include many cytotoxic agents (such as chemotherapies). Non-vesicants include
fluids such as parenteral nutrition and antibiotics that can cause damage primarily due to the mechanical
forces exerted. The distinction between ‘extravasation’ (i.e. leakage of a vesicant) and ‘infiltration’ (i.e.
leakage of a non-vesicant) can sometimes cause undue confusion as these two types of event are often
indistinguishable externally.3
Prevalence of extravasation injuries and risk factors
There is some uncertainty about the incidence of extravasation injuries in children in the NHS because of the
absence of a centralised register, a paucity of data available from prospective studies and heterogeneity in
definitions used to describe injury occurrence.1 Estimates of between 0.01% and 7% have been reported,
although there is some evidence to suggest that this has reduced considerably since 2002.1 Age is an
important risk factor and injuries that result in tissue necrosis seem to be more prevalent in neonates and
younger infants. This is likely to be owing to their immature skin, fragile veins, lack of subcutaneous tissue,
likelihood of needing longer periods of i.v. treatment and their limited ability to report pain.4,5 A UK-based
survey of regional neonatal intensive care units5 (NICUs), published in 2004, estimated the incidence of
extravasation injuries resulting in skin necrosis to be 38 per 1000 babies. Most (70%) of these occurred in
preterm infants born before 27 weeks’ gestation.5 More recently, a Greek study4 of 1409 neonates reported
a severe injury rate of 2.4%, and a Canadian children’s hospital-based study6 reported an overall rate of
0.04% per patient-day, in a population with a median age of 10 months. Nearly all of the injuries were at
peripheral i.v. sites.6
The Great Ormond Street Hospital guidelines for the recognition, management and prevention of infiltration
and extravasation injuries2 categorise risk factors as being device related, drug related, patient related and
clinician related. Device-related factors refer to how the drug was administered and include the infusion site
(distal limb vs. centrally placed), the type of cannula used and how the cannula was secured. Drug-related
factors refer to what was administered and include the vesicant potential of the solution, the volume of fluid
that is extravasated and the concentration of the drug. Patient-related factors refer to characteristics such as
age and communication impairment. Finally, clinician-related factors refer to those administering the i.v.
treatment and include: lack of knowledge of extravasation events, lack of i.v cannula or catheter placement
skills and interruptions or distractions during i.v. treatment.
Managing these risk factors to prevent extravasation occurring is preferable to treating an injury.
Immediate removal of the catheter and prompt treatment is thought to be important in such cases. This is
often hampered by the unreliability of alarms on i.v. pumps in detecting elevated perfusion pressures that
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may indicate extravasations. These alarms are not intended to detect extravasations but are often the only
warning sign the clinicians have to indicate flow faults during infusions.7 These devices have been shown
to detect extravasation in only 19% of cases because of the variability in resistance to flow due to the rate
and site of infusion.8
Litigation in extravasation injuries
About 65% of clinical negligence claims in paediatric surgery in the UK result in payment to the claimant.9
Of these, between 2% and 4% are due to extravasation events.10,11 However, a severe extravasation injury
does not constitute negligence in itself. Any claims would be assessed with careful consideration of the risk
factors outlined above.12,13 Specifically, it is the failure to take special precautions to minimise the potential
for extravasation injury that determines fault. Demonstration of the following would be important:
effective securement of the i.v. device, appropriate monitoring of the site, timely recognition of the
extravasation, immediacy of intervention and the completeness of documentation.
Severity of injury
Extravasation injuries have been classified into four stages of increasing severity, which are thought to be
useful in predicting injury prognosis and in determining the best treatment results.14 The four stages are:
l Stage 1: a painful i.v. site, no erythema and swelling, flushes with difficulty.
l Stage 2: a painful i.v. site, slight swelling, redness, no blanching, brisk capillary refill below infiltration
site, good pulse volume below infiltration site.
l Stage 3: a painful i.v. site, marked swelling, blanching, cool to touch, brisk capillary refill below
infiltration site, good pulse volume below infiltration site.
l Stage 4: a painful i.v. site, very marked swelling, blanching, cool to touch, capillary refill of > 4 seconds,
decreased or absent pulse, skin breakdown or necrosis.
Objectively assessing injuries according to these criteria has been recommended both in treatment and in
research so that accurate outcome data can be collected. Researchers have suggested that these can be
used to guide assessments and interventions. Clifton-Koeppel8 goes further, stating that using a protocol
based on these criteria would improve consistency in assessment, increase compliance, decrease the
incidence of extravasation and allow for prompt treatment. The author also suggests that stage 4 injuries
should be further categorised to include a stage 5 injury that is distinguishable from a stage 4 injury by also
including extensive or very deep wounding. However, this extra criterion has not been widely adopted.
There have been attempts to adapt, rather than subdivide, the stages of injury.3 The Infusion Nurses Society
adapted the scale by including guidelines3 for the size of the injury and by suggesting that infiltrations
involving vesicant solutions should automatically be considered as stage 4 injuries. Other researchers have
argued that the Millam guidelines are not appropriate for paediatric populations.3,15 The smaller size of
children means that similarly sized injuries (to those seen in adults) are actually much more severe. To
counter this, researchers have proposed alternative guidelines.3,15 Amjad et al.3 accomplished this by
referring to the number of joints involved, rather than overall size of the injury, to determine scale of injury.
Similarly, Simona15 used percentage of the limb affected, rather than measurements, to determine the
injury’s grading.
Treatment options
The main objective for treating extravasation injuries is to prevent pain and progression to tissue necrosis,
ulceration, and scarring.16 However, there is no consensus on the best approach to management.17–19
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The intervention strategies used are normally driven by the type and extent of the injury and by the time
interval between injury and intervention. Treatment options are many and varied, but broadly fall under
the following categories.
Conservative management strategies
This typically involves elevating the affected limb to reduce oedema by decreasing the hydrostatic
pressure in the capillaries. Carers may administer hot or cold dressings. Heat promotes the absorption of
extravasated fluids and oedema, whereas cold dressings may limit inflammation. The standard dressing
of wounds and administration of analgesics would come under this category of treatment.
Topical treatments
Topical treatments are most often used when an open wound is present. These include nitroglycerin or
silver sulfadiazine ointment and dimethyl sulfoxide (DMSO). These attempt to promote a moist wound
environment, which, it is argued, reduces healing time, reduces likelihood of infection and prevents
scarring.8
Antidotes
Some vesicant solutions may have a particular antidote which can be infused or injected into an affected
area. This approach appears to be most often used for treating chemotherapy extravasations. Among the
antidotes recommended for use are sodium thiosulfate for mechlorethamine, hyaluronidase for plant
alkaloids and dexrazoxane for anthracyclines.20 However, guidelines published by the European Society
for Medical Oncology1 indicate that specific antidotes are not commonly used and their effectiveness
has been questioned. It should also be noted that the specific antidotes have limited access for use in
European countries.1
Hyaluronidase injections
Subcutaneous hyaluronidase injections can be used in an attempt to break down connective tissue and
facilitate absorption of the extravasated fluid into the vascular and lymphatic systems. It has been
recommended that the administration of these injections should take place within one hour of the
extravasation.18
Saline flush-out and liposuction
Both saline flush-out and liposuction are administered with the aim of removing the extravasated fluid
before it can cause damage. As such, there is an implicit requirement that these treatments are
undertaken as soon as possible. Gault21 has described both techniques, which can be administered alone
or together, although various modifications to these techniques have also been reported.
Flush-out techniques typically involve skin incisions being made in the extravasation injury and saline
injected into each incision, the aim being that this process will flush out the infusate via the remaining
puncture points. The process is sometimes preceded by injection of hyaluronidase to break down the
hyaluronic acid in connective tissues, thus aiding infusate dispersal. The procedure is often performed
under a local anaesthetic, although a general anaesthetic may sometimes be necessary, especially if
liposuction is also to be performed. Liposuction is a minimally invasive surgical technique in which a
cannula with side holes is inserted into the wound, and fluid and subcutaneous fat is aspirated out.
Surgery
If less invasive treatments are unsuccessful and necrotic tissue is unresolved after an extended period of
time, the next option on the treatment pathway is surgical debridement, or plastic surgery, or both. The
purpose of debridement is the removal of necrotic tissue (eschar), which impairs wound healing. It typically
involves either a surgical technique (the use of sharp instruments to excise the eschar under general
anaesthesia) or an enzymatic approach (which promotes softening of eschar tissue). Once the wound is
clean, application of a skin graft or artificial skin may be necessary.
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Current guidelines on treatment
Few treatment guidelines have been published, and recommendations are often conflicting.1,8,16,18,19 For
example, the saline flush-out treatment, as originally proposed by Gault21 has been described as very
effective and to be recommended,8 as having achieved good results,2 as potentially effective but lacking
in evidence18 and as not to be recommended as routine management.1 This finding is unsurprising given
the inconsistency of the approach to treatment and given that many of the published, peer-reviewed
guidelines and reviews that exist are based on limited research evidence.17,19,22,23 Reviews of the area
highlight a paucity of good-quality comparative research between treatments for extravasations of
cytotoxic drugs. The literature appears even sparser for the management of paediatric populations and
for treating extravasation injuries resulting from non-cytotoxic drugs.16,24
Despite published guidelines,2 evidence from surveys suggests there is a lack of consensus on the best
course of treatment for extravasation injuries. The lack of consensus is also illustrated by the existence of
the many local hospital guidelines on management as indicated by UK survey findings.5 The pattern
appears to be replicated internationally, as reported in surveys conducted in the USA25 and Australia and
New Zealand.26 A British survey conducted by Wilkins et al.5 found that exposing the wound to the air
alone was used for 29% of cases, 43% of cases were treated with saline wash-out (85% of which also
included the use of hyaluronidase), 20% were treated with hydrocolloids and 5.5% with hydrogels. A
similar survey was conducted in Australia and New Zealand by Restieux et al.26 This study found that limb
elevation was used in 63% of cases, saline wash-out in 67%, hyaluronidase in 38% and 27% used a
specific antidote. There is a very different distribution of treatments between the two regions, with only
the proportion of hyaluronidase use being equivalent. Pettit et al.25 used a sample in the USA to look
specifically at hyaluronidase and phentolamine use. They found that only 57% had a procedure for
hyaluronidase use and only 29% had a procedure for phentolamine.
Aside from the specifics of the management techniques reported in these surveys, two of the surveys
revealed that there appeared to be a significant proportion of centres which did not have a written policy
for the treatment of extravasation injuries. Restieaux et al.’s26 survey of 27 NICUs in Australia and New
Zealand reported this rate as 35%, whereas Pettit and Hughes’25 survey of nine geographical areas in the
USA reported a rate of 27%.
The lack of consensus in sites, and within and between these surveys, is concerning, particularly with
regard to the finding in the UK study5 that a substantial minority of cases were being treated solely by
exposure to air. However, it should be noted that this study is somewhat outdated, with current NHS
practice likely to be different. An up-to-date survey is therefore warranted. Despite this, it is still apparent
that policies are largely based on historical practice within hospitals, on prior experience and on expert
opinion, rather than on published guidelines.22
Overall aims and objectives of the study
This study aims to begin the process of resolving the uncertainty surrounding which treatments are the
best for treating extravasation injuries in babies and young children. Results from a scoping review will
determine which treatments are likely to be the most promising, and results from a NHS survey will inform
on which treatment approaches are currently used across the NHS and provide opinions about which
interventions are most worthy of future research.
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Chapter 2 Scoping review of treatments for
extravasation injuries
Methods
Our scoping review was undertaken based on the methodological framework proposed in papers by
Arksey and O’Malley,27 Levac et al.28 and Daudt et al.29 Briefly, the framework involves six core stages:
identifying the research question; identifying relevant studies; study selection; charting the data (data
extraction); collating, summarising, and reporting results; and consultation (consumer and stakeholder
involvement). This is an area of review methodology which continues to evolve.30 A key difference
between a scoping review and a systematic review is that scoping reviews do not usually encompass a
formal quality assessment of all included studies. It seems likely that, for many scoping reviews, some form
of quality assessment – whether formal or informal – of at least some of the included studies may be
necessary to allow informed recommendations for research.
Literature searching
The aim of the literature search was to identify studies of interventions for treating extravasation injuries
in infants, children or adolescents. An information specialist developed the search strategy in MEDLINE
(via Ovid). The strategy included a set of terms covering extravasation injuries, combined using the Boolean
operator ‘AND’, with a set of terms for infants, children and adolescents. No date, language, geographical
or study design limits were applied to the strategy. The MEDLINE strategy was adapted for use in all
resources searched.
The searches were carried out during February 2017. The following databases were searched without date
restrictions: MEDLINE (including: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE Daily and Ovid MEDLINE), British Nursing Index, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative Index to Nursing & Allied Health
(CINAHL Plus), Database of Abstracts of Reviews of Effects (DARE), Excerpta Medica dataBASE (EMBASE),
Ovid Emcare, Health Technology Assessment (HTA) Database, Maternity and Infant Care, PubMed and
Science Citation Index.
The following resources were searched for ongoing, unpublished or grey literature: ClinicalTrials.gov,
Conference Proceedings Citation Index: Science, EU Clinical Trials Register, Proquest Dissertations &
Theses: UK & Ireland, PROSPERO and the WHO (World Health Organization) International Clinical Trials
Registry Platform portal.
A search for relevant guidelines was carried out via the following websites: National Institute for Health
and Care Excellence (NICE), National Guideline Clearinghouse and the Turning Research into Practice
database. Reference lists of key studies were scanned for any further relevant studies. The search results
were imported into EndNote X8® (Clarivate Analytics, PA, USA) and deduplicated. The full search strategies
for all sources searched can be found in Appendix 1. The reference lists of reviews were also checked for
any further relevant studies.
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Study selection
The following criteria were used to select studies for inclusion:
l Population: children (aged < 18 years) with an extravasation or infiltration injury associated with central
or peripheral i.v. access. Animal studies were excluded. For the purposes of this review we were
interested in extravasation injuries which involved leakage into the skin or subcutaneous tissue, or
into muscle tissue. Studies of injuries termed as ‘extravasation’ but which related to leakages into
cavities or viscera were excluded (these references are documented in Appendix 2). Our definition
of extravasation covers ‘infiltrations’ (i.e. it includes leakages of vesicants and non-vesicants).
l Interventions: any intervention for treating an extravasation injury.
l Comparators: any comparator (or no comparator).
l Outcomes: any of the following – wound healing time, scarring, infection, pain, contractures,
functional impairment, disfigurement, requirement for surgery, mortality, anaphylactic reactions to
extravasation treatments.
l Study design: any study design was eligible including comparative studies, case series, case reports,
reviews and guidelines.
Two reviewers independently assessed titles and abstracts for these eligibility criteria. The full text of
potentially relevant titles and abstracts were sought and assessed independently by two reviewers. Any
reviewer disagreements were resolved through discussion and, when necessary, through consultation with
a third member of the study team. Titles, abstracts and full papers were screened using EPPI-Reviewer 4
software (Evidence for Policy and Practice Information and Co-ordinating Centre, University of London,
London, UK). For the titles and abstracts the ‘key term highlighting’ function was used to help make
decisions more quickly. Terms which indicated an abstract that may have been an ‘exclude’ appeared as
red text, and terms suggesting that an abstract might have been relevant to the review appeared in green.
Full papers published in French and German were single-screened by native speakers (and data were
extracted, when appropriate, with the help of one of the review team). Full papers published in Spanish
were screened (and data were extracted) by one of the review team who spoke Spanish as a second
language.
In addition to the studies in children identified, we also used any reviews which had a focus on treatments,
and guidelines identified, to provide the basis for an overview of the evidence for extravasation treatments
more broadly (i.e. studies which included adults because it was possible that some of this evidence might
have been more methodologically robust than the studies in children).
Data extraction
Data extraction forms were developed for three different study designs: comparative studies, non-
comparative studies and case reports. These forms were piloted on a selection of studies and amended
when necessary; few iterations were needed. The extracted data included details of basic study methods,
population characteristics (such as age, type of vesicant, injury severity), intervention (type, number and
frequency of treatments), comparators, outcome measures and results. Any recommendations for future
research that were relevant to this review were also extracted. Data were extracted by one researcher and
checked by another, with discrepancies resolved by discussion or consultation with a third member of the
study team where necessary.
Collating, summarising and reporting results
Study details were presented in structured tables based first on study design and then on intervention
type. For each type of study design, the extent, range and nature of the identified research was described.
Study parameters and results were then described and summarised narratively.
SCOPING REVIEW OF TREATMENTS FOR EXTRAVASATION INJURIES
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Results
Quantity and quality of research available
Following the removal of duplicates retrieved from the database searches, a total of 3830 records were
identified for title and abstract screening, from which 289 records were selected as potentially being of
interest. Of those records excluded at the title and abstract phase, 63 were excluded for relating to events
which were termed ‘extravasation’ but which did not involve skin or muscle tissue, for example events
such as cardiac tamponade or pleural effusion (these studies are listed in Appendix 2). Copies of the full
texts of 271 papers were assessed for inclusion in the review. Six papers were identified from other
sources: checking references or citation searching of key papers. Figure 1 illustrates the flow of studies
through the review process and the number of included studies, by study design. Translators were not
available for the nine foreign-language papers published in languages other than French, German or
Spanish. Of the 26 group studies included in the scoping review,4,21,31–54 only two were comparative.16,55
Records identified through database searching
(n = 7210)
Records screened
(n = 3836)
Duplicates removed
(n = 3380)
Excluded on abstract
(n = 3464)
Full text unobtainable
(n = 8)
Could not translate paper
(n = 9)
Excluded on abstract as
‘other extravasation’ 
(n = 63)
Records identified from
other sources 
(n = 6)
Included on abstract
(n = 309)
Full-text articles screened
(n = 292)
Included
group studies
(n = 26:
29 papers)
Excluded on full text
(n = 147)
• On population, n = 21
• On treatment, n = 11
• On outcome, n = 108
• Excluded as ‘other
   extravasation’, n = 7
Included
reviews
(n = 3)
Included case
reports or
multiple case
reports
(n = 106)
Included
guidelines
(n = 6:
7 papers)
FIGURE 1 Flow chart showing the number of studies identified and eligible for inclusion.
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Primary studies of clinical effectiveness and safety
Comparative studies
Only two comparative studies were identified and included in the review, and both were set in the
USA.16,55 Full details of the studies are presented in Table 1. In 1979, Brown et al.55 published results for a
quasi-randomised study which compared three types of treatment: silver sulfadiazine cream with sterile
saline cleansing, povidone-iodine with sterile saline cleansing and sterile saline cleansing alone. The 34 study
participants had extravasation injuries resulting in skin loss, and were mostly aged < 1 year. Each of the
three treatments was given according to one of two possible protocols, depending on the type of skin loss,
classified as either full-thickness loss (24 participants) or partial-thickness loss (10 participants). Participants
were allocated treatment according to calendar month. The types of infusate causing injury varied, but they
mostly comprised parenteral nutrition, with or without antibiotics. The main outcome reported was the time
required for wound healing. The authors reported that there were no significant differences between the
three treatment protocols in the rate of healing. Four of the children in the full thickness group died and a
further two participants died before receiving treatment.
The second study was a pre–post study on the implementation and evaluation of a guideline for using
hyaluronidase.16 Although very few population details were reported, the study cohorts appeared quite
different from the Brown trial,55 as patients were treated quite quickly (within a few hours of injury).
Most of the no-hyaluronidase group were treated before the guideline was implemented and most of
the hyaluronidase group were treated post implementation. The mean time to receiving treatment was
125 minutes before guideline implementation and 76 minutes post implementation. Most of the outcomes
studied did not relate to the effectiveness or safety of hyaluronidase treatment. The exception was the
reporting of Agency for Healthcare Research and Quality (AHRQ) Common Format harm scores. To
determine if hyaluronidase treatment resulted in less harm, subjects were collapsed into two groups: those
receiving hyaluronidase (n = 37) and those not (n = 76). The mean harm scores were very similar, that is,
5.29 and 5.27, respectively. No events resulted in permanent harm, severe permanent harm or deaths
(i.e. a harm score of > 6).
Summary
The comparative study evidence identified was scarce and had important limitations in relation to the aims
of this scoping review. The Brown et al.55 study is an old trial of treatments which are little used in the
NHS. It was performed in a population of patients with quite severe wounds, where the extravasation
injuries may not have been identified for quite some time. The quasi-randomised design meant that
the study results may have been influenced by selection bias. The study was also small and, therefore,
underpowered to detect treatment differences. The Hanrahan hyaluronidase guideline study16 was
not really designed to evaluate treatment effectiveness. Although it did endeavour to determine if
hyaluronidase treatment resulted in less harm than no hyaluronidase treatment, the before-and-after
design, lack of population details and lack of details on interventions given to the no hyaluronidase
group mean that the study’s ‘harm score’ result should not be regarded as a reliable estimate of
hyaluronidase effectiveness.
Non-comparative group studies
Details of the identified non-comparative studies are presented in Tables 2–6. Studies were published over
the time period 1975–2016. Most were set in Europe or North America and four studies were set in the
UK.21,31,32,57 Most studies were published as full papers, but the exceptions were two studies that were
published as letters.32,33 The included studies covered conservative management interventions (n = 7),34–40
flush-out methods with or without hyaluronidase (n = 7),4,21,31,32,41,42,57 hyaluronidase injections without flush
out (n = 2),45,46 artificial skin treatments (n = 2),33,41 and debridement and/or plastic surgery (n = 7).21,48–53
SCOPING REVIEW OF TREATMENTS FOR EXTRAVASATION INJURIES
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TABLE 1 Prospective comparative studies of extravasation treatments
Study details Population characteristics Injury details Intervention Results
Authors
Brown et al. 197955
Age
Range: 5 days–12 years.
22 were aged < 1 year
Method of delivery
Varied, but mostly infusions
All patients had their i.v. therapy
stopped, the apparatus removed and the
affected area elevated. Patients were
then allocated one of the following
treatments –
Timeforwoundhealing
Silversulfadiazine:rangedbetween
3and10weeks inthe11childrenwith
full-thickness loss,and1–5weeks inthe
fourchildrenwithpartialthickness loss
For patients with partial-thickness skin
loss:
1. Apply silver sulfadiazine cream
every 8 hours and cover with
semi-permeable dressing. Wash
area with sterile saline between
applications, or
2. Apply povidone-iodine ointment
every 8 hours and cover with
semi-permeable dressing. Wash
area with sterile saline between
applications, or
3. Wash area with sterile saline every
8 hours but keep dry and covered
with ‘Sta-Tite’ in the intervals
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
4
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
4
6
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
8
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
C
o
rb
ett
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercial
rep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
9
TABLE 1 Prospective comparative studies of extravasation treatments (continued )
Study details Population characteristics Injury details Intervention Results
Design
Quasi-randomised study.
Treatment allocation changed
with the calendar month. The
study ran for 6 months. Each of
the three treatments was
therefore used for 2 full months
Comorbidities
Varied range, with respiratory
distress syndrome, leukaemia,
septicaemia, necrotising
enterocolitis and Wilm’s
tumour among the most
frequent
Types of eligible injury
Only children with skin loss:
partial (e.g. blistering or
discolouration) or full
thickness
For patients with full-thickness skin loss:
1. Apply silver sulfadiazine cream every
4 hours. Wash area with sterile saline
between applications, cover with
‘Sta-Tite’ in the intervals, or
2. Apply wet-to-dry povidone-iodine
solution dressings, covered with
‘Sta-Tite’, every 4 hours, or
3. Apply wet-to-dry saline dressings,
covered with Sta-Tite, every 4 hours
Povidone-iodine:rangedbetween
2and6weeks inthesixchildrenwith
full-thickness lossand3weeks inthe
onechildwithpartialthickness loss
Setting
Children’s hospital in PA, USA
Duration of i.v.
NR
Sites
Mostly dorsum of foot or the
hand. Some injuries on shin,
ankle, wrist, scalp, arm and
abdomen
Saline:rangedbetween4and8weeks
inthefourchildrenwithfull-thickness
lossand2and3weeks inthethree
childrenwithpartialthickness loss
Sample size
34
Mean time to treatment
NR
Infusates
Varied, but mostly parenteral
nutrition (0.5% to 2% amino
acids in 10% to 12.5%
glucose solution) sometimes
with antibiotics
No significant difference in the rate
of healing among the three treatment
protocols is readily apparent.
Nevertheless, primary healing
occurred in all patients without the
need for skin grafting and without
loss of function of the affected part
Four of the full thickness group died.
A further two patients died before
receiving treatment
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Study details Population characteristics Injury details Intervention Results
Authors
Hanrahan 201316
Age
NR (‘paediatric population’)
Injury details NR Hyaluronidase (n= 37) or no
hyaluronidase (n= 76)
AHRQ Common Format harm scores
were used as an outcome measure
Design
Before-and-after study of the
implementation of a guideline
for using hyaluronidase.56
Other outcomes included costs,
knowledge, extravasation
incident reports, hyaluronidase
usage reports
Comorbidities
NR
To determine if treatment resulted in less
harm, subjects were collapsed into two
groups: those receiving hyaluronidase
(n= 37) and those who did not (n= 76).
Mean harm scores were similar: 5.29 and
5.27, respectively
Setting
Children’s hospital in Iowa,
USA
Duration of i.v.
NR
Most of the no hyaluronidase group
were treated before the guideline
was implemented and most of the
hyaluronidase group were treated
post implementation. An increase in
the frequency of treatment with
hyaluronidase was reported from
baseline (9%) to implementation (63%)
No events resulted in permanent harm,
severe permanent harm, or deaths (harm
score > 6)
Sample size
113
Mean time to treatment
Pre implementation:
125 minutes (SD = 75)
Post implementation:
76 minutes (SD = 38)
NR, not reported; SD, standard deviation.
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1
Conservative management
Seven case series studies described using a conservative management approach to treatment.34–40 A minority
of patients also went on to receive surgery in one study.34 Study details are reported in Table 2. Only one
study was performed prospectively.39 Sample sizes ranged from 6 to 19 participants. The studies covered the
following interventions: hot compress with topical ointment;37 antibiotic/anti-inflammatory ointment mixture
followed by dressing;36 wet dressing and localised massage;35 alcohol based dressing;34 cold compresses
and elevation;38 a wound care protocol comprising aqueous gel; a hydrofibre sheet; and a hydrocolloid
dressing.39 The final study used a mixed-management approach utilising puncture points (similar to those
made in the Gault21 technique) followed by hydrocolloid dressing before scalpel debridement only of dead
tissue (so anaesthesia was not needed).40 The approach used in this study was decided on the basis of the
uncertainty encountered when selecting adequate treatments at an early stage because of difficulties in
determining the depth and extent of injuries. The treatment goals were to remove infusates and promote
wound healing by inducing autolytic debridement and providing a moist environment.
Five of the studies were of neonates,34–36,39,40 one was of infants (mean age 4 months)37 and one did not
report on age.38 Only two studies reported details relating to the delay between the extravasation event
and treatment for the extravasation.34,40 Both the types of infusate extravasated and the extravasation sites
varied widely.
Two studies of milder injuries reported that all injuries healed well and without complications.37,38 The four
studies which covered more severe injuries such as full-thickness defects,36 stage III and IV injuries34,39 and
calcinosis cutis35 reported long recovery times (typically between 1 and 8 weeks) and scarring in some
patients. The mixed-management approach study reported on different severities of injury caused by
parenteral nutrition extravasations in preterm neonates.40 Wound healing times ranged from 8 to 41 days,
with one contracture, no secondary infections and minor scarring.40 It was also reported that parents were
‘satisfied with the final results’. Although 2 out of the 12 patients presented with necrotic lesions, nine
patients eventually progressed to full-thickness open wounds.
Across studies, the outcomes used and result details reported were generally limited, although one study
did report total scores on the Vancouver Scar Scale (VSS).34
Flush-out methods
Seven studies reported using a flush-out technique,4,21,31,32,41,42,57 with sample sizes ranging from 14 to
96 patients. All but one of the studies21 was published after the year 2000. Study details are presented in
Table 3. Two studies were prospective case series,32,57 with the remainder being retrospective case series
(or having unclear methods).4,21,31,41–43 Four studies used hyaluronidase before saline flush-out21,31,42,57 and
three used saline flush-out alone in all patients,4,32 or nearly all patients.41 Two studies additionally used
liposuction in nearly all patients42 or only in a few patients.21 Two studies reported on both an early
referral group (seen within 24 hours) which received flush-out, and a late referral group which received
surgical interventions.21,41
Three studies were in neonates,4,32,42 three studies had populations with mean ages of around 3 years,31,41,57
and in one study the mean age was around 10 years.21 Where such data were reported, patients were
treated within 24 hours of the extravasation event, with the quickest treatment (within 10–30 minutes)
seen in a study of preterm neonates with stage III and IV extravasation injuries (Millam criteria were used
for staging).4 Infusate types and the extravasation injury sites varied both within and across studies.
For the three studies of neonates, two reported generally positive results but provided little in terms of
result details.32,42 The study of 34 (mostly) preterm neonates presented more result details, reporting good
responses with clinical findings subsiding significantly within 24 hours and wound healing in 1 to 25 days.
Twenty-one neonates showed no signs of soft tissue damage 24 hours after treatment and only minor
findings, such as blistering and epidermolysis, were still present in seven neonates in the next few days.
One child had hypoplasia of the toenails at 26 months. One neonate had compartment syndrome;
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TABLE 2 Non-comparative studies of conservative management interventions for extravasation injuries
Study details Population characteristics Injury details Intervention Results
Authors
An and Ning 201537
Age
Mean 4 months (range
1–9 months)
Method of delivery
NR
Wet-hot compresses by small sterile
gauze 3 or 4 times per day, with
temperature at 40–45 °C and
duration of 20–30 minutes per
session. Next, MPS cream was applied
topically, followed by tender massage
for 3–5 minutes
After a median duration of 3 days’
treatment, all patients had complete
fluid absorption and were discharged
without adverse outcomes at 3 months
Design
Retrospective case series
Comorbidities
Respiratory tract infection
Types of injury
Swelling, masses
Setting
Children’s hospital
emergency department,
China
Duration of i.v. therapy
2–3 days
Sites
All scalp
Sample size
Six
Mean time to treatment
NR
Infusates
Mezlocillin and sulbactam sodium
Authors
Moon et al. 201236
Age
Mean 20 days (31 weeks’
gestation) [range 14–50 days
(28–35 weeks’ gestation)]
Method of delivery
NR
Local conservative management was
given with healing by secondary
intention. An antibiotic and anti-
inflammatory ointment mixture was
topically applied to the whole region
of the wound site, followed by a
dressing. This was performed twice a
day during the acute phase and once
a day during the convalescent phase.
Systemic prophylactic antibiotics were
also given. The necrotic tissue was
removed when it was clearly
demarcated. After wound closure,
topical oil moisturisation and mild
compression were applied
The defects had completely closed
14 to 55 days after injury, the vast
majority by wound contraction.
Parents were shown photos of the
initial defects and the final scar. The
degree of the parents’ satisfaction was
excellent in nine cases of pinpoint
scars and linear scars, good in three
cases of depressed or mild contracted
linear scars and fair in two cases of
round hypertrophic scars
Design
Retrospective case series
Comorbidities
Prematurity
Types of injury
Full-thickness defects
Setting
Plastic surgery
department, South Korea
Duration of i.v. therapy
NR
Sites
Hand/wrist (n= 5), ankle/foot
(n= 8) and elbow (n = 1)
Sample size
13 (14 injuries)
Mean time to treatment
NR
Infusates
Total parenteral nutrition
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TABLE 2 Non-comparative studies of conservative management interventions for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Mu et al. 199935
Age
NR (neonates)
Method of delivery
NR
Wet dressing and localised massage,
followed by rehabilitation programme
It took 18 to 50 days for functional
recovery. Five lesions still had cosmetic
residuals but none required a skin
graft
Design
Case series (unclear
whether retrospective or
prospective)
Comorbidities
All had neonatal hypocalcaemia.
Premature (n= 4) and perinatal
asphyxia (n= 2)
Types of injury
Calcinosis cutis
Setting
Paediatric department,
Taiwan
Duration of i.v. therapy
Range 5–11 days
Sites
Wrist (n= 4), forearm (n= 4),
elbow (n = 3), ankle (n= 3)
Sample size
Nine
Mean time to treatment
NR
Infusates
Calcium gluconate
Authors
Nandiolo-Anelone et al.
201434
Age
Mean 3.6 days. (range 1–9 days)
Method of delivery
NR
Alcohol-based dressing 48 hours to
72 hours (n = 6), pre-surgical pro-
inflammatory dressing up to 15 days
(n = 6), graft excision (n= 4 primary;
n= 4 secondary), including 1 with
fasciotomy
Total scores VSS: 53% with scores 0
or 1, 26% with scores 2–4, 13% with
score 9, 6% lost to follow-up
Two deaths: linked to prematurity
(n = 1) and oesophageal atresia (n= 1)Design
Retrospective case series
Comorbidities
Maternal and fetal infections
(n= 6), fetal distress (n= 4),
respiratory distress (n= 4),
premature birth (n= 2), denutrition
(n= 1) and oesophageal atresia
(n= 1)
Types of injury
Stage III (n= 6) and IV (n= 9)
extravasation injuries
Setting
Children’s Hospital, Ivory
Coast
Duration of i.v. therapy
NR
Sites
Upper (n = 9) and lower limbs
(n= 6)
Sample size
15
Time to injury treatment
Mean 3.93 days, (range 1–9 days)
Infusates
Serum 10% glucose and calcium
chloride
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Study details Population characteristics Injury details Intervention Results
Authors
Sawatzky-Dickson and
Bodnaryk 200639
Age
1–40 days (24 to 40 weeks’
gestation)
Method of delivery
NR
Wound care protocol developed by
the authors. Aqueous gel was applied
to coat the area of tissue damage but
not the surrounding skin. A hydrofibre
sheet was placed over the gel. A thin
hydrocolloid dressing covered the area
for 7 days (or changed sooner if
necessary). Antibiotics were given for
wound infections
Wound healing times ranged from
1 to 6 weeks. No wounds showed
any signs of infection. One patient
died before wound healed.
Notes on research design:
l the number of injuries occurring in
a year is small so a randomised
controlled trial was not possible
Design
Prospective case series
Comorbidities
NR
Types of injury
Sloughing or necrosis. Stage III or
IV injuries
Setting
Neonatal intensive care
unit, Canada
Duration of i.v. therapy
NR
Sites
Foot (n= 5), hand (n = 3) and
forearm (n= 1)
Sample size
Nine
Mean time to treatment
NR
Infusates
Blood transfusion, sodium
bicarbonate, parenteral nutrition
and dextrose
Authors
Sung and Lee 201640
Age
30–39 weeks’ gestation
Method of delivery
NR
Multiple wound punctures (using
scalpel blade tip) were made and a
hydrocolloid dressing applied. This
was changed every 6 hours on the
first day and with decreasing
frequency thereafter. Debridement
performed gradually when devitalised
tissue began to be demarcated and
autolysed – done with a scalpel and
without anaesthesia. Mean duration
of treatment was 25 days. After
healing, silicone gel was
recommended for 3 months to
prevent hypertrophic scars
l Two of the 12 patients presented
with necrotic lesions and nine
patients eventually progressed to
full-thickness open wounds
l Wound healing times ranged from
8 to 41 days. There were no
secondary infections and minor
scarring
l Parents were ‘satisfied with the
final results’
l There was one contracture of the
wrist
Notes on research design:
l controlled prospective studies
necessary to confirm findings
Design
Retrospective case series
Comorbidities
Nine were preterm
Types of injury
Skin discolouration (n = 7), bleb
(n= 2), necrosis (n = 2) and
swelling (n= 1). Nine eventually
progressed to full-thickness open
wounds
Setting
Plastic surgery
department, South Korea
Duration of i.v. therapy
NR
Sites
Wrist (n= 5), ankle (n= 5), hand
(n= 1) and antecubital (n= 1)
Sample size
12
Mean time to treatment
Between 1 and 10 hours for all but
one patient (52 hours)
Infusates
Parenteral nutrition
continued
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TABLE 2 Non-comparative studies of conservative management interventions for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Wang 200738
Age
NR
Method of delivery
Injections
Cold compresses and elevation All wounds healed without necrosis
Design
Retrospective case series
Comorbidities
NR
Types of injury
Swelling (n= 13) and pain (n= 4)
Setting
NR, USA
Duration of i.v. therapy
NR
Sites
Arm (n = 10), hand (n = 3),
shoulder (n= 1), ankle (n= 1),
foot (n= 1) and groin (n = 1)
Sample size
17
Mean time to treatment
NR
Infusates
Contrast agent
MPS, mucopolysaccharide polysulphate; NR, not reported.
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TABLE 3 Non-comparative studies of flush-out techniques for extravasation injuries
Study details Population characteristics Injury details Intervention Results
Authors
Andres et al. 200641 (published
in Spanish)
Age
Mean 3 years
Method of delivery
NR
For cases of < 24 hours, the Gault
method with saline (500 cc) was used.
In two patients hyaluronidase was
used before saline flush-out. Includes
eight patients who received artificial
skin, see Table 5
Seven of the 10 patients treated by
the Gault method avoided necrosis
and recovered fully
Design
Retrospective case series
Comorbidities
One with necrotising enterocolitis,
one with hyaline membrane
disease, five oncology patients,
one severe head trauma and one
liver transplant patient
Types of injury
Not reported for whole cohort
though five patients had
established necrosis
Setting
Paediatric hospital, Spain
Duration of i.v. therapy
NR
Sites
Dorsum of hand or foot (n= 14)
and forehead (n= 1)
Sample size
15 (includes eight patients who
received artificial skin, see
Table 5)
Mean time to treatment
< 24 hours
Infusates
Parenteral nutrition (n= 7),
calcium gluconate (n = 4) and
doxorubicin (n = 4)
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TABLE 3 Non-comparative studies of flush-out techniques for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Casanova et al. 200142
Age
20 days (1 day to 6 months)
(mean weight 2.5 kg)
Method of delivery
NR
Gault procedure with hyaluronidase
under general anaesthesia in 11 cases.
Mild aspiration with a 2-mm
microcannula, following a liposuction
technique, was then performed
through the micro incisions. Aspiration
with a 20-mm syringe or by mild
mural aspiration. Procedure repeated
several times, rinsing the area with
saline after each infiltration of
hyaluronidase. Extravasation site
protected with an oily dressing. In two
cases saline was used instead of
hyaluronidase. In one case, only the
hyaluronidase flush-out was
performed
Eleven patients improved, with
no skin involvement in ten
cases. In one case a pre-existing
blister subsided and healed.
Three patients developed skin
necrosis, which was treated and
healed spontaneously
Design
Retrospective case series
Comorbidities
Six babies were premature
Types of injury
Swelling, discolouration, skin
damage, blisters, induration
Setting
Plastic surgery department,
France
Duration of i.v. therapy
NR
Sites
Foot/ankle (n= 9), hand/wrist
(n= 3), elbow (n = 1) and
forehead (n= 1)
Sample size
14
Mean time to treatment
3–12 hours
Infusates
Dopamine (n= 9), caffeine
(n= 2), beta-blocker (n = 1),
calcium (n = 1), calcium and
amikacine (n= 1)
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Study details Population characteristics Injury details Intervention Results
Authors
Ching 2014;31 Wong 201543
Age
Mean 36 months (1 day to
17 years)
Method of delivery
NR
A total of 62% of patients received an
early saline wash-out using the Gault
technique. The technique involved
creating multiple skin punctures
around the periphery of the injury
area with an atraumatic cannula and
flushing each puncture with 0.9%
sodium chloride. All the wash outs
also used hyaluronidase
None of the patients who received
the Gault technique developed
complications. Of the remainder,
there were three cases of
associated infection, one case of
ischaemic toe with subsequent digit
amputation and one case of
calcinosis cutis (involving prolonged
hospitalisation and readmission for
secondary infection)
Design
Retrospective case series
Comorbidities
Prematurity (40%),
gastrointestinal (21%),
cardiorespiratory (16%),
sepsis (16%) and other (7%)
Types of injury
NR
Setting
Plastic surgery department, UK
Duration of i.v. therapy
NR
Sites
Upper limb (65%; 40% on the
dorsum of hand), lower limb
(25%) and other (10%)
Sample size
69
Mean time to treatment
4 hours (range 0.2–24 hours)
Infusates
32% maintenance fluids
(glucose, or sodium or potassium
chloride), 23% TPN and 45%
others
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TABLE 3 Non-comparative studies of flush-out techniques for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Gault 199321
Age
Mean 10 years (range 0–70 years).
The study includes some adults but
the mean age (and range) suggests
most of the population were
children
Method of delivery
NR
‘Early referral’ group: of the 44 patients
seen within 24 hours, 37 were treated
with saline flush-out (500ml) following
prior infiltration with hyaluronidase.
One with liposuction alone, and six
with both. Prophylactic antibiotics were
also used for immunosuppression.
Following flush-out, a layer of
Jelonet™ (Smith & Nephew, Canada)
and betadine-soaked gauze was
applied, and limb was elevated for
1 day. ‘Late referral’ group needed
extensive reconstructive surgery
(see Table 6)
Flush-out group (early referral): no
tissue damage (n= 39), minor skin
necrosis or delayed healing (n = 5)
Design
Retrospective case series
Comorbidities
NR
Types of injury
NR
Setting
Plastic surgery unit, UK
Duration of i.v. therapy
NR
Sites
Varied greatly but mostly hand/
forearm or foot/ankle
Sample size
96 (includes patients needing
surgery see Table 6)
Mean time to treatment
44 patients within 24 hours
Infusates
Varied greatly but mostly
calcium, parenteral nutrition,
dextrose, vincristine,
daunorubicin or doxorubicin
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Study details Population characteristics Injury details Intervention Results
Authors
Ghanem et al. 201557
Age
Mean 3.2 years, median 0.2 years
(range 1 day–16.7 years)
Method of delivery
89% peripheral lines, 9% central
lines and 2% other
Evaluation of a hospital guideline
of early referral to plastic surgeons
and wash out of high-risk cases.
Extravasation injuries were diagnosed
in 48 out of 82 cases (i.e. vesicant
involved). The rest were classed as
infiltration injuries. Twenty-two out of
the 48 extravasation injuries required
wash-out with hyaluronidase, the
remainder were treated conservatively
with elevation and analgesia. None of
the infiltration injuries required
wash-out
Limited outcome data reported.
Three patients had tissue necrosis.
There was satisfactory healing with
no requirement for surgical
intervention. Two of these three
cases were referred later than
24 hours after the injury
Design
Prospective case series (audit)
Comorbidities
NR
Types of injury
NR
Setting
Children’s hospital, UK
Duration of i.v. therapy
NR
Sites
Varied, but most were the upper
limbs (60%) or lower limbs
(30%)
Sample size
78 (82 injuries)
Time to injury treatment
Mean 8.3 hours
Infusates
Varied, though TPN for 46% of
the extravasation injury group
(n= 48). Antibiotics and sodium
chloride caused over half the
injuries classed as infiltration. No
chemotherapeutic extravasation
injuries
Authors
Harris et al. 200132,44
Age
NR (neonates)
Method of delivery
NR
Modification of Gault’s saline flush-out
technique: 500ml of saline, to exit via
puncture wounds
No episodes of skin or soft tissue
loss were recorded and no
reconstructive surgery was required
Design
Prospective case series (reported
in a letter)
Comorbidities
NR
Types of injury
NR
Setting
Neonatal unit, UK
Duration of i.v. therapy
NR
Sites
NR
Sample size
56 confirmed injuries from
82 referrals
Time to injury treatment
Unclear ‘immediately assessed’
Infusates
Parenteral nutrition, inotropes,
dextrose, calcium, potassium,
and bicarbonate
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TABLE 3 Non-comparative studies of flush-out techniques for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Kostogloudis et al. 20154
Age
Mean age 11.6 days. Four
neonates were extremely preterm,
nine were very preterm, 14 were
late preterm and seven were full
term. Gestational age range:
24–42 weeks
Method of delivery
Peripheral i.v. infusion
Normal saline flush-out (mean 60ml,
range 10–160ml), two to six full-
thickness incisions made. Dressing
(paraffin- and povidone-iodine-soaked
gauze) and elevation for 24 hours.
Dressing changed daily until healing
complete
Wound healing in 1–25 days.
All infants responded well to
wash-out – clinical findings subsided
significantly within 24 hours.
Twenty-one neonates showed no
signs of soft tissue damage 24 hours
after treatment and only minor
findings, such as blistering and
epidermolysis were still present in
seven neonates in the next few daysDesign
Case series (unclear whether or
not prospective)
Comorbidities
NR
Types of injury
Neonates with stage III and IV
extravasation injuries were
included in the study
Setting
Neonatal intensive care unit,
Greece
Duration of i.v. therapy
NR
Sites
Ankle (n= 22 patients), dorsum
of hand (n= 6), dorsum of foot
(n= 3) and thigh (n= 3)
Sample size
34
Time to injury treatment
Range 10–30 minutes
Infusates
Parenteral nutrition (n= 28),
dextrose 10% (n= 4) and
cephalosporin (n= 2)
Ischaemic signs recorded in six
neonates by day 2, but gradually
subsided within 25 days. Incisions
healed uneventfully within
7–13 days and with minimal scar
formation
Hypoplasia of the toenails noted
in one case at 26 months. One
neonate had compartment
syndrome – emergency fasciotomies,
followed by saline irrigation were
performed. All incisions healed
uneventfully by secondary intention,
resulting in fully functional upper
extremities with aesthetically
acceptable scar formation
NR, not reported; TPN, total parenteral nutrition.
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therefore, emergency fasciotomies, followed by saline irrigation were performed. All incisions healed
uneventfully by secondary intention with aesthetically acceptable scar formation.4 This study also reported
that gestational age was not significantly related to the incidence of extravasation injuries (p = 0.87),
although it did affect the incidence of skin necrosis after severe extravasation injury (p = 0.009); this was
more common in extremely low-birthweight neonates. Similar to most of the neonatal studies, there was a
lack of detailed results data for the four studies of older children,21,31,41,43,57 with outcome reporting largely
focusing on presence/absence of necrosis.
Other studies of hyaluronidase
Two retrospective studies evaluated hyaluronidase injections without flush out.45,46 One was a study of
extravasations from iodinated contrast material and included both adults and children.45 For the eight included
children, the only treatment-related details presented were that two were treated with hyaluronidase, and
brief details were reported for one child whose extravasation had a prolonged course. The other study was of
13 neonates and infants, treated within a median time since injury of around 6 hours. Treatment comprised
hyaluronidase injections followed by massage with Hirudoid Cream™ (Mobilat Produktions GmbH,
Pfaffenhofen, Germany) around the affected area.46 Brief results were presented with the authors reporting
that symptoms improved and no complications were noted at the 48-hour and 3-month follow-ups.
Another study had a much broader scope: to summarise adverse drug event reporting.47 In this retrospective
hospital database study, extravasation injuries accounted for 10% of the 863 events. The paper reported
that infants were ‘treated with hyaluronidase’ for 31 out of the 38 parenteral nutrition extravasations, but
no details were reported about whether or not flush-out was also used. Details of the population studied
and details on outcome data were also very limited. Study details are presented in Table 4.
Artificial skin treatments
Two studies reported the use of artificial skin.33,41 One was of 26 preterm neonates with partial- and full-
thickness wounds arising from hypertonic solutions.33 The treatment was Hyalomatrix PA (Anika Therapeutics,
Bedford, MA, USA), a tissue reconstruction matrix composed of two layers. Eighteen patients had restoration
of dermal quote and a rapid re-epithelialisation process after 21 days. Patients were followed up for up
to 14 months; four patients had pathological scars and four had debilitating scar contractures needing
secondary surgery. The other study reported on the use of artificial skin with two membranes (silicone and
bovine tendon collagen mesh) and debridement and skin grafts in children with necrotic extravasation
injuries.41 All eight patients recovered full functionality with only minor scars; no secondary surgery or
amputation was necessary. Study details are presented in Table 5.
Debridement and plastic surgery
Seven studies, which were all retrospective, reported on patients who needed debridement and/or plastic
surgery.21,48–53 Most studies were small (sample sizes ranged from 4 to 51 patients) and all except one50
were published before the year 2000. Study details are presented in Table 6. Three studies reported on
outcomes following debridement,48,50,53 three reported on debridement and skin grafts,49,51,52 and one
reported different types of reconstructive surgery.21
Three studies were in neonates and all evaluated debridement techniques.48,50,53 Two were of skin necrosis
wounds caused by calcium gluconate,50,53 one of them being in preterm neonates.53 The other was in
preterm neonates with full-thickness injuries, mostly caused by parenteral nutrition.48
Two studies were in older children: one in children (mean age 5.6 years) with full-thickness tissue loss arising
from different types of infusate,51 and one in children with cancer diagnoses such as acute myelogenous
leukaemia or lymphoma who had extensive injuries caused by doxorubicin hydrochloride.49 In two studies,
only limited population details for surgery patients were available.21,52
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TABLE 4 Non-comparative studies of other (non flush-out) hyaluronidase interventions for extravasation injuries
Study details Population characteristics Injury details Intervention Results
Authors
Cochran et al. 200245
Age
3 months to 9 years
Method of delivery
Four were manual injection
Two were treated with
hyaluronidase
No results data relating to all eight
children were presented other than
‘one extravasation had a prolonged
course’; brief details were reported
for this childDesign
Retrospective database study
Comorbidities
NR
Types of injury
NR
Setting
Radiology department, USA
Duration of i.v. therapy
NR
Sites
NR
Sample size
Eight children (study also
reported data for adults)
Mean time to treatment
NR
Infusates
All contrast material
Authors
Yan et al. 201446
Age
Mean 26 days (range 5–150 days)
Method of delivery
NR
Hyaluronidase injections and
Hirudoid Cream. A 25-gauge
needle was used and a total of
1-ml solution (150 U/ml) of
hyaluronidase was divided into five
0.2-ml injections: one in the centre
and four along the edge of the
extravasation sites. Some cases
needed another injection several
hours after the first injection
(contained five 0.2-ml injections).
Hirudoid cream was massaged
around the affected area
After the treatment, the
symptoms improved, and no
complications were noted at the
follow-up within 48 hours and
3 months. Negligible loss of
functional movements of the
fingers, hands, arms, feet, or
legs was noticed
Design
Retrospective case series
Comorbidities
Prematurity (n = 5), pneumonia
(n= 4), gastrointestinal disorders
(n= 2), malnutrition (n= 1) and
neonatal jaundice (n= 1)
Types of injury
Swelling in all 13, with erythema
(n= 5), blister (n = 3) and necrosis
(n= 1)
Setting
Neonatal department, China
Duration of i.v. therapy
NR
Sites
Hand (n= 4), leg (n = 3), forearm
(n= 3) wrist, armpit and scalp
(all n= 1)
For the calcium chloride-treated
patient, a scar developed 2 days
after treatment, and calcinosis
developed 3 weeks after hospital
discharge
Sample size
13
Mean time to treatment
Median 6.4 hours for 12 cases.
For the calcium chloride-treated
patient, the hyaluronidase was
given after 14 hours
Infusates
Total parenteral nutrition (n= 9),
calcium chloride, 10% dextrose,
immunoglobin and para-
aminomethylbenzoic acid+
etamsylate (all n = 1)
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Study details Population characteristics Injury details Intervention Results
Authors
Crowther et al. 201147
Age
Mean 28 days (range 2–93 days)
for the 38 patients with
extravasation of parenteral
nutrition
Method of delivery
Mostly peripheral i.v. lines
‘Treated with hyaluronidase’ for
31 of the 38 parenteral nutrition
extravasations. No further details
were reported about how
hyaluronidase was used
A total of 46% full recovery,
remainder were referred to wound
care (10%) or did not have a
documented outcome (44%)
Design
Retrospective hospital database
study
Comorbidities
NR
Infusates
A total of 42% parenteral nutrition,
other agents such as dopamine,
dextrose, potassium chloride,
contrast media, ciprofloxacin and
fentanyl each made up ≤ 5% of
total
Setting
Children’s hospital, USA
Duration of i.v. therapy
NR
Types of injury
NR
Sample size
90
Time to injury treatment
NR
Sites
NR
Other treatments included
elevation, hot or cold compresses,
and analgesic use but these were
not consistently documented
NR, not reported.
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TABLE 5 Non-comparative studies of artificial skin interventions for extravasation injuries
Study details Population characteristics Injury details Intervention Results
Authors
Andres et al. 200641 (published
in Spanish)
Age
Mean 3 years
Method of delivery
NR
For cases of < 24 hours, the Gault
method with saline (500 cc) was
used. In five patients, where
necrosis was already established
(and in three in which it started
after the flush-out), the area was
covered with artificial skin
consisting of two membranes: one
comprised a three-dimensional
porous fibrillar mesh of bovine
tendon collagen next to
chondroitin-6-sulfate. The other
was a thin sheet of silicone.
Necrotic tissue was debrided and
after 2 or 3 weeks a partial skin
graft was performed
In total, eight patients needed the
artificial skin and skin grafts. All
recovered full functionality with
only minor scars; no secondary
surgery or amputation was
necessaryDesign
Retrospective case series
Comorbidities
One with necrotising enterocolitis,
one with hyaline membrane
disease, five oncology patients,
one severe head trauma and one
liver transplant patient
Types of injury
Not reported for whole cohort
although five patients had
established necrosis
Setting
Paediatric hospital, Spain
Duration of i.v. therapy
NR
Sites
Dorsum of hand or foot (n= 14)
and forehead (n= 1)
Sample size
15 (includes 10 flush-out
patients, see Table 3)
Mean time to treatment
< 24 hours
Infusates
Parenteral nutrition (n= 7), calcium
gluconate (n = 4) and doxorubicin
(n= 4)
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Study details Population characteristics Injury details Intervention Results
Authors
Onesti et al. 201233
Age
Mean gestational age 32 weeks
(range 28–36 weeks)
Method of delivery
NR
Hyalomatrix PA (a dermal substitute
composed of two layers): first,
topical collagenase was applied,
then 72 hours later debridement,
followed by application of
Hyalomatrix PA. After 1 week the
area was cleaned and Hyalomatrix
PA applied and kept in place for
7 to 11 days. This procedure was
continued for a total of 21 days
Eighteen patients had restoration
of dermal quote and a rapid
re-epithelialisation process after
21 days. Patients were followed up
for up to 14 months. Four had
pathological scars, four had
debilitating scar contractures needing
secondary surgery. There were no
wound infections
Design
Case series (reported in a letter).
Unclear whether or not
prospective
Comorbidities
Preterm neonates
Types of injury
Patients with partial and full-
thickness wounds. Cutaneous
eschar (n= 8), ulcers, blisters and
erythematous wound margins
(n= 18)
Setting
Plastic surgery department, Italy
Duration of i.v. therapy
Mean 3 days
(range 2 days–1 week)
Sites
Dorsum of hand (n= 11), dorsum
of foot (n= 6), forearm (n = 3),
ankle (n= 1), leg (n = 3) and scalp
(n= 2)
Sample size
26
Time to injury treatment
NR
Infusates
Hypertonic solution
NR, not reported.
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TABLE 6 Non-comparative studies of debridement and plastic surgery interventions for extravasation injuries
Study details Population characteristics Injury details Intervention Results
Authors
Falcone et al. 198948
Age
Mean gestational age 28.5 weeks
(range 26–33 weeks)
Method of delivery
NR
Enzymatic debridement All wounds healed completely with
no infections and no functional scar
contractions at up to 16 months’
follow-up. No skin grafts were
needed
Design
Retrospective case series
Comorbidities
Preterm, hyaline membrane
disease, rule out sepsis, patent
ductus arteriosus, necrotising
enterocolitis, seizures and
bronchopulmonary dysplasia
Types of injury
Full-thickness injury
Setting
Plastic surgery department, USA
Duration of i.v. therapy
NR
Sites
Foot (n= 13), hand (n= 2) and
scalp (n = 1)
Sample size
15 (16 injuries)
Mean time to treatment
NR
Infusates
Parenteral nutrition (n= 9),
electrolyte solution (n= 3)
and unknown (n = 3)
Debridement and topical
fibrinolysin/deoxyribonuclease
ointment (Elase, Parke-Davis,
Morris Plains, NJ, USA) every
8 hours. After 5–7 days, process is
repeated until the wound begins
to re-epithelialise (3–4 weeks)
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Study details Population characteristics Injury details Intervention Results
Authors
Gault 199321
Age
Mean 10 years (range 0–70 years).
The study includes some adults but
the mean age (and range) suggests
that most of the population were
children
Method of delivery
NR
‘Early referral’ group: 44 patients,
see Table 3
Late referral: no tissue damage
(n= 8 patients), minor skin necrosis
or delayed healing (n= 17), scar
revision (n= 5), skin graft (n= 6),
contractures (n= 6), flap coverage
required (n= 6), amputation (n= 3
neonates) and infection (n= 1)
Design
Retrospective case series
Comorbidities
NR
Types of injury
NR
Setting
Plastic surgery unit, UK
Duration of i.v. therapy
NR
Sites
Varied greatly but mostly hand/
forearm or foot/ankle
Sample size
96 (includes patients receiving
flush-out, see Table 3)
Mean time to treatment
44 patients within 24 hours
Infusates
Varied greatly but mostly calcium,
parenteral nutrition, dextrose,
vincristine, daunorubicin or
doxorubicin
‘Late referral’ group: 15 of the
51 patients needed extensive
reconstructive surgery
Authors
Linder et al. 198349,54
Age
From 6 months to 14 years
Method of delivery
Some i.v. drip, some push
Surgery – debridement and wound
closure: mostly split-thickness skin
grafts or delayed primary closure
The mean time for wound closure
was 49 days (range 10–85 days).
Three patients died before wound
closure. At least one patient
needed a split thickness skin graft
but could be more as results not
given separately for children and
adults. One child developed
sympathetic dystrophy syndrome.
Some children developed
permanent joint stiffness. Other
negative outcomes are mentioned
but unclear if they were
experienced by the child sample
Design
Retrospective case series
Comorbidities
Mostly acute myelogenous
leukaemia or lymphoma
Types of injury
Only patients with extensive
injuries, defined as 300 cm2 of
tissue loss
Setting
Plastic surgery department, USA
Duration of i.v. therapy
NR
Sites
Upper arm, forearm or hand, foot
and leg
Sample size
18 (study also included
22 adults)
Mean time to treatment
Range 6–62 days
Infusates
Doxorubicin hydrochloride
Sodium hypochlorite dressings
All patients had at least two
operations
continued
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TABLE 6 Non-comparative studies of debridement and plastic surgery interventions for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Sivrioglu 201450
Age
26 days (range 1 day–3 months)
Method of delivery
NR
Injuries were initially flushed with
saline and a cold compress applied.
Oily dressings were applied and
skin necrosis developed within a
week. Debridement with the
VersajetTMHydrosurgerical system
(Smith & Nephew, London, UK)
(a waterjet debriding tool) under
general anaesthesia. Oily dressings
used after debridement
Wounds healed spontaneously by
re-epithelialisation. The mean time
of full epithelialisation was 14 days.
At 1 year, minimal scar formation
was noted with no hypertrophic
scars
Design
Retrospective case series
Comorbidities
NR
Types of injury
Skin necrosis
Setting
Plastic surgery department,
Turkey
Duration of i.v. therapy
NR
Sites
Hand/wrist (n= 5), foot (n= 3) and
scalp (n = 1)
Sample size
Nine
Mean time to treatment
All within 12 hours
Infusates
Calcium gluconate
Authors
Upton et al. 197951
Age
5.6 years (range 1 week–11 years)
Method of delivery
Varied
Debridement and skin grafts. All
patients needed two or more
operations
Below elbow amputation (n= 1),
contractures (n= 2), extensor loss
(n= 2), hair loss (n= 1), loss of
motion (n= 1) and reconstruction
needed (n= 1)Design
Retrospective case series
Comorbidities
Varied, including acute leukaemia,
head trauma and gastroenteritis
Types of injury
Major injuries with full-thickness
tissue loss
Setting
Various departments in five
US hospitals
Duration of i.v. therapy
NR
Sites
Hand, scalp, forearm, wrist, foot or
ankle
Sample size
Seven (study also reported on
24 adults)
Mean time to treatment
Range 1–42 days
Infusates
Varied including dextrose,
potassium chloride, doxorubicin
hydrochloride, tetracycline
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Study details Population characteristics Injury details Intervention Results
Authors
von Heimburg and Pallua 199852
(published in German)
Age
Five infants (no further details
other than minimum age
2 weeks)
Method of delivery
NR
Debridement, temporary wound
coverage by allogeneic donor tissue
grafts, and autologous split-skin
graft
After 15 days there was full healing
(defined as time at which no
further wound coverage changes
were required) in all five infants
Design
Actual design is retrospective
comparative study. But
extractable data for five infants
Comorbidities
NR
Types of injury
Late phase, requiring surgical
intervention
Setting
Germany, specialised clinic for
plastic, hand and burns surgery
Duration of i.v. therapy
NR
Sites
Bridge of foot
Sample size
Extractable: five infants (one case
report)
Mean time to treatment
19 days (range 2–10 weeks), but
these figures include 19 adult
cases
Infusates
NR
continued
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TABLE 6 Non-comparative studies of debridement and plastic surgery interventions for extravasation injuries (continued )
Study details Population characteristics Injury details Intervention Results
Authors
Weiss 197553
Age
NR (but premature neonates)
Method of delivery
NR
Wet dressings and repeated
economical debridement
Wounds healed well in 15 to
40 days. Scars were visible but
without discolouration
Design
Retrospective case series
Comorbidities
Neonatal hypocalcaemia
Types of injury
Localised skin necrosis
Setting
Department of premature
infants, Israel
Duration of i.v. therapy
Up to 15 days
Sites
All scalp
Sample size
Four
Mean time to treatment
NR, but lesions developed after
needle removal
Infusates
Calcium gluconate
NR, not reported.
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As would be expected in studies of more severe injuries, the delay between the extravasation event and
(surgical) treatment was longer than in the studies of the interventions previously discussed. However, in
one neonatal study of debridement, patients were treated within 12 hours of injury.50 This was because
this study actually used a combination of intervention approaches, rather than just debridement. It used
conservative management methods and flush-out before debridement using a waterjet debriding tool.50
Only basic result details were reported for the debridement studies in neonates. The two calcium gluconate
studies reported wound healing in 15 to 40 days,53 and a mean of 14 days for full epithelialisation,50 with
minimal scar formation at 1 year.50 The parenteral nutrition study, which was of enzymatic debridement,
reported that all 16 wounds healed completely, with no infections and no functional scar contractions
at up to 16 months.48 A study of five infants receiving debridement and skin grafts reported full healing at
15 days.52 The study in seven older children (mean age 5.6 years) reported an amputation, two contractures,
hair loss and loss of motion.51 The doxorubicin hydrochloride study of children with extensive injuries reported
a mean time for wound closure of 49 days.49 Other outcomes were reported, but this study also reported on
adults and separate results for children were not always available.
Summary
Although many types of extravasation injury treatments have been studied in non-comparative studies,
the limitations inherent in these studies makes it very difficult to compare results across treatments. Some
results have probably been subject to chance effects or biases because most studies were very small and
were retrospective in design: 17 out of the 24 studies had sample sizes of < 20 and only three studies
were reported as having a prospective design. Furthermore, there was considerable clinical heterogeneity
across study populations in factors such as age, types of infusate, injury severity, location of injury and the
time gaps between injury and treatment. Differences in results might be a reflection of variation in one or
more of these parameters, rather than differences in treatment effect. Volume of infusate may have been
another important factor, though this was very rarely reported. Although data on injury severity grading
could have helped with interpreting the importance of these issues, few studies reported such data. Finally,
the results sections for most studies were very brief and reported limited data for outcomes which were
often related to short-term time points. No studies reported pain as an outcome and few studies
quantified outcomes, for example, by using measures of scarring, such as scar scores. Only one study
reported on whether or not interventions resulted in adverse effects.46
Uncertainty exists regarding which treatments may be the most promising, particularly with respect to how
to treat earlier stage injuries (i.e. injuries which have not become necrotic). Some of the better evidence
(in terms of study size and a prospective design) relates to studies of saline flush-out techniques. Notwithstanding
the reporting limitations of the results sections of many studies, these techniques appear to be quite promising
treatments. The effect of prior infiltration with hyaluronidase before wash out is unclear though.
Neonates were the most frequently studied population, being evaluated in around half of the non-
comparative studies. Neonates have more fragile skin and veins and are less able to communicate the
presence of injuries compared with older infants; Sung and Lee40 suggested that the use of flush-out
methods in neonates may be too invasive to perform and, therefore, proposed a middle ground between
conservative management and flush-out: puncture points and hydrocolloid dressing. However, although
2 out of the 12 (mostly) preterm neonates in this South Korean study presented with necrotic lesions,
nine eventually progressed to full-thickness open wounds. Additionally, two group studies have performed
flush-out treatments in neonates.4,32 One of them was prospectively performed in a UK neonatal unit, but
it was only published as a letter and so only reported the population as ‘neonates’ along with very basic
results.32 The other was conducted in a Greek neonatal intensive care unit in mostly very preterm or late
preterm neonates with quite severe (stage III or IV) extravasation injuries.4 This study reported impressive
results with 21 out of the 34 neonates showing no signs of soft tissue damage 24 hours after treatment,
and only minor findings (blistering and epidermolysis) still present in seven neonates in the following few
days. These results might therefore suggest that flush-out treatments may be more worthy of further
study than the middle ground of puncture (without flush-out) and dressing. However, this is merely a
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suggestion, as although both the studies were of parenteral nutrition extravasations, they differed in an
important way: in the Greek study the neonates were treated within 10–30 minutes of injury compared
with between 1 and 10 hours in the South Korean study.
Case report studies
There were 106 case report studies identified,58–163 23 of which detailed more than one
participant.62,64,70,75,79,87,102,104,108–111,121,123,129,147,148,153,157,159–162 In total, 163 individual participants were studied.
Study characteristics are summarised in Table 7 with full treatment, intervention and outcome details
presented in Appendix 3. The age range of the participants was from newborn to 17 years old, with a
mean age of 2.1 years. The majority of the case reports were on neonates or young infants with 93 case
reports detailing those < 1 month old and 122 examining those < 1 years old.
TABLE 7 Basic characteristics of case report studies
Study authors
and date Design Age Infusate Intervention
Abraham et al.
201258
Case report 9 years Chloramphenicol and
ampicillin
Fasciotomy
Altan et al. 201359 Case report 23 days Packed red blood
cells
Conservative, nitroglycerin
Altmann et al. 201460 Extractable: case
report
2 years Doxorubicin Conservative, debridement
Amano et al. 200861 Case report 3 years Parenteral nutrition Conservative, antibiotics,
silver sulfadiazine,
debridement
Amaya 201662 Multiple case reports
(four patients)
4–32 weeks old
(three preterm)
Parenteral nutrition Saline wash, fasciotomy,
debridement, skin graft
Amhaz et al. 201663 Case report 10 days Adrenalin Conservative, antibiotics
Aribit et al. 200064 Multiple case reports
(two patients)
6 and 11 months Parenteral nutrition
and intralipid
Antibiotics, drainage
Baker et al. 199165 Case report 7 years Nafcillin sodium Antibiotics (n = 1),
silver sulfadiazine (n= 2),
debridement (n = 1),
skin graft (n= 1)
Bassi et al. 200766 Case report 10 months Contrast agent Conservative, fasciotomy
Berger et al. 1974162 Multiple case reports
(three patients)
2 days to 1 month
(two preterm)
Unspecified antibiotic Debridement, skin graft
Beytut et al. 2014163 Case report 7 years NR Honey, debridement, skin
graft
Bhosale et al. 201267 Case report 16 years Blood Conservative, saline wash
Borman et al. 199868 Case report 4 years Glucose 10% (n = 1),
NR (n= 1)
Saline wash
Boyar et al. 201469 Case report 3 weeks (preterm) Calcium gluconate Debridement (n= 2),
antibiotics (n = 2)
Broom et al. 201670 Multiple case reports
(two patients)
6 months to
1 year
NR Conservative, topical,
oxygenotherapy
Chait et al. 197571 Case report 2 years Dopamine Antibiotics, debridement,
skin graft
Chen et al. 201072 Case report 4 days (preterm) NR Fasciotomy
Chiang et al. 200473 Case report 11 days (preterm) Calcium gluconate
(10%)
Conservative, antibiotics,
fasciotomy (n= 2)
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TABLE 7 Basic characteristics of case report studies (continued )
Study authors
and date Design Age Infusate Intervention
Ching et al. 201474 Case report 4 days Calcium gluconate
(10%)
Conservative, antibiotics
Cho et al. 200775 Multiple case reports
(five patients)
17 to 50 days Calcium gluconate Conservative
Cohan et al. 199076 Case report 12 months Iopamidol Conservative
D’Acunto et al.
201577
Case report 2 months
(preterm)
Balanced electrolyte
solution
Conservative,
debridement, skin graft
Davé 199378 Case report 3 years Undefined fluids
(no drugs)
Conservative,
debridement, skin graft
Davies et al. 199479 Multiple case reports
(two patients)
26 and 11 days
(both preterm)
Dopamine Conservative, nitroglycerin
Denkler et al. 198980 Case report 1 day (preterm –
two sites: hand/
foot)
Dextrose and 25%
normal saline
Conservative
Domizio et al. 200681 Case report 2 days (two sites) Doxorubicin Debridement, skin graft
Dunn et al. 198482 Case report 5 months Dextrose saline Conservative
Duray et al. 198683 Case report 5 years Calcium gluconate Conservative
Eckersall et al. 199684 Case report 3 years i.v. fluids Antibiotics, debridement,
skin graft
Eroglu et al. 200485 Case report 17 years Parenteral nutrition
(lipid infusate)
Drainage
Garcia-Alverez et al.
199986
Case report 2 weeks
(administered over
first 3 days of life)
Sodium bicarbonate Conservative
Gibboney et al.
198687
Multiple case reports
(two patients)
17 days and
4 weeks (both
preterm)
Dextrose solution
(5%), 25% saline and
potassium chloride
Conservative, fasciotomy,
skin graft
Govind et al. 201488 Case report 27 days (preterm) Erythromycin Conservative, saline wash,
debridement, skin graft
Grabois et al. 200889 Case report 19 days (preterm) Phenytoin Fasciotomy
Handler 199090 Case report 4 years Calcium gluconate
(10%)
Conservative, debridement
Hankin et al. 198491 Case report 17 years Vincristine Hyaluronidase
Harb et al. 201092 Case report 1 year (preterm) Parenteral nutrition Antibiotics, hyaluronidase
Hasija et al. 201493 Case report 3 years Dextrose solution Conservative,
hyaluronidase
Hey et al. 200594 Case report 12 months Sodium bicarbonate Conservative,
hyaluronidase
Hironaja et al. 198295 Case report 6 days Parenteral nutrition
(lipids) plus antibiotics
Conservative, hydrogel
Hirsch et al. 201696 Case report 4 days (preterm) Anthracycline
(idarubicin)
DMSO
Hooke 200597 Case report Adolescent Antibiotics, NR Silver sulfadiazine, honey,
hydrogel, hyaluronidase
Kameo et al. 201598 Case report 2 years NR Conservative
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TABLE 7 Basic characteristics of case report studies (continued )
Study authors
and date Design Age Infusate Intervention
Khan et al. 201499 Case report 29 days (preterm) Calcium gluconate Conservative, antibiotics,
oxygenotherapy,
debridement
Kishi et al. 2014100 Case report 17 years Intralipid and
parenteral nutrition
Conservative
Kuensting 2010101 Case report 6 days Calcium gluconate Conservative
Kumar et al. 2001102 Multiple case reports
(six patients)
Neonate (preterm)
to 2 years
Propofol and
lidocaine
Saline wash, debridement,
skin graft
Lee et al. 2013103 Case report 1 month (preterm) Sodium bicarbonate
(NaHCO3)
ACTICOAT™ (Smith &
Nephew, London, UK)
Lehr et al. 2004104 Multiple case reports
(three patients)
4 to 24 days
(two preterm)
Arginine Conservative,
debridement, skin graft
Leung et al. 1980105 Case report 6.5 years Phenobarbital Antibiotics, debridement,
skin graft
Llinares et al. 2005106 Case report 4 years NR Ultrasound, hydrogel,
debridement
Martin et al. 1994107 Case report 4 months Phenytoin NR
Meszes et al. 2017108 Multiple case reports
(six patients)
Neonates (range
1–23 days)
NR Antibiotics, debridement
Mohr et al. 2014109 Multiple case reports
(two patients)
3 weeks
(preterm), 19 days
(preterm)
Parenteral nutrition
(dextrose, calcium,
potassium, etc)
Saline wash,
hyaluronidase
Morrison et al.
1999110
Multiple case reports
(four patients)
Neonates
(preterm)
Dopamine Phentolamine
Mukherjee et al.
1977111
Multiple case reports
(four patients)
5 years and NR Phenytoin (diazepam
before)
Conservative,
hydrocortisone
Nissim et al. 2008112 Case report 1 day Calcium gluconate None
Onesti et al. 2012113 Case report 2 days (preterm) Calcium gluconate Antibiotics
O’Reilly et al. 1988114 Case report Neonate Ceftriaxone sodium Conservative, fasciotomy
Ozcan et al. 2015115 Case report 14 years Mannitol Fasciotomy
Pantelides et al.
2013116
Case report 1 day (preterm) Dextrose Conservative, drainage,
antibiotics
Park et al. 2015117 Case report 7 months Two NR, one
hydration
Conservative (n = 1) and
fasciotomy (n= 2)
Phillips et al. 2009118 Case report 3 months Calcium gluconate Antibiotics, debridement
Raffaella et al.
2009119
Case report
(two extravasations)
5 years Calcium solution Other surgery
Ravenel 1983120 Case report 6 days Dextrose Conservative,
hyaluronidase
Reilly et al. 1977121 Multiple case reports
(three patients)
13, 15 and 17
years
Calcium solution Conservative, antibiotics
Reynolds 2007122 Case report 2 days (preterm) Dopamine Conservative (n = 1) and
nitroglycerin (n = 1)
Roberts 1977123 Multiple case reports
(five patients)
Neonates (range
1 day–1 year)
Calcium gluconate Conservative
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TABLE 7 Basic characteristics of case report studies (continued )
Study authors
and date Design Age Infusate Intervention
Rosales et al. 2004124 Case report 75 days (preterm) Dopamine and
tromethamine
Debridement, skin graft
and other surgery (n= 1)
Roth et al. 2006125 Case report 31 days Nafcillin sodium Conservative (n = 1),
hyaluronidase (n= 2) and
skin graft (n= 1)
Rustogi et al. 2005126 Case report 4 days (preterm) Flucloxacillin, calcium
gluconate, human
immunoglobulin,
sodium bicarbonate,
dextrose solution and
20% lipid nutrition
Conservative, debridement
(n = 3), skin graft
Salameh et al.
2004127
Case report 3.5 years Fatty acid, lipid and
amino acid infusion
(n = 4), glucose
(n = 1) and
dobutamine (n= 1)
Conservative (n = 3),
hydrogel (n = 2),
debridement (n = 1) and
none (n= 1)
Samiee-Zafarghandy
et al. 2014128
Case report 1 day (preterm) Adriamycin Conservative (n = 1),
antibiotics (n = 1) and
hydrocortisone (n= 1)
Sanpera et al.
1994129
Multiple case reports
(two patients)
3 days and
neonate (preterm)
Dextrose (10%) or
calcium solutions
Debridement, skin graft
(n = 4)
Santoshi et al.
2008130
Case report Neonate (preterm)
(seen at 5 years)
Fluids or electrolyte
solution (n= 5; 1 plus
erythromycin) and
phenytoin (n= 1)
Saline wash, debridement,
skin graft (n= 2)
Schäfer et al. 2005131 Case report 2 weeks Parenteral nutrition
(sixth case blood
transfusion)
Antibiotics, debridement
(n = 2)
Schie et al. 2013132 Case report 33 weeks
(preterm)
Calcium gluconate Antibiotic corticosteroid
Schumacher et al.
1987133
Case report 7 years Azithomycin Conservative, antibiotics
Sharief et al. 1994134 Case report (two
extravasations)
1 day (and 3 days) 8.4% bicarbonate
20 ml, 10% calcium
gluconate 10 ml,
50% glucose 5 ml,
1 : 1000 adrenaline
3 ml and 4.5%
human albumin
solution 50ml
Saline wash, liposuction,
hyaluronidase
Shenaq et al. 1996135 Case report 10 years Parenteral nutrition Topical
Sindal et al. 2015136 Case report Neonate (preterm) Dextrose solution
(12.5%)
Conservative
Siu et al. 2007137 Case report 2 days (preterm) Calcium gluconate Antibiotics
Siwy et al. 1987138 Case report 2 days Dopamine Phentolamine
Sokol et al. 1998139 Case report 14 months
(preterm)
Arginine and 10%
glucose
Conservative
Sonohata et al.
2006141
Case report 14 years Arginine
monohydrochloride
(10% in sodium
chloride)
Conservative, silver
sulfadiazine
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TABLE 7 Basic characteristics of case report studies (continued )
Study authors
and date Design Age Infusate Intervention
Sonohata et al.
2008140
Case report 3 days 6 cc arginine
monohydrochloride,
50% diluted in 12 cc
of sodium chloride
0.9%
Conservative, topical,
Debridement
Soon et al. 2001142 Case report 38 weeks NR Honey
Spenny et al. 2004144 Case report 3 years Oncovin dauno
rubicin
Conservative
Stahl et al. 2000143 Case report 10 years Parenteral nutrition Saline wash,
hyaluronidase
Subedi et al. 2011145 Case report 16 years Mannitol (20%) Fasciotomy
Subhani et al.
2001146
Case report 1 day Doxorubicin Conservative, DMSO,
debridement, skin graft
Talbot et al. 2011147 Multiple case reports
(three patients)
7 to 10 months Hydroxyzine Conservative, silver
sulfadiazine
Tilden et al. 1980148 Multiple case reports
(four patients)
15 days to
4 months
Contrast medium
(sodium iothalamate
54%)
Antibiotics, debridement,
skin graft
Tiras et al. 2005149 Case report 2 days Calcium gluconate Skin graft
Tobin 2007150 Case report 1 day (preterm) Blood, fluids and
antibiotics
Other surgery
Tuncer et al. 2006151 Case report 6 years Phenytoin Hyaluronidase
Vanwijck and Lengele
1994152
Case Report 9 years Parenteral nutrition Conservative, antibiotics
von Muhlendahl
2012153
Multiple case reports
(six patients)
14 days (preterm)
to 14 months
Arginine
monohydrochloride
(10%)
Conservative, silver
sulfadiazine, debridement,
skin graft
Wada et al. 2003154 Case report Neonate Dextrose solution; NR
(rehydration)
Debridement, skin graft
Wiegand et al.
2010155
Case report 17 years Parenteral nutrition Conservative, silver
sulfadiazine, debridement,
artificial skin
Wolfe et al. 1983156 Case report 2 days Dopamine Conservative, topical,
antibiotics, debridement
Wong et al. 1992157 Multiple case reports
(two patients)
4 and 15 days
(both preterm)
Calcium solution and
NR
Debridement
Wong et al. 2015158 Case report 4 days Calcium disodium
edetate (EDTA)
Conservative
Yamamoto et al.
1994159
Multiple case reports
(two patients)
1 and 4 years Adriamycin
(doxorubicin)
Debridement, skin graft
Yosowitz et al.
1975160
Multiple case reports
(seven patients)
2 days to 10 years
(two preterm)
Meglumine
ioxitalamate
Conservative, antibiotics,
saline wash, drainage
Zenk et al. 1981161 Multiple case reports
(three patients)
3 days to
4 months
Calcium solution Conservative,
debridement, skin graft
EDTA, ethylenediaminetetraacetic acid; NR, not reported.
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The range of extravasated fluids examined was varied. The majority of individual case reports examined
calcium gluconate, amounting to 19% (n = 31) of the total. Parenteral nutrition and dextrose solutions
made up the next highest frequency at 12% (n = 19) and 9% (n = 15), respectively. Other extravasated
fluids examined were dopamine at 5% (n = 8), nafcillin sodium at 4% (n = 7), phenytoin at 4% (n = 6),
arginine at 2% (n = 4), sodium bicarbonate at 2% (n = 4) and doxorubicin at 2% (n = 3). The extravasated
material was not reported in 8% of case reports (n = 13).
The extent and quality of reporting of extravasation treatments varied across the studies. The majority of
the studies (n = 56) reported the use of conservative management at least initially.58,59,61,63,65,66,71–74,76–78,80,82,
84,86,89–92,94–97,100–104,108,112,113,115,116,118,119,121–123,127,128,133,141,144,145,147,150,152,154–158,161,163 Only 17 of these studies,
however, reported using conservative management in isolation for any case report.58,71,74,76,82,84,86,89,112,116,
121–123,133,147,157,158 Topical treatments were reported in 14 studies,61,62,65,69,96,97,100,104,106,108,109,113,132,148 including
seven examining silver sulfadiazine,61,65,96,100,109,113,148 two using DMSO,97,106 three using medical honey62,69,109
and four reporting on hydrogel.104,108,109,132 Hyaluronidase was used in 11 studies79,98,99,101,103,107,109,137,139,155,161
and saline wash out in 10 studies.63,64,79,92,109,117,125,137,152,153
Surgical techniques were required in at least one participant in 49 of the studies,59,60,62,65–68,70,72,75,77,78,83,85,87,90–93,
95–97,102,105,108,110,111,113,117–119,125,127,129,131,132,135,136,143,144,147–149,153,154,159–162 a significant proportion at 46%. Of these,
11 studies included fasciotomies,59,68,70,72,85,90,93,117,143,144,147 37 included case reports where debridement was
necessary60,62,65–67,75,77,78,83,87,91,92,95–97,102,105,108,111,113,117–119,125,127,129,131,132,135,136,148,149,153,154,159,160,162 and 26 studies
had case reports that required skin grafts.60,62,65,67,77,78,83,87,90,92,97,102,105,110,111,117,125,127,131,135,148,153,154,159–161 Only one
study reported a skin graft that had not also undergone debridement or a fasciotomy.110
Outcomes were generally poorly reported and lacking in detail. The majority of studies (n = 90) reported a
functional or full recovery for all their participants.58–67,69–90,92–95,97–110,112,114,116,119–123,125–127,130–132,134,136–147,149–151,
153,155–163 However, few of these (n = 25) reported on whether or not adverse outcomes such as scarring
occurred.58,61,65,66,69,71,75,79,81,85,94,97,100,102,105,107,110,114,116,120,130,139,146,150,153 Of these 25 studies, 17 indicated some
scarring but how this was reported was inconsistent across studies and was usually vague.58,61,65,66,69,71,79,85,97,
100,102,105,110,130,139,150,153 In addition, the time points at which scars were assessed varied widely across the
studies, ranging from within 24 hours to three years.
Summary
Overall, the case reports point to a lack of methodological consistency in the area. Little, if any,
information is given about the extent of injury before treatment, and outcomes were measured and
reported inconsistently. In a similar vein to the non-comparative studies, inconsistency of treatment
variables such as dosage and delay until treatment make any comparisons of the findings of these reports
of limited use.
Reviews and guidelines
Reviews
Three reviews, one narrative8 and two systematic,17,164 were identified that synthesised the evidence on
treatment for extravasation events and injuries. Clifton-Koeppel8 conducted a broad narrative review of
extravasation injuries across a range of patient populations which included a review of initial treatments
and subsequent wound care options. The author recommended the use of clinical staging criteria of the
severity of wounds to help determine the appropriate treatment. The author also indicated that, although
there was agreement that immediate treatment is needed for the best outcomes, there is no consensus
regarding which treatments are best. Saline wash-out and hyaluronidase treatments appeared to be
frequently studied. The review also reported that reduced wound healing time and scarring can be
achieved from the promotion of a moist environment using topical ointments/gels and dressings, while
also noting the toxicity problems that may result from using topical treatments in newborns. The local
application of heat or cold were not well studied treatments, with no studies found in newborns. Although
this review was not systematic (so some relevant studies may have been missed), the author’s conclusions,
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in which they lament the very limited evidence available and call for further research, nevertheless,
seem appropriate.
The second review was a Cochrane systematic review which examined the evidence for a specific type
of technique, saline irrigation with or without prior hyaluronidase, on wound care in neonates with
extravasation injuries.17 The authors conducted an extensive search of the literature with clear search
criteria to identify randomised controlled trials (RCTs) and quasi-RCTs comparing the intervention with
no intervention or normal wound care. Despite the rigorous methodology, the authors found no eligible
studies. They repeated the searches without an age restriction but still identified no studies that matched
the inclusion criteria. They therefore performed a descriptive review of some case reports, case series and
cohort studies. These indicated that several different methods were in current practice for the management
of extravasation injuries; therefore, the review authors expressed the opinion of an impression that mild
injuries (stages 1 and 2) may heal well under conservative management, whereas more severe injuries
(stages 3 and 4) may need more invasive treatment. However, these recommendations are based on a very
limited evidence base.
In 2015, Harrold et al.164 published a systematic review of the management of cytotoxic chemotherapy
extravasations. The review focused on strategies aimed at preventing the need for surgical debridement.
Six databases were searched and eligibility criteria were specified for including studies in the review. Study
quality was evaluated using a levels of evidence approach. The 31 included studies were mostly case series
which evaluated dextrazoxane, DMSO, saline wash-out, hyaluronidase or steroids with or without sodium
thiosulphate. However, no conclusive evidence was found to favour one strategy over another. The authors
noted that, despite this, some ‘expert opinion’ guidelines favour the use of specific antidotes over saline
wash-out. The authors also noted that no studies evaluated outcomes relating to patient experience or
patient perspective on extravasation management.
Guidelines
The searches identified seven references relating to guidelines on the management of extravasation
injuries.1,2,18,19,165–167 Two of the references165,166 reported on the same set of guidelines but both were
available only as conference abstracts, limiting the information that could be extracted from them.
Of the remaining five references, one was a general document which included guidelines for all types of
extravasation injuries,2 one focused on a paediatric population,19 and the remaining three limited their
scope according to the type of fluid extravasated.1,18,167
Great Ormond Street Hospital published a set of guidelines online, which cover the prevention, recognition
and management of extravasation injuries.2 The guidelines emphasised the need for immediate
management of extravasation injuries by immediately stopping the infusion and aspirating the area of the
wound, but the device should not be flushed. Plastic surgeons should determine treatment which includes
analgesia, as required; elevation of the affected limb; conservative management, which may involve the
use of hot or cold compresses, or antidotes; and saline wash-out. Extravasation kits should be available to
the plastic surgeon. This guideline made reference to only a few studies that its recommendations were
based on. It did not clarify the basis by which studies were selected, and the quality (i.e. strengths/
weaknesses) of the studies was not assessed or discussed. The guideline did not state the circumstances
where they are best applied and did not report on the potential harms or side effects that may occur from
the listed treatments.
Flemmer and Chan19 limited their guidelines to the management of extravasation injuries in paediatric
populations. Their article described a hospital treatment protocol developed to identify and treat
extravasation injuries. Consistent with other guidelines, they reported on the inconsistency of approaches
but discounted the practice of injecting treatments around the infiltrated site, as they argued this made
infection and skin breakdown more likely. Rather, they proposed aspirating the wound to remove the
extravasated fluid, then infiltrating it with the chosen treatment. They emphasised that appropriate
treatment is dependent on the degree of severity of the wound, indicating that a stage 1 or 2 infiltrate can
SCOPING REVIEW OF TREATMENTS FOR EXTRAVASATION INJURIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
normally be managed conservatively through elevation. They stated that warm or cold packs have not
been shown to significantly alter the clinical course. They recommended a more aggressive approach to
treating stage 3 and 4 infiltrates, emphasising immediate and intrusive intervention. They recommended
hyaluronidase treatment within 2 hours of the injury, together with glyceryl trinitrate (a vasodilator).
Phentolamine was considered effective for treating vasoconstrictor extravasations.
Flemmer and Chan’s guideline19 is narrower in scope than Great Ormond Street’s guidelines and is,
therefore, somewhat clearer in defining the health question. They stated that they conducted a review of
the literature before creating the guideline but it is unclear if the recommendations are made on the basis
of the literature search or on the clinical experience of their team. Despite conducting a review, the criteria
on which they included studies, the nature of these studies and an assessment of their quality were not
reported in the article. Some potential adverse treatment effects were mentioned. The article was
published in 1993 and is, therefore, very likely to be out of date.
The guideline published by Bellin et al.18 was specifically targeted towards contrast medium extravasations.
They highlighted infants, young children, unconscious and debilitated patients as being particularly at risk
for these types of injuries. Those receiving chemotherapy were also considered at risk because of the
fragility of their vein walls. The guidelines stated that there is no consensus regarding treatment but that
most extravasations involve small amounts of fluid inducing minimal swelling or redness. However, they
emphasised that necrosis and ulceration do occur more commonly with high-volume extravasations than
with low-volume extravasations. Despite the acknowledgement of these risk factors, the guidelines argued
that it is not possible to predict whether these types of injuries will resolve or worsen at initial examination,
but skin blistering, altered tissue perfusion, paraesthesia and persistent pain after 4 hours suggest severe
injuries. They suggested that most contrast medium extravasations are not serious and only require
conservative management. Silver sulfadiazine ointment was recommended for blistering to prevent
secondary infections. Hyaluronidase injections (administered within 1 hour) have been used for large
extravasations of contrast medium and chemotherapeutic agents, although conflicting efficacy results have
been published.45–47 DMSO, corticosteroids and vasodilators were mentioned as potential treatments but
studies have either failed to demonstrate benefits or treatments have not been tested for extravasations of
this type.
Bellin et al.’s18 guidelines have a clear focus, acknowledge the limitations of the evidence and back up
statements by reference to relevant studies. However, similar to the previous guidelines, they do not assess
the quality of the studies they base their assertions on nor give the criteria with which they included these
studies. This guideline is also somewhat dated, having been published in 2002.
The guideline published by Pérez Fidalgo et al.,1 which focused primarily on chemotherapy extravasations,
emphasised the importance of classifying extravasated fluids by their potential to cause damage (vesicant,
irritant and non-vesicant categories were used). The authors noted a number of difficulties in recommending
appropriate treatment, including the lack of any RCTs, likely due to ethics complications and potential
difficulties in recruiting patients. The authors stated that an extravasation kit containing instructions, materials
and medication to handle any incidence should be always available. The guideline covered many treatment
options. Hydrocortisone injections have been shown to have some potential in preventing tissue necrosis
but intralesion corticoids seem to do more harm than good. Subcutaneous corticoids were, therefore, not
recommended. They reported that topical DMSO is an option for treating extravasation of anthracyclines,
mitomycin C or platin salts, but the concentration of the drug should be kept low (50%). Dexrazoxane was
also recommended for anthracycline extravasations. Hyaluronidase (injected through the existing i.v. line)
was recommended to prevent skin necrosis following vinca alkaloid extravasation. Subcutaneous wash-out
procedures were also reported to have shown encouraging results. The authors reported that around one-
third of cytotoxic extravasations lead to ulceration and, hence, surgical procedures should be limited to those
patients where conservative therapy has failed. They recommended surgical debridement of wounds
for unresolved necrosis lasting > 10 days, followed by a skin graft where necessary.
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These guidelines1 have a precise focus which, although making for a clear definition of the health
question, restricts the generalisability to a paediatric population. The authors made no mention of the
criteria with which they included the studies on which they based their recommendations. They did,
however, provide details of the included studies and made explicit links to the recommendations and the
supporting evidence. Levels of evidence gradings were also provided. The guidelines are also relatively
current, having been published in 2012.
In 2015, Boulanger et al.167 published a guideline on the management of antineoplastic agent
extravasations to inform clinical practice in Quebec. Studies were identified using a search of PubMed,
although few eligibility criteria were stated. Levels of evidence were used to grade recommendations.
Separate guidance was made for peripheral line and central line extravasations of specific chemotherapies.
Recommendations were similar to those published by Pérez Fidalgo et al.1 and included dry warm
compress, dry cold compress, DMSO, dexrazoxane and hyaluronidase. However, most recommendations
were based on studies supported by little or no empirical evidence.
Only abstracts were available for the remaining two guideline articles.165,166 An algorithm was developed
guiding wound care for three potential wound types but little detail was provided.165
Summary
Of the three reviews identified, none found any substantial comparative studies examining treatment
effectiveness.8,17,164 All reviews agreed that, although immediate treatment is needed for the best outcome,
there is no consensus regarding which treatments are the best practice. They all mention saline wash-out
with or without hyaluronidase as a frequently studied treatment, but no review could make conclusive
statements on its effectiveness compared with other treatments, because of the limited quality of evidence.
Seven published guidelines were discovered which detailed the management of extravasation
injuries.1,2,18,19,165–167 All were limited in their applications to different patient groups and few reported on
the potential harms or side effects that may occur from a particular course of treatment. In addition,
the criteria on which studies were included and an assessment of the quality of these studies were not
reported in any of the published guidelines. Their recommendations were often conflicting on treatments,
such as for saline wash-out,1,2 specific antidotes1,19 and conservative management. They did report some
similar findings on hyaluronidase as being an effective treatment and on corticosteroids as being an
ineffective treatment. They also agreed that treatment should be started as soon as possible after injury.
Overall, the results from the reviews and guidelines that included evidence from studies in adults add little
to the evidence seen in the primary studies in babies and children for identifying the most promising
treatments for extravasation injuries.
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Chapter 3 Survey of NHS practice
The primary aims of the survey were to determine how extravasation injuries in babies and youngchildren are treated across the NHS, and to elicit opinions regarding future research studies.
Methods
A survey questionnaire was designed and distributed using Qualtrics software (version May 2017;
Qualtrics, Provo, UT, USA). A systematic approach was used to develop the survey content which was
informed by initial findings from the scoping review, peer-to-peer consultation and patient and public
involvement feedback. The questionnaire was piloted among peers at neonatal and paediatric units in
York, Bradford and Leeds. Our aim was to distribute the survey via the e-mail lists of the National Neonatal
Audit Programme, the British Association of Perinatal Medicine (BAPM), the Neonatal Nurses Association,
the Paediatric Intensive Care Audit Network and the Children’s Cancer and Leukaemia Group (CCLG).
However, access could only be obtained to the BAPM and CCLG lists (for BAPM, the survey weblink was
sent as part of an e-mailed newsletter).
Therefore, we had to utilise our extensive personal contact e-mail lists to achieve adequate distribution of
the survey. This list was comprised primarily of consultant neonatologists, consultant paediatricians and
consultant paediatric oncologists. A snowballing approach was adopted, with the e-mail recipients asked
to either complete the questionnaire or to forward the link to another appropriate member of staff.
Responses were made anonymously, although responders had the option of providing an e-mail address
should they wish to be notified about the publication of this report. As such, and bearing in mind the
survey link was also sent out in a BAPM newsletter, it was not possible to calculate an overall response
rate. The survey was distributed between May and August 2017.
The survey asked questions about the use of guidelines for treating extravasation injuries, types of injury,
frequency of use of specific treatments, litigation cases and thoughts on future research priorities/
preferences. The full content of the questionnaire can be found in Appendix 4. No imputations were used
for missing data in partially completed questionnaires. Data were assumed to be missing at random, with
the most likely reasons for missing data assumed to be lack of time (the questionnaire was begun but
the respondent did not have time to complete it) and a lack of information or knowledge (to hand) to
complete the survey.
Results were analysed and presented narratively, with accompanying figures where appropriate. The unit
of analysis was at the individual level for all questions, except for questions relating to unit-level protocols
and lists; for these unit-level analyses, if any responses from within the same unit were found to be
contradictory the response from the most senior individual was used.
Results
A total of 63 questionnaires were received from 56 different hospitals. Fifty-five questionnaires (87%) were
fully completed and eight (13%) were partially completed. Key summary results relating to each question
are presented below. Additional results data for some questions are reported in Appendix 5.
Respondent characteristics
Forty-eight (76%) questionnaires were received from units in England, six (10%) from Scotland, five (8%)
from Northern Ireland and two (3%) from Wales. Although the survey was intended to be only of NHS
units, the snowballing approach used resulted in two responses from outside the NHS: one from the USA
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and one from Canada. Given that the responses on these two questionnaires were broadly in line with
those from other questionnaires, these data were included in our analyses.
Forty-five (71%) responses were from neonatal units, 13 (21%) were from principal oncology/haematology
units and five (8%) were from paediatric intensive care units (PICU). Most responders were either consultant
neonatologists (31 responders, 48%), nursing staff (10 responders, 16%) or consultant paediatricians (eight
responders, 13%). Details of all responder positions are presented in Table 8.
Hospital unit documentation
Does your unit have a written protocol or guideline for treating extravasation injuries?
This answer was analysed at the hospital-unit level (rather than by individual respondents). Overall, of the
57 unit responses to this question, 47 (82%) said they had a written protocol or guideline, nine (18%) said
they did not and one (2%) did not know. In neonatal units, 29 (73%) had a written protocol or guideline,
10 (25%) did not and one unit (3%) did not know. All 13 principal oncology/haematology units and all
four PICUs had a written protocol or guideline. Units answering ‘yes’ to this question were then asked
about the inclusion of an injury severity staging system.
Does the protocol or guideline contain a staging system for grading severity of extravasation injury?
Of the 30 responses from neonatal units, 11 (37%) were ‘yes’, 16 (53%) were ‘no’ and three (10%) were
‘do not know’. Of the 13 principal oncology/haematology unit responses, 5 (38%) were ‘yes’ and 8 (62%)
were ‘no’. Of the four PICU responses, one was ‘yes’ and three were ‘no’.
Does your unit have a list which identifies infusates which may cause serious problems when extravasated?
Overall, of the 55 units responding, 39 (71%) did have a list and 16 (29%) did not have a list. For
neonatal units, 23 had a list and 16 did not. All 13 principal oncology/haematology unit responses and all
three PICU responses were ‘yes’.
TABLE 8 Positions of survey responders
Position Number (%) of responders
Consultant neonatologist 31 (48)
Nursing staff 10 (16)
Consultant paediatrician 8 (13)
PICU consultant 4 (6)
Consultant paediatric oncologist 2 (3)
Clinical nurse educator 2 (3)
Specialist registrar 2 (3)
Associate specialist 1 (2)
Paediatric registrar 1 (2)
Ward manager 1 (2)
Neonatal midwife 1 (2)
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Injury parameters
Please select the type of access site most associated with extravasation injuries in your unit’s patients.
Of the 42 responses from individuals in neonatal units, 40 (95%) chose peripheral line and two (5%)
chose peripheral central line. Of the 13 principal oncology/haematology unit responses, eight (62%) chose
peripheral line, three (23%) indicated that extravasation injuries were too rare to choose an access site
option, one (8%) chose central line and one (8%) did not know. All five PICU responses were peripheral line.
Please select the type of infusate which causes the largest proportion of all the extravasation injuries in
your unit’s patients.
For this question, more than one answer could be selected if the proportions were equal. For neonatal
units, 29 out of the 59 answers (49%) identified parenteral nutrition as the infusate causing the largest
proportion of injuries. Other infusates were calcium (nine answers, 15%), blood (8 answers, 14%), do not
know (5 answers, 8%), antibiotics (3 answers, 5%), inotropes or pressors (2 answers, 3%), 10% dextrose
(2 answers, 3%) and caffeine (1 answer, 2%).
Vesicant chemotherapies caused the largest proportion of injuries in principal oncology/haematology units
(9 out of 17 answers, 53%), followed by non-vesicant chemotherapies (three answers, 18%) and blood,
saline and sodium bicarbonate (one answer each). One respondent opted for ‘do not know’ and one
noted that there were ‘too few incidents to comment’. The seven PICU answers varied, without any
infusate dominating; they included parenteral nutrition, calcium, antibiotics, 10% dextrose, ‘sodium
benzoate, phenytoin, acyclovir’ and ‘i.v. fluids’.
The following question was asked of those responders selecting parenteral nutrition/calcium/blood or
vesicant chemotherapies for the previous question:
What proportion of the extravasation injuries in your unit would you estimate is caused by extravasation of
infused parenteral nutrition/calcium/blood/vesicant chemotherapies?
Of the 29 responders from neonatal units who said that parenteral nutrition caused the largest proportion
of injuries, most indicated that these injuries constituted a large or very large majority of all the
extravasation injuries encountered (Figure 2).
0
2
4
6
8
10
12
14
75 – 100 50 – 74 25 – 49 11 – 24 1 – 10 Not sure,
but > 50
Not sure,
but < 50
N
u
m
b
e
r 
o
f 
su
rv
e
y
 r
e
sp
o
n
d
e
rs
Percentage of extravasation injuries
FIGURE 2 Percentage of neonatal unit extravasation injuries caused by parenteral nutrition in units indicating
parenteral nutrition as the main cause of injuries.
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For the neonatal unit calcium extravasation responses, 5 out of 9 chose the 75–100% option. For the eight
blood extravasation responses, the proportions were more varied (see Appendix 5). Of the principal
oncology/haematology unit responses which indicated that vesicant chemotherapies caused the largest
proportion of extravasation injuries, 6 out of 9 indicated that the proportions were large (see Appendix 5).
Interventions used to treat extravasation injuries
Please consider the list below of possible treatments for extravasation injuries. How frequently is each of
them used in your unit?
The results of neonatal unit responders are reported in Table 9. The most frequently used intervention
approaches were elevation of the affected area and administration of analgesics. In most units, warm or
cold compresses were rarely or never used. There was notable variation across the responses regarding the
use of occlusive dressings, ranging from always being used (8% of responses) to never being used (31%
of responses). Variation in the use of saline irrigation, either with or without hyaluronidase, was also
evident; these interventions seem to be either usually used or sometimes used in around half of neonatal
units, although they are never used in around one-third of units. Results for principal oncology/
haematology units (Table 10) and PICUs (Table 11) were broadly similar to the neonatal units results.
However, there were some key differences in the principal oncology/haematology unit responses, including
a more widespread use of cold and warm compresses and the use of antidotes to specific infusates.
Approximately what proportion of extravasations injuries that you have actively treated have resulted in a
need for plastic surgery at any stage?
Forty-four of the 59 responders (75%) answered ‘< 5%’. Nine responders (15%) did not know. Four
responders answered ‘5–24%’ (three were from neonatal units) and two responders answered ‘> 50%’
(one each from a PICU and a principal oncology/haematology unit).
Litigation
In the last 10 years did any of the extravasation injuries which occurred in your unit result in litigation?
Of the 59 responses to this question, 30 (51%) answered ‘no’, 23 (39%) answered ‘do not know’ and six
(10%) answered ‘yes’. The litigation cases related to injuries in three neonatal units, two PICUs and one
principal oncology/haematology unit.
TABLE 9 Extravasation injury treatments used in neonatal units
Treatment
Number of responses (% of total) Total
number of
respondersAlways Usually Sometimes Rarely Never
Elevation of affected area 12 (29) 12 (29) 13 (31) 4 (10) 1 (2) 42
Warm compress 1(3) 2 (6) 3 (8) 13 (36) 17 (47) 36
Cold compress 1(3) 0 3 (9) 11 (33) 18 (55) 33
Analgesia 9 (21) 19 (45) 10 (24) 4 (10) 0 42
A specific topical cream or ointment 0 3 (8) 7 (19) 6 (17) 20 (56) 36
Occlusive dressing 3 (8) 6 (15) 8 (2) 10 (26) 12 (31) 39
Saline irrigation without hyaluronidase 0 6 (15) 15 (38) 5 (13) 13 (33) 39
Saline irrigation with hyaluronidase 2 (5) 9 (23) 11 (28) 7 (18) 11 (28) 40
Antidotes to specific infusates 0 2 (6) 2 (6) 7 (20) 24 (69) 35
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For those units which indicated there had been litigation, the following question was asked:
How many litigation cases were there in the last 10 years?
Four units reported one case, one unit did not know the number of cases and one PICU reported six cases.
Research
Regarding a future research study in this area, do you think a randomised trial design can be successfully
undertaken to compare different treatments for extravasation injuries in babies and young children?
Of the 57 responses, 37 (65%) thought a future RCT might be viable, 12 (21%) did not think a RCT was
viable and eight (14%) did not know. However, the results varied by setting; the proportion answering
‘yes’ to this question was 83% of the 40 neonatal unit responses, 33% of the 12 principal oncology/
haematology unit responses (33% also responded ‘no’ and 33% responded ‘do not know’) and 0% of
PICUs (of the five responses, three thought ‘no’ and two ‘do not know’).
TABLE 10 Extravasation injury treatments used in principal oncology/haematology units
Treatment
Number of responses (% of total) Total
number of
respondersAlways Usually Sometimes Rarely Never
Elevation of affected area 4 (40) 3 (30) 2 (20) 1 (10) 0 10
Warm compress 2 (22) 1 (11) 5 (56) 0 1 (11) 9
Cold compress 3 (33) 0 5 (56) 0 1 (11) 9
Analgesia 6 (67) 1 (11) 2 (22) 0 0 9
A specific topical cream or ointment 3 (33) 1 (11) 3 (33) 0 2 (22) 9
Occlusive dressing 0 0 3 (38) 1 (13) 4 (50) 8
Saline irrigation without hyaluronidase 1 (11) 0 2 (22) 2 (22) 4 (44) 9
Saline irrigation with hyaluronidase 2 (22) 1 (11) 3 (33) 1 (11) 2 (22) 9
Antidotes to specific infusates 3 (50) 0 1 (17) 0 2 (33) 6
TABLE 11 Extravasation injury treatments used in PICUs
Treatment
Number of responses (% of total) Total
Number of
respondersAlways Usually Sometimes Rarely Never
Elevation of affected area 4 (80) 1 (20) 0 0 0 5
Warm compress 0 0 0 1 (25) 3 (75) 4
Cold compress 0 0 0 2 (50) 2 (50) 4
Analgesia 3 (60) 1 (20) 1 (20) 0 0 5
A specific topical cream or ointment 1 (25) 0 0 2 (50) 1 (25) 4
Occlusive dressing 0 0 0 2 (40) 3 (60) 5
Saline irrigation without hyaluronidase 1 (20) 0 3 (60) 0 1 (20) 5
Saline irrigation with hyaluronidase 2 (40) 0 2 (40) 1 (20) 0 5
Antidotes to specific infusates 0 0 1 (33) 0 2 (67) 3
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For those who thought a future RCT was viable, the following question was asked:
Please tell us which treatment(s) you would most like to see studied in a randomised trial.
This was answered using a free text field. Almost all of the 28 responders mentioned one or more
treatments: saline irrigation/wash-out, hyaluronidase and conservative management. Few details were
given about conservative management approaches, although dressings, analgesia and hydrocolloid were
mentioned. Two responders suggested trialling glyceryl trinitrate (GTN): comparing its use with no GTN, or
compared with wash-out. The results are best summarised as a word cloud (Figure 3).
For those respondents who thought a future RCT was not viable, the following question was asked:
It would be helpful if you could say why a randomised trial design might not be viable. If you have any
thoughts on alternative study designs, which you think might be more appropriate, please also state
them here.
Of the five responders from neonatal units who did not think a RCT was viable, four provided further
details. Two responders referred to there being too many variables, in terms of types of injury and other
clinical factors (beyond infusate and volume) which could affect outcomes. One responder noted that, for
total parenteral nutrition, the infusates may ‘be very different day by day, or between units’. Issues around
timeliness of treatment when using randomisation, low numbers of patients and unwillingness to deviate
from current practice were also stated as potential problems.
All the responders from principal oncology/haematology units (n = 4) and PICUs (n = 3) who did not think
a RCT was viable provided further details. In principal oncology/haematology units, the rarity of extravasation
events was mentioned as a potential problem by two responders. Reluctance to deviate from current practice
(‘procedures which are currently working well’) was mentioned by the other two responders; the exception
was blood transfusion extravasations where there were no guidelines on appropriate management
(mentioned by one responder). In PICUs, the low incidence of injuries was raised as an issue. One responder
thought that, although there was no equipoise for a placebo controlled trial, a comparison between two
therapeutic options might be viable.
FIGURE 3 Word cloud representing treatment suggestions for a randomised trial.
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Are you aware of any summary data on the effectiveness or safety of treatments for extravasation injury
which we are unlikely to have been identified in our searches of literature databases (e.g. unpublished data)?
None of the 55 responders were aware of any unpublished summary data (46 responded ‘no’ and nine
responded ‘do not know’).
Any other comments or suggestions about this study?
Three principal oncology/haematology unit responders mentioned how rare extravasation injuries were,
with two stating that they were so rare they struggled to provide answers for some questions (other than
‘do not know’). Three neonatal responders also mentioned the rarity of extravasation events, especially
significant injuries (in other words, most of the injuries seen in practice are mild).
One principal oncology/haematology unit responder wanted to stress that their treatment protocol
describes very specific management based on the infusate. A responder from a neonatal unit thought that
the use of BadgerNet© (Clevermed Ltd, Edinburgh, UK) data would be good in order to study variation in
the incidence of extravasation injuries (and the possible reasons for variation).
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Chapter 4 Discussion
Principal findings
The evidence identified in the scoping review mostly comprised small, retrospective, uncontrolled group
studies (such as case series) or case report studies. Although the published studies covered a wide range
of treatments for extravasation injuries, few studies formally graded injury severity at baseline and the
results sections of most studies were brief and lacking important information. Furthermore, there was
considerable clinical heterogeneity across study populations in age, types of infusate, injury severity,
location of injury and the time gaps between injury identification and subsequent treatment. Differences
in results across studies might be a reflection of variation in one or more of these parameters, rather than
differences in treatment effect. Consequently, uncertainty exists regarding which treatments may be the
most promising, particularly with respect to how to treat earlier stage injuries (i.e. injuries which have not
become necrotic). Notwithstanding the study limitations, some of the better evidence, in terms of study
size and a prospective design, related to studies of flush-out techniques, which appear to be quite
promising treatments. However, the effect of prior infiltration with hyaluronidase before flush-out is
unclear.
The use of a scoping review, rather than a full systematic review, to assess the literature was justified on
the expectation that any review was very unlikely to produce evidence robust enough to allow treatment
recommendations to be made with sufficient confidence. Scoping reviews are broader and more
exploratory in nature than full systematic reviews. They are often undertaken when an evidence base is
expected to be either very large or have important limitations; the latter being the case for this review.
The NHS survey results showed that, although most units (82%) had a written protocol or guideline for
treating extravasation injuries, a staging system for grading severity of extravasation injury was included in
just over one-third of protocols or guidelines. Almost all responders indicated that peripheral lines were the
access site most associated with extravasation injuries. In neonatal units, parenteral nutrition caused the
largest proportion of extravasation injuries, whereas in principal oncology/haematology units, the largest
proportion of injuries was due to the extravasation of vesicant chemotherapies.
The survey showed that the most frequently used intervention approaches were elevation of the affected
area and analgesics. The results also revealed that, in most units, warm or cold compresses were rarely or
never used. In neonatal units, there was notable variation regarding the use of occlusive dressings, ranging
from always being used (8% of responses) to never being used (31% of responses). Variation in the use of
saline irrigation (or wash-out), either with or without hyaluronidase, was also evident; these interventions
seem to be usually or sometimes used in around half of the neonatal units, although they are never used
in around one-third of units. Results for principal oncology/haematology units and PICUs were broadly
similar to the neonatal unit results.
When asked about a future research study, most responders (65%) thought a RCT would be viable,
although these results varied by setting: 83% of neonatal unit responses, 33% of principal oncology/
haematology unit responses and 0% of PICUs. Almost all the responders who thought a RCT was viable
mentioned one or more of the following treatments when asked which treatments they would most like
to see studied: saline irrigation/wash-out, hyaluronidase and conservative management. Of those who
thought a RCT was not viable, the reasons included too many variables which could affect outcomes,
timeliness of treatment when using randomisation, low numbers of patients and unwillingness to deviate
from current practice.
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Strengths and limitations
The scoping review was performed using systematic, reproducible, transparent and robust methods. Our
bibliographic database searches were comprehensive to allow identification of all relevant published
studies and searches were also made to identify any unpublished studies. These methods minimised the
possibility of publication or language biases affecting the review. The possibility of reviewer errors and
biases affecting this review were minimised by performing review processes in duplicate. The sample for
our NHS survey was large and diverse enough to be representative of NHS staff who treat extravasation
injuries. The main limitation of the scoping review related to the evidence identified. Most studies were
limited in helping to evaluate which treatments might be best and also in presenting ideas regarding which
direction future research studies should take.
Patient (parent) and public involvement
Extravasation injuries are quite rare events and patient groups specifically in this area do not exist.
However, one of our clinical team discussed this study with the parents of an infant who had suffered a
severe extravasation injury. This proved to be useful in informing the survey content. For example, in the
section of the survey where we asked questions about how frequently specific interventions were used,
there was initially no question about use of analgesics. The importance of pain relief was emphasised by
this parental input and, consequently, a question on analgesic use was added to the survey.
Future research on treatments for extravasation injuries
The survey results indicated that, across NHS neonatal units generally, there was optimism about
randomised trial feasibility, although this was not the case for other types of units. The scoping review
studies yielded little information about future research. Only three of the comparative or non-comparative
studies mentioned issues relating to research study design.31,39,40 In two studies, this was very brief: mention
was made of the need for a prospective controlled study for confirmation of findings,40 and that a
randomised trial was not possible because of the low incidence of injuries.39 The authors of the third study
commented, somewhat vaguely, that optimal management is uncertain because of ethics considerations
limiting controlled research, although they added that a centralised register of extravasation events would be
a useful means to monitor, assess and review outcomes.31 One of the systematic reviews (of chemotherapy
extravasations) also discussed the challenges of undertaking further research, noting key issues which may
preclude the use of a randomised design.164 These included the sporadic occurrence and low incidence of
extravasations, and the complexity involved in controlling the many extraneous variables associated with
extravasations: age, sex, comorbidities, type of infusate, site and volume of extravasation and time to
intervention. The authors commented that the sample size required to properly control for these factors will
probably be prohibitively large. Notwithstanding the discussion in this systematic review,164 the very limited
insight on future research provided by the scoping review studies means that further exploration is needed.
This is in relation to decisions regarding the study design, treatments to be studied, population to be studied
and the outcome measures needed. Such decisions should not be made independently of each other. For
example, a randomised trial would probably involve fewer, and more defined, interventions and a narrower
population than an observational database study. As these two study designs, randomised trial and a
database study, appear to be important options for any future study, the key issues relating to each will be
discussed to help inform a decision on future research.
Randomised trials
Exploration of feasibility issues
Treatment delays and selection bias
Extravasation injuries require urgent treatment. The time gap between identifying and treating an injury
is a key factor which determines important clinical outcomes. However, the process of recruiting and
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randomising patients into a clinical trial often results in treatment delays. Initial delays may arise when
ascertaining whether or not a patient is eligible to participate. For those who are eligible, further delays
may arise from the randomisation process. This is most likely to occur where the procedure of allocating
treatment is performed in real time. For example, some delay would be inevitable when contacting a
central randomisation service provider, either via the internet or by telephone. The scoping review
identified that the time delay between injury identification and treatment varied widely across studies.
Important questions when considering trial procedures are ‘what is the typical time gap between
identification and treatment of an injury in the NHS?’, and, ‘is this short enough to accommodate a delay
due to randomisation?’ (i.e. would the randomisation delay be acceptable or difficult to justify clinically?).
Arguably, the most impressive results identified in the scoping review were from a study in which neonates
with stage III and IV injuries were treated within just 10–30 minutes of injury.4
A frequently used method of randomisation is the use of sequentially numbered, opaque, sealed envelopes
containing randomly generated treatment allocations. Adoption of this method might minimise such delays,
but this approach has been demonstrated to be prone to investigator selection bias. Reports of surgeons
opening envelopes in order to subvert randomisation, and of trials using sequentially numbered, opaque,
sealed envelopes being more likely to show statistically significant treatment effects than trials using more
secure allocation methods, suggest that envelope-based methods should be used cautiously.168 The risk of
bias might only be reduced when the personnel with access to the envelopes are different from those
actually recruiting participants. Of course, having an added layer of trial personnel involved in the recruitment
process might itself add to treatment delays (and also to the administrative cost and burden of the trial).
However, these concerns may have more limited relevance to trials performed in emergency or urgent care
settings, where there is some evidence to suggest that the risks of selection bias may be low.169
In trials where interventions exist in discrete packs and look indistinguishable from each another, or can be
made to look so, a different type of time-saving method may overcome concerns about using envelopes.
In this approach, randomisation identification labels which are pre-coded would be attached to
‘extravasation kits’ which would then be placed in order and allocated to patients sequentially. The pre-
coded labels would be meaningless to the investigator, who would have only very restricted access to the
randomisation coding system (e.g. where a serious adverse event was suspected). Heat-sealed bags could
be used to reduce the risk of tampering and subverting the randomisation sequence. This type of method
should obviate concerns about both selection bias and delays in receiving treatment as a result of
randomisation because the randomisation process would simply involve the next kit being taken, used
and recorded.
Nevertheless, many interventions cannot be code labelled as identical-looking, discrete packages, for
example, different types of debridement or surgery. In these situations, a real-time randomisation process
may be needed, which could lead to treatment delays. A possible alternative here might be the use of
quasi-randomisation methods. This typically involves the use of a pre-defined participant or setting characteristic,
such as date of birth or day of the month, to determine treatment allocation (e.g. odd days indicate treatment
A and even days treatment B). The scoping review identified an old quasi-randomised trial reported by Brown
et al.55 which allocated treatment according to calendar month. Quasi-randomised studies often allocate
treatments based on day of the month, but, given the scarcity of extravasation events, this idea of using
alternate months seems a pragmatic approach to recruitment and treatment allocation. Quasi-randomisation
would solve the time delay issue, but the selection bias issue would remain; however, as already noted, the
risks of selection bias appear to be low in urgent care trials.
The requirement for urgent treatment also raises the issue of consent to participate, as this might also lead
to treatment delays. However, in urgent care settings, a case can be made for using deferred consent,
rather than prior consent. Deferred consent enables children to be included in trials without prior informed
parental/carer consent, but requires such consent to be acquired as soon as possible for continued trial
participation.
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Recruitment
Perhaps the most important barriers to successfully executing a randomised trial are those which hinder
the accrual of enough participants to yield meaningful and reliable results. Extravasation injuries are quite
rare events which are also subject to variation, particularly in terms of patients (ages, comorbidities),
causes (infusates), injury sites and severities and the speed at which injuries are detected and treated.
Consequently, careful consideration would be needed when devising trial eligibility criteria to enable the
recruitment of both a sufficiently homogeneous sample of participants and a sample which would be large
enough to minimise the impact of chance differences across treatment groups in any of these factors.
Failure to do so would increase the risk of false-positive trial results; small trials are more prone to yielding
chance results than larger trials.
It is likely that a large number of participating hospital sites would be needed to allow adequate
recruitment. Although the scoping review focused on children, it also involved an informal assessment of a
broader range of papers on extravasation treatments in adults; however, only one randomised trial was
identified.170 The trial, reported as a conference abstract, compared different cooling treatments for
doxorubicin extravasation; after 7 years, only 37 patients had been randomised (the study began in 1987
and ended in 1994).171 This example serves to highlight the recruitment difficulties which might be
encountered in any future RCT in children.
The discontinuation of randomised trials wastes research resources and also raises ethical concerns.
A study of 1017 RCTs172 found that 25% were discontinued, the most frequent reason being poor
recruitment (occurring in 10% of the 1017 trials). Trials discontinued because poor recruitment achieved
a median percentage of target sample size of 41%. Trials with investigator sponsorship (compared with
industry sponsorship) and trials with smaller planned sample sizes were at higher risk of discontinuation
because of poor recruitment. A UK HTA study of 114 multicentre RCTs,173 which were funded by the
Medical Research Council or the NHS (HTA), found that less than one-third of trials recruited their original
target within the time originally specified and around one-third had extensions. The following factors were
observed more frequently in trials that recruited successfully: having a dedicated trial manager, being a
cancer or drug trial and use of treatments only available within the trial setting. Results from a survey of
181 principal investigators in a large US paediatric hospital174 found that the method of recruitment
appeared to be the only significant and independent factor associated with achieving 80% or more of
target enrolment; protocols that used recruitment in person were 4.6 times (95% confidence interval
1.3 to 15.9; p = 0.02) more likely to achieve 80% or more of their target enrolment when compared with
those that used other recruitment methods. Utilisation of electronic data recorded in clinical practice
databases or registries could reduce recruitment problems; therefore, randomised registry trials, sometimes
referred to as pragmatic randomised electronic point of care trials, may be a useful approach and will be
discussed in Database studies.
Alternative trial designs to maximise recruitment Small sample sizes are a common problem in
paediatric trials, which, consequently, are often insufficiently powered to detect true treatment effects.
Innovative approaches may, therefore, be considered to overcome this issue.175 Sample size estimation
can be a particular challenge when designing paediatric trials; this would be an issue for any trial of
extravasation treatments because the effectiveness data available to inform such calculations will be
minimal. However, in trials using a ‘sequential’ design, the sample size at the end of the trial is not known
at the beginning; trial stopping rules are defined based on the accumulated data and, therefore, trials can
end on the basis of efficacy or futility. This design may be suitable in trials where outcome results are
available quickly in relation to the patient recruitment rate. Analyses from a systematic review of paediatric
sequential trials176 (24 were published between 1963 and 2005) indicated a median reduction in sample
size of 52 subjects (range −22 to 229 subjects) or 35% (range −42% to 90%) for sequential trials when
comparing with a classical fixed sample size approach. Only nine trials reported sufficient information
about assumptions to allow calculation of a corresponding fixed sample size. Thirteen of the 24 trials were
performed in a NICU setting. Although for any given sequential trial it remains a possibility that the
eventual sample size may turn out to be larger than the fixed sample size, it is evident that fewer patients
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are generally necessary to reach a conclusion, compared with a fixed sample size design, thus providing
some ethical advantages. The unknown sample size at the start of sequential trials may be problematic for
funders, although some trials pre specify a maximum number of participants.176
Another strategy to address likely sample size problems is responsive–adaptive randomisation: a ‘play the
winner’ approach that maximises allocation to the most effective treatment. Outcomes for previous
participants affect subsequent treatment allocation probabilities. This design is, therefore, also limited to
studies which assess outcomes quite quickly. However, the Food and Drug Administration177 has expressed
concerns regarding the magnitude of the risk of bias and the size of the potential bias, and how to
eliminate these effects, as they are not yet well understood for adaptive trial designs.
Blinding
A lack of blinding (also known as treatment masking) could be a source of bias in a trial of treatments for
extravasation injuries. Although blinding would certainly be possible for some treatments, for example,
hyaluronidase injections, where placebos could be used, it would not be viable for others, for example,
when comparing saline flush-out with a conservative management intervention. In an extravasation trial of
infants, there would be two mechanisms by which a trial might be biased by lack of blinding. First, via
systematic differences between the care provided (e.g. cointerventions) to the different treatment groups
(i.e. performance biases), and second, where outcomes assessors are aware of intervention assignments
(i.e. detection biases). For example, detection bias may occur where it would be possible to distinguish
between an injury treated with saline flush-out, which may still have puncture marks, and one treated with
conservative management, which will not. With this in mind, it is not helpful that most outcomes in an
extravasation trial would be subjective in nature (e.g. scarring, wound healing time). However, the risk of
detection bias can be considered to be low if the outcome assessor used is an independent researcher,
rather than a trial investigator; the latter may have treatment preferences, the former probably would not.
Blinded assessment of photographs may also be a useful way of evaluating wounds over time. The use of
parental assessment of outcomes could also be considered. An evaluation of performance bias can be
made by recording, and later assessing, any deviations in the care provided which are beyond what would
be expected in usual practice.
Treatments, populations and outcomes
The low rates and sporadic incidence of extravasation injuries are important issues to consider in any future
research; this was evident from the survey where low incidence of injuries was noted several times as a
barrier to a RCT, particularly any trial involving principal oncology/haematology units. As outlined in
Chapter 1, Prevalence of extravasation injuries and risk factors, the incidence of extravasation injuries
seems to be higher in preterm neonates (particularly those receiving an i.v. intervention at a peripheral site)
than in other infants, making this, perhaps, the most viable population for a randomised trial. Restriction
to parenteral nutrition infusions should further reduce population heterogeneity, although one survey
respondent noted that, even here, there may be significant heterogeneity to overcome. Our survey results
indicate that parenteral nutrition infusions at peripheral sites are the most frequent cause of extravasations
in neonates. It is unclear, however, whether the preterm neonate population would be large enough for a
randomised trial. The severities of injury to include in a trial would depend on the treatments being studied
and on which paediatric injury grading scale is adopted.3,15
For a preterm neonate population, the likely treatments to compare could be a specific form of
conservative management compared with a saline flush-out technique. This is based on both the scoping
review and survey results. The parameters used for saline flush-out can vary, such as the number of
puncture points and the volume of saline; fewer puncture points and lower volumes (than is used for older
infants) would seem appropriate in preterm neonates.
Although it is medically plausible to expect that prior hyaluronidase injection plus saline flush-out may
be more effective than saline flush-out alone, there is little robust clinical research evidence to support
this. The magnitude of any differences in outcome between these treatments could be small; therefore,
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a sizeable trial would be needed to allow such a difference to be demonstrated. Also, the appropriateness
of using hyaluronidase in pre-term neonates is unclear. One study included in the scoping review noted
that infiltration with hyaluronidase is an invasive procedure and the British National Formulary46 has advised
caution in the use of hyaluronidase in infants and to control the speed and total volume of injection.
The degree of scarring following extravasation injury treatment will be an important outcome in any future
study. In the scoping review, very few studies quantified scarring outcomes. Several measures exist for
assessing scarring, but there is little consensus as to which is the optimal scale or tool to use.178 A gold
standard scar scale does not currently exist, although, ideally, such a scale should address cosmetic,
functional and psychological sequelae.179 Outcomes which involve parental evaluation, in addition to
clinician evaluation, should also be considered for certain assessments, including scarring. The reliability
and validity of outcome measures would need to be established for use in neonatal populations.
Database studies
Exploration of feasibility issues
A prospective database or registry study may be appropriate where a randomised trial is not considered
to be viable for practical reasons. A database study would likely result in a larger sample than would be
obtained in a RCT because of simpler recruitment processes and a broader population from which to
recruit. The downside, or trade-off, with adopting such a non-randomised approach to comparing
interventions is that the results would inherently be less reliable than those of a RCT; although, as
previously discussed, RCTs which do not recruit enough participants may also produce unreliable results.
The most important methodological difference between randomised and non-randomised studies arises
as a result of confounding, caused by selection bias, which will often be encountered in non-randomised
studies. Methods exist to adjust for confounding, such as regression analysis, propensity scoring,
instrumental variables, stratification and matching, but it is unclear which methods are most appropriate
in any given circumstance.180 When aiming to generate believable estimates from non-randomised studies,
it is necessary to identify the important confounding factors which need to be measured validly and
precisely.181 The risk of confounding arising from some factors might also be reduced by narrowing eligibility
criteria. This would, however, limit the generalisability of the study results to wider patient groups.
However, we have already noted the extent of variation in important baseline characteristics in the studies
identified in the scoping review: consideration would be needed regarding adjustments for variation in
comorbidities, injury sites, methods of delivery, duration of i.v. therapy, the amount of fluid extravasated
(very difficult to estimate) and the speed at which injuries are detected and treated. It could, perhaps, be
argued that the latter four factors might be covered by use of a staging system for grading the severity of
injuries. However, our survey results indicate that most units do not use a staging system to grade injury
severity. Furthermore, variation is likely across units which do use such a system, since different approaches
to grading injury severity have been published (see Chapter 1). An observational database study would also
inevitably result in variation in the treatments given, even where they might be considered to be the same.
For example, for flush-out techniques, variation exists in the number of puncture points made and the
volume of saline used.
Nevertheless, a database study would be considerably cheaper to undertake than a randomised trial,
especially if it were to utilise existing relevant database facilities such as the UK National Neonatal Research
Database (NNRD). This database holds data entered by UK neonatal professionals. However, it does not
currently routinely record data on extravasation injuries.
Randomised registry trials
If such data were recorded in a database in the future, the possibility of a randomised registry trial (also
known as pragmatic randomised electronic point of care trials) could be explored, as the results of a UK
survey of neonatal health professionals suggest this approach would be both feasible and acceptable in
neonates.182 Randomised registry trials are pragmatic randomised trials performed in usual clinical care
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conditions, which utilise routinely collected data. Trial interventions fall within accepted professional
standards but, as yet, have uncertain comparative effectiveness. Ideally, the recruitment and follow-up
procedures would be naturalistic and mimic actual clinical decisions and practices, except for the
randomisation process.183
These trials use the registry as a platform for recruitment and trial administration. Theoretically, this
approach is appealing because it keeps the best aspects of both RCTs (i.e. robust, unbiased estimates of
effectiveness) and registry studies (i.e. larger sample sizes) and, consequently, dispenses with some of the
worst aspects (e.g. small samples with limited generalisability and estimates which are inherently unreliable).
Importantly, registry RCTs should also be cheaper and quicker to undertake than conventional RCTs. A more
detailed discussion of this trial design, including example trials, was published in 2016.184
Some of the challenges to consider when planning a registry RCT include ensuring that the data are of
high enough quality, consideration of blinding and the standardisation and adjudication needed for certain
outcomes.185 For any extravasation trial some key issues could include achieving a consistent use of a single
staging system to grade injury severity when recruiting patients, the degree of standardisation/consistency
needed when administering the studied treatments and the choice of outcome measures, which would
need to be clinically practicable yet also demonstrate adequate reliability and validity.
Treatments, populations and outcomes
The treatments, populations and outcomes most viable for a randomised registry trial would be the same
as those discussed in the previous section on randomised trials. But consideration should also be made
regarding which treatments and populations might be studied in a prospective observational (i.e. non-
randomised) database or registry study.
Usually, a key advantage of a prospective database study over a randomised trial is that a larger number of
treatment approaches and a broader population could be studied. However, in this area of research, such
benefits might, in reality, be quite small. Consider, for example, a population such as children receiving
i.v. chemotherapy. The scarcity of chemotherapy extravasations, evident from the survey, coupled with the
wide variation in infusates, subpopulations and injury treatment approaches, evident from reviews and
guidelines, mean that accruing a cohort sufficiently large enough to produce meaningful comparative
results may be very difficult. It is somewhat unclear to what extent this might be said for extravasations of
other infusates such as calcium, contrast agents and blood. In mitigation, database studies by their very
nature are able to accrue data over very many years. A database study might be useful for evaluations
where there is less variation in the treatment options available. For example, for injuries which have
become necrotic, comparison might be made of outcomes following different methods of debridement:
mechanical, enzymatic and surgical.
Although beyond the scope of this review, research is also needed on interventions to prevent extravasation
injuries. Ideally this would begin with a systematic review.
Summary
Careful thought is needed when considering any future comparative study of extravasation injury
treatments. Decisions regarding the study design, treatments, population and outcome measures should
not be made independently of each other. Some of the practicalities involved in undertaking a
conventional RCT, such as recruiting adequate numbers, avoiding treatment delays and selection bias,
could be difficult to overcome. Although a prospective observational database study would maximise the
number of patients recruited, and eliminate concerns about treatment delays, its results would inherently
be subject to uncertainty as a result of the likelihood of selection bias.
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Several alternatives exist to a conventional RCT design, which still include a randomisation element.
Perhaps the most promising is the randomised registry trial, which incorporates many of the best aspects
of both conventional RCTs and observational database studies. Although this design is relatively new,
and few trials have been performed, its relevance to a trial of treatments for extravasation injuries is
worthy of exploration. However, a key relevant database, the UK NNRD, does not currently record data on
extravasation injuries. Further issues to be considered in any randomised registry trial of neonates include
the lack of a protocol or guideline for treating extravasation injuries in 25% of units, and the absence of
the use of a staging system for grading injury severity in over half of the units which do have access to a
protocol or guideline.
The low rates and sporadic incidence of extravasation injuries and population heterogeneity are key issues
when considering the population to be studied. As such, preterm neonates receiving i.v. parenteral
nutrition at a peripheral site may perhaps be the most viable population for any randomised trial. The main
treatment candidates receive are a standardised conservative management intervention, saline flush-out
without hyaluronidase and saline flush-out with hyaluronidase; the choice of treatment would depend on
the injury severity grades chosen to be eligible for inclusion. A number of different methods exist for
grading injury severity, with variation likely across the NHS; for example, some units do not formally grade
injury severity. A paucity of standardised outcome measures used in previous studies in neonates is also a
concern. Outcome measures used in a future study would need to be clinically practicable yet also
demonstrate adequate reliability and validity.
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Chapter 5 Conclusions
A lthough studies exist that, together, cover a wide range of treatments for extravasation injuries, moststudies are small and lack comparator groups. The studies are also very varied in terms of patient,
intervention and outcome characteristics. The quality of evidence overall is, therefore, very low. Consequently,
there is uncertainty about which treatments are most promising, particularly with respect to treating earlier-
stage injuries. Notwithstanding the evidence limitations, the results of studies of flush-out techniques suggest
that these treatments may be worthy of further research. This finding was echoed in the NHS survey results,
with flush-out techniques, hyaluronidase and conservative management frequently suggested as being the
treatments where further study would be most worthwhile.
In planning a future comparative study of extravasation injury treatments, population heterogeneity and
low rates and sporadic incidence of injuries are key issues. The most viable population for any randomised
trial may, therefore, be preterm neonates receiving i.v. parenteral nutrition at a peripheral site. However,
a paucity of standardised relevant outcome measures used in previous studies in neonates is a concern.
Outcome measures used in a future study would need to be clinically practicable, yet also demonstrate
adequate reliability and validity. Some of the practicalities involved in undertaking a conventional RCT,
such as recruiting adequate numbers, avoiding treatment delays and selection bias, could be difficult to
overcome. Although a prospective observational database study would maximise the number of patients
recruited, and eliminate concerns about treatment delays, its results would inherently be subject to
uncertainty because of the likelihood of selection bias. An alternative to a conventional RCT design is the
randomised registry trial, which incorporates many of the best aspects of both conventional RCTs and
observational database studies. However, a key relevant database – the UK NNRD– does not currently
record data on extravasation injuries. Further issues to be considered in any randomised registry trial of
neonates include the lack of a protocol or guideline for treating extravasation injuries in 25% of units,
and the absence of the use of a staging system for grading injury severity in over half of the units which
do have access to a protocol or guideline.
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Appendix 1 Database search strategies
MEDLINE [Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)]
Via Ovid; http://ovidsp.ovid.com/.
1946 to present.
Searched on: 1 February 2017.
Records retrieved: 1969.
Search strategy
1. “Extravasation of Diagnostic and Therapeutic Materials”/ (3147)
2. extravasat$.ti,ab. (15,523)
3. (infiltrat$ adj2 (intravenous$ or IV or infus$ or catheter$ or cannula$)).ti,ab. (239)
4. infiltrat$ adj2 (injur$ or wound$)).ti,ab. (874)
5. ((intravenous$ or IV or infus$) adj2 leak$).ti,ab. (152)
6. (infus$ adj2 (injur$ or wound$)).ti,ab. (289)
7. (PIV adj2 (injur$ or wound$)).ti,ab. (2)
8. (PIV adj2 infiltrat$).ti,ab. (3)
9. (catheter$ adj2 (injur$ or wound$)).ti,ab. (708)
10. or/1-9 (19,211)
11. exp Child/ (1,703,797)
12. exp Infant/ (1,029,438)
13. Adolescent/ (1,782,430)
14. (child$ or infant$ or infancy or pediat$ or paediat$ or preschool$ or pre school$ or schoolchild$ or
school age$ or schoolage$ or schoolboy$ or schoolgirl$).ti,ab. (1,552,190)
15. (girl or girls or boy or boys or kid or kids).ti,ab. (201,718)
16. (adoles$ or young people or young person$ or teen$ or youth$ or preteen$ or juvenil$).ti,ab.
(345,875)
17. (neonat$ or neo nat$).ti,ab. (225,315)
18. (newborn$ or new born$ or newly born$).ti,ab. (146,891)
19. (preterm or preterms or pre term or pre terms).ti,ab. (58,825)
20. (preemie$ or premie or premies).ti,ab. (140)
21. (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (13,561)
22. (low adj3 (birthweight$ or birth weight$)).ti,ab. (29,760)
23. (lbw or vlbw or elbw).ti,ab. (6880)
24. (baby or babies).ti,ab. (60,639)
25. or/11-24 (3,777,516)
26. 10 and 25 (2131)
27. exp animals/ not humans/ (4,311,358)
28. 26 not 27 (1969)
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Key
/ = indexing term [medical subject heading (MeSH) heading]
exp = exploded indexing term (MeSH heading)
$ = truncation
ti,ab = terms in either title or abstract fields
adj2 = terms within two words of each other (any order)
British Nursing Index
Via ProQuest; www.proquest.com/.
1994 to present.
Searched on: 1 February 2017.
Records retrieved: 30.
Search strategy
(TI,AB(extravasat*) OR TI,AB(infiltrat* NEAR/2 (intravenous* OR IV OR infus* OR catheter* OR cannula*))
OR TI,AB(infiltrat* NEAR/2 (injur* OR wound*)) OR TI,AB((intravenous* OR IV OR infus*) NEAR/2 leak*)
OR TI,AB(infus* NEAR/2 (injur* OR wound*)) OR TI,AB(PIV NEAR/2 (injur* OR wound*)) OR TI,AB(PIV N2
infiltrat*) OR (catheter* NEAR/2 (injur* OR wound*))) AND ((SU.EXACT.EXPLODE(“Infants”) OR SU.EXACT.EXPLODE
(“Neonates”) OR SU.EXACT.EXPLODE(“Children”) OR SU.EXACT(“Adolescents”) OR SU.EXACT(“Neonates:
Birthweight”) OR TI,AB(child* OR infant* OR infancy OR pediat* OR paediat* OR preschool* OR pre-school* OR
schoolchild* OR school-age* OR schoolage* OR schoolboy* OR schoolgirl*) OR TI,AB(girl OR girls OR boy OR boys
OR kid OR kids) OR TI,AB(adoles* OR “young people” OR “young person” OR “young persons” OR teen* OR
youth* OR preteen* OR juvenil*) OR TI,AB(neonat* OR neo-nat*) OR TI,AB(newborn* OR new-born* OR “newly
born”) OR TI,AB(preterm OR preterms OR pre-term OR pre-terms) OR TI,AB(preemie* OR premie OR premies) OR
TI,AB(prematur* NEAR/3 (birth* OR born OR deliver*))) OR TI,AB(low NEAR/3 (birthweight* OR “birth weight” OR
“birth weights”)) OR TI,AB(lbw OR vlbw OR elbw) OR TI,AB(baby OR babies))
Key
SU.EXACT = subject heading
SU.EXACT.EXPLODE = exploded subject heading
TI,AB = terms in the title or abstract fields
NEAR/2 = terms within two words of each other (any order)
* = truncation
” “ = phrase search
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Cochrane Central Register of Controlled Trials
Via Wiley Online Library; http://onlinelibrary.wiley.com/.
Issue 1 of 12, January 2017.
Searched on: 1 February 2017.
Records retrieved: 200.
Search strategy
The strategy below was used to search CENTRAL and CDSR.
1. MeSH descriptor: [Extravasation of Diagnostic and Therapeutic Materials] this term only (54)
2. extravasat*:ti,ab,kw (312)
3. (infiltrat* near/2 (intravenous* or IV or infus* or catheter* or cannula*)):ti,ab,kw (41)
4. (infiltrat* near/2 (injur* or wound*)):ti,ab,kw (349)
5. ((intravenous* or IV or infus*) near/2 leak*):ti,ab,kw (7)
6. (infus* near/2 (injur* or wound*)):ti,ab,kw (154)
7. (PIV near/2 (injur* or wound*)):ti,ab,kw (0)
8. (PIV near/2 infiltrat*):ti,ab,kw (0)
9. (catheter* near/2 (injur* or wound*)):ti,ab,kw (106)
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 (934)
11. MeSH descriptor: [Child] explode all trees (212)
12. MeSH descriptor: [Infant] explode all trees (14,891)
13. MeSH descriptor: [Adolescent] this term only (89,013)
14. (child* or infant* or infancy or pediat* or paediat* or preschool* or pre next school* or schoolchild*
or school next age* or schoolage* or schoolboy* or schoolgirl*):ti,ab,kw (120,389)
15. (girl or girls or boy or boys or kid or kids):ti,ab,kw (6504)
16. (adoles* or young next people or young next person* or teen* or youth* or preteen* or juvenil*):ti,
ab,kw (113,415)
17. (neonat* or neo next nat*):ti,ab,kw (13,221)
18. (newborn* or new next born* or newly next born*):ti,ab,kw (20,677)
19. (preterm or preterms or pre next term or pre next terms):ti,ab,kw (7960)
20. (preemie* or premie or premies):ti,ab,kw (20)
21. (prematur* near/3 (birth* or born or deliver*)):ti,ab,kw (1473)
22. (low near/3 (birthweight* or birth next weight*)):ti,ab,kw (3916)
23. (lbw or vlbw or elbw):ti,ab,kw (1157)
24. (baby or babies):ti,ab,kw (4157)
25. {or 11-24} (201,937)
26. 10 and 25 (209)
27. 10 and 25 in Cochrane Reviews (Reviews and Protocols) (7)
28. 10 and 25 in Trials (200)
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
ti,ab,kw = terms in either title or abstract or keyword fields
near/2 = terms within two words of each other (any order)
next = terms are next to each other
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Cochrane Database of Systematic Reviews
Via Wiley Online Library; http://onlinelibrary.wiley.com/.
Issue 1 of 12, January 2017.
Searched on: 1 February 2017.
Records retrieved: 7.
See above under CENTRAL for search strategy used.
Cumulative Index to Nursing and Allied Health
Via EBSCOhost; www.ebscohost.com/.
Inception to 31 January 2017.
Searched on: 1 February 2017.
Records retrieved: 382.
Number Search term Hits
S1 (MH “Extravasation of Diagnostic and Therapeutic Materials”) 930
S2 TI extravasat* OR AB extravasat* 1224
S3 TI ( infiltrat* N2 (intravenous* or IV or infus* or catheter* or cannula*) ) OR AB ( infiltrat* N2
(intravenous* or IV or infus* or catheter* or cannula*) )
94
S4 TI ( infiltrat* N2 (injur* or wound*) ) OR AB ( infiltrat* N2 (injur* or wound*) ) 214
S5 TI ( (intravenous* or IV or infus*) N2 leak*) ) OR AB ( (intravenous* or IV or infus*) N2 leak*) ) 23
S6 TI ( infus* N2 (injur* or wound*) ) OR AB ( infus* N2 (injur* or wound*) ) 73
S7 TI ( PIV N2 (injur* or wound*) ) OR AB ( PIV N2 (injur* or wound*) ) 2
S8 TI PIV N2 infiltrat* OR AB PIV N2 infiltrat* 3
S9 TI ( catheter* N2 (injur* or wound*) ) OR AB ( catheter* N2 (injur* or wound*) ) 144
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 2265
S11 (MH “Infant+”) 185,131
S12 (MH “Child+”) 475,232
S13 (MH “Adolescence+”) 370,678
S14 TI ( (child* or infant* or infancy or pediat* or paediat* or preschool* or pre N1 school* or
schoolchild* or school N1 age* or schoolage* or schoolboy* or schoolgirl*) ) OR AB ( (child* or
infant* or infancy or pediat* or paediat* or preschool* or pre N1 school* or schoolchild* or school
N1 age* or schoolage* or schoolboy* or schoolgirl*) )
393,895
S15 TI ( girl or girls or boy or boys or kid or kids ) OR AB ( girl or girls or boy or boys or kid or kids ) 37,933
S16 TI ( adoles* or young N1 people or young N1 person* or teen* or youth* or preteen* or juvenil* ) OR AB
( adoles* or young N1 people or young N1 person* or teen* or youth* or preteen* or juvenil* )
122,298
S17 TI (neonat* or neo N1 nat*) OR AB (neonat* or neo N1 nat*) 38,395
S18 TI ( newborn* or new N1 born* or newly N1 born* ) OR AB ( newborn* or new N1 born* or newly N1 born* ) 18,282
S19 TI ( preterm or preterms or pre N1 term or pre N1 terms ) OR AB ( preterm or preterms or pre N1
term or pre N1 terms )
18,728
S20 TI ( preemie* or premie or premies ) OR AB ( preemie* or premie or premies ) 220
S21 TI ( prematur* N3 (birth* or born or deliver*) ) OR AB ( prematur* N3 (birth* or born or deliver*) ) 2597
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Number Search term Hits
S22 TI ( low N3 (birthweight* or birth N1 weight*) ) OR AB ( low N3 (birthweight* or birth N1 weight*) ) 7601
S23 TI ( lbw or vlbw or elbw ) OR AB ( lbw or vlbw or elbw ) 1922
S24 TI ( baby or babies ) OR AB ( baby or babies ) 19,968
S25 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 847,079
S26 S10 AND S25 382
Key heading
MH= indexing term (CINAHL Plus heading)
*= truncation
TI= terms in the title
AB= terms in the abstract
N2= terms within two words of each other (any order)
Database of Abstracts of Reviews of Effects
Via www.crd.york.ac.uk/CRDWeb/.
Inception to 31 March 2015.
Searched on: 1 February 2017.
Records retrieved: 9.
Search strategy
The strategy below was used to search DARE and the HTA database.
1. MeSH DESCRIPTOR Extravasation of Diagnostic and Therapeutic Materials IN DARE,HTA (5)
2. (extravasat*) IN DARE, HTA (12)
3. ((infiltrat* NEAR2 (intravenous* or IV or infus* or catheter* or cannula*))) IN DARE, HTA (3)
4. (((intravenous* or IV or infus* or catheter* or cannula*) NEAR2 infiltrat*)) IN DARE, HTA (0)
5. (((intravenous* or IV or infus*) NEAR2 leak*)) IN DARE, HTA (0)
6. ((leak* NEAR2 (intravenous* or IV or infus*))) IN DARE, HTA (1)
7. ((infiltrat* NEAR2 (injur* or wound*))) IN DARE, HTA (3)
8. (((injur* or wound*) NEAR2 infiltrat*)) IN DARE, HTA (13)
9. ((infus* NEAR2 (injur* or wound*))) IN DARE, HTA (5)
10. (((injur* or wound*) NEAR2 infus*)) IN DARE, HTA (5)
11. ((PIV NEAR2 (injur* or wound* or infiltrat*))) IN DARE, HTA (0)
12. (((injur* or wound* or infiltrat*) NEAR2 PIV)) IN DARE, HTA (0)
13. ((catheter* NEAR2 (injur* or wound*))) IN DARE, HTA (3)
14. (((injur* or wound*) NEAR2 catheter*)) IN DARE, HTA (12)
15. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 (47)
16. MeSH DESCRIPTOR child EXPLODE ALL TREES IN DARE,HTA (3236)
17. MeSH DESCRIPTOR infant EXPLODE ALL TREES IN DARE,HTA (1704)
18. MeSH DESCRIPTOR adolescent IN DARE,HTA (2377)
19. ((child* or infant* or infancy or pediat* or paediat* or preschool* or pre-school* or schoolchild* or
school-age* or schoolage* or schoolboy* or schoolgirl*)) IN DARE, HTA (8684)
20. ((girl or girls or boy or boys or kid or kids)) IN DARE, HTA (196)
21. ((adoles* or “young people” or “young person” or “young persons” or teen* or youth* or preteen*
or juvenil*)) IN DARE, HTA (3352)
22. (neonat* or neo-nat*) IN DARE, HTA (1345)
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23. ((newborn* or “new born” or “new borns” or “newly born”)) IN DARE, HTA (1324)
24. ((preterm or preterms or “pre term” or “pre terms”)) IN DARE, HTA (826)
25. ((preemie* or premie or premies)) IN DARE, HTA (0)
26. ((prematur* NEAR3 (birth* or born or deliver*))) IN DARE, HTA (182)
27. (((birth* or born or deliver*) NEAR3 prematur*)) IN DARE, HTA (31)
28. ((low NEAR3 (birthweight* or “birth weight” or “birth weights”))) IN DARE, HTA (317)
29. (lbw or vlbw or elbw) IN DARE, HTA (43)
30. (baby or babies) IN DARE, HTA (425)
31. 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29
OR 30 (10,207)
32. 15 AND 31 (10)
Key
MeSH DESCRIPTOR = indexing term (MeSH heading)
* = truncation
NEAR2 = terms within two words of each other (order specified)
” “ = phrase search
Excerpta Medica dataBASE
Via Ovid; http://ovidsp.ovid.com/.
1974 to 2017 January 31.
Searched on: 1 February 2017.
Records retrieved: 2413.
Search strategy
1. extravasation/ (12,184)
2. drug extravasation/ (717)
3. injection site extravasation/ (177)
4. contrast medium extravasation/ (3027)
5. extravasat$.ti,ab. (20,642)
6. (infiltrat$ adj2 (intravenous$ or IV or infus$ or catheter$ or cannula$)).ti,ab. (328)
7. (infiltrat$ adj2 (injur$ or wound$)).ti,ab. (1228)
8. ((intravenous$ or IV or infus$) adj2 leak$).ti,ab. (196)
9. (infus$ adj2 (injur$ or wound$)).ti,ab. (447)
10. (PIV adj2 (injur$ or wound$)).ti,ab. (3)
11. (PIV adj2 infiltrat$).ti,ab. (5)
12. (catheter$ adj2 (injur$ or wound$)).ti,ab. (951)
13. or/1-12 (27,430)
14. exp infant/ (1,003,813)
15. prematurity/ (97,200)
16. exp low birth weight/ (53,279)
17. exp child/ (2,555,921)
18. exp adolescent/ (1,418,617)
19. juvenile/ (62,534)
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20. (child$ or infant$ or infancy or pediat$ or paediat$ or preschool$ or pre school$ or schoolchild$ or
school age$ or schoolage$ or schoolboy$ or schoolgirl$).ti,ab. (1,915,425)
21. (girl or girls or boy or boys or kid or kids).ti,ab. (261,278)
22. (adoles$ or young people or young person$ or teen$ or youth$ or preteen$ or juvenil$).ti,
ab. (431,418)
23. (neonat$ or neo nat$).ti,ab. (287,782)
24. (newborn$ or new born$ or newly born$).ti,ab. (176,924)
25. (preterm or preterms or pre term or pre terms).ti,ab. (80,398)
26. (preemie$ or premie or premies).ti,ab. (200)
27. (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (17,938)
28. (low adj3 (birthweight$ or birth weight$)).ti,ab. (36,605)
29. (lbw or vlbw or elbw).ti,ab. (9134)
30. (baby or babies).ti,ab. (80,717)
31. or/14-30 (3,867,788)
32. 13 and 31 (2670)
33. (animal/ or nonhuman/) not exp human/ (5,056,272)
34. 32 not 33 (2413)
Key
/ = indexing term (Emtree heading)
exp = exploded indexing term (Emtree heading)
$ = truncation
ti,ab = terms in either title or abstract fields
adj2 = terms within two words of each other (any order)
Ovid Emcare
Via Ovid; http://ovidsp.ovid.com/.
1995 to 2016 week 49.
Searched on: 6 February 2017.
Records retrieved: 572.
Search strategy
1. extravasation/ (2254)
2. drug extravasation/ (151)
3. injection site extravasation/ (63)
4. contrast medium extravasation/ (927)
5. extravasat$.ti,ab. (2870)
6. (infiltrat$ adj2 (intravenous$ or IV or infus$ or catheter$ or cannula$)).ti,ab. (94)
7. (infiltrat$ adj2 (injur$ or wound$)).ti,ab. (290)
8. ((intravenous$ or IV or infus$) adj2 leak$).ti,ab. (42)
9. (infus$ adj2 (injur$ or wound$)).ti,ab. (102)
10. (PIV adj2 (injur$ or wound$)).ti,ab. (1)
11. (PIV adj2 infiltrat$).ti,ab. (2)
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12. (catheter$ adj2 (injur$ or wound$)).ti,ab. (171)
13. or/1-12 (4719)
14. exp infant/ (150,126)
15. prematurity/ (30,020)
16. exp low birth weight/ (17,249)
17. exp child/ (492,360)
18. exp adolescent/ (264,126)
19. juvenile/ (30,797)
20. (child$ or infant$ or infancy or pediat$ or paediat$ or preschool$ or pre school$ or schoolchild$ or
school age$ or schoolage$ or schoolboy$ or schoolgirl$).ti,ab. (484,484)
21. (girl or girls or boy or boys or kid or kids).ti,ab. (63,264)
22. (adoles$ or young people or young person$ or teen$ or youth$ or preteen$ or juvenil$).ti,ab.
(151,694)
23. (neonat$ or neo nat$).ti,ab. (56,554)
24. (newborn$ or new born$ or newly born$).ti,ab. (27,827)
25. (preterm or preterms or pre term or pre terms).ti,ab. (25,003)
26. (preemie$ or premie or premies).ti,ab. (66)
27. (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (3898)
28. (low adj3 (birthweight$ or birth weight$)).ti,ab. (10,789)
29. (lbw or vlbw or elbw).ti,ab. (3242)
30. (baby or babies).ti,ab. (19,426)
31. or/14-30 (790,276)
32. 13 and 31 (600)
33. (animal/ or nonhuman/) not exp human/ (292,084)
34. 32 not 33 (572)
Key
/ = indexing term (Emtree heading)
exp = exploded indexing term (Emtree heading)
$ = truncation
ti,ab = terms in either title or abstract fields
adj2 = terms within two words of each other (any order)
Health Technology Assessment database
Via www.crd.york.ac.uk/CRDWeb/.
Inception to 31 January 2017.
Searched on: 1 February 2017.
Records retrieved: 1.
See above under DARE for search strategy used.
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Maternity and Infant Care
Via Ovid; http://ovidsp.ovid.com/.
1971 to December 2016.
Searched on: 1 February 2017.
Records retrieved: 65.
Search strategy
1. extravasat$.ti,ab,de. (45)
2. (infiltrat$ adj2 (intravenous$ or IV or infus$ or catheter$ or cannula$)).ti,ab,de. (5)
3. (infiltrat$ adj2 (injur$ or wound$)).ti,ab,de. (10)
4. ((intravenous$ or IV or infus$) adj2 leak$).ti,ab,de. (3)
5. (infus$ adj2 (injur$ or wound$)).ti,ab,de. (4)
6. (PIV adj2 (injur$ or wound$)).ti,ab,de. (0)
7. (PIV adj2 infiltrat$).ti,ab,de. (0)
8. (catheter$ adj2 (injur$ or wound$)).ti,ab,de. (4)
9. or/1-8 (65)
Key
ti,ab,de = terms in either title or abstract or descriptor fields
$ = truncation
adj2 = terms within two words of each other (any order)
PubMed
Via www.ncbi.nlm.nih.gov/pubmed/.
Searched on: 1 February 2017.
Records retrieved: 327.
Search strategy
Search (((((((((((((((“Extravasation of Diagnostic and Therapeutic Materials”[Mesh:noexp])) OR extravasat*
[Title/Abstract]) OR ((infiltrat*[Title/Abstract]) AND (intravenous*[Title/Abstract] OR IV[Title/Abstract] OR
infus*[Title/Abstract] OR catheter*[Title/Abstract] OR cannula*[Title/Abstract]))) OR ((infiltrat*[Title/Abstract])
AND (injur*[Title/Abstract] OR wound*[Title/Abstract]))) OR (((intravenous*[Title/Abstract] OR IV[Title/Abstract]
OR infus*[Title/Abstract])) AND leak*[Title/Abstract])) OR ((infus*[Title/Abstract]) AND (injur*[Title/Abstract] OR
wound*[Title/Abstract]))) OR ((PIV[Title/Abstract]) AND (injur*[Title/Abstract] OR wound*[Title/Abstract]))) OR
((PIV[Title/Abstract]) AND infiltrat*[Title/Abstract])) OR ((catheter*[Title/Abstract]) AND (injur*[Title/Abstract]
OR wound*[Title/Abstract])))) AND ((((((((((((((“Child”[Mesh]) OR “Infant”[Mesh]) OR “Adolescent”[Mesh:noexp])
OR ((child*[Title/Abstract] OR infant*[Title/Abstract] OR infancy[Title/Abstract] OR pediat*[Title/Abstract] OR
paediat*[Title/Abstract] OR preschool*[Title/Abstract] OR pre-school*[Title/Abstract] OR schoolchild*[Title/
Abstract] OR school-age*[Title/Abstract] OR schoolage*[Title/Abstract] OR schoolboy*[Title/Abstract] OR
schoolgirl*[Title/Abstract]))) OR ((girl[Title/Abstract] OR girls[Title/Abstract] OR boy[Title/Abstract] OR boys[Title/
Abstract] OR kid[Title/Abstract] OR kids[Title/Abstract]))) OR ((adoles*[Title/Abstract] OR young people[Title/
Abstract] OR “young person”[Title/Abstract] OR “young persons”[Title/Abstract] OR teen*[Title/Abstract] OR
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youth*[Title/Abstract] OR preteen*[Title/Abstract] OR juvenil*[Title/Abstract]))) OR ((neonat*[Title/Abstract] OR
neo-nat*[Title/Abstract]))) OR ((newborn*[Title/Abstract] OR “new born”[Title/Abstract] OR “new borns”[Title/
Abstract] OR “newly born”[Title/Abstract]))) OR ((preterm[Title/Abstract] OR preterms[Title/Abstract] OR “pre
term”[Title/Abstract] OR “pre terms”[Title/Abstract]))) OR ((preemie*[Title/Abstract] OR premie[Title/Abstract] OR
premies[Title/Abstract]))) OR ((prematur*[Title/Abstract]) AND (birth*[Title/Abstract] OR born[Title/Abstract] OR
deliver*[Title/Abstract]))) OR ((low[Title/Abstract]) AND (birthweight*[Title/Abstract] OR “birth weight”[Title/
Abstract] OR “birth weights”[Title/Abstract]))) OR ((lbw[Title/Abstract] OR vlbw[Title/Abstract] OR elbw[Title/
Abstract]))) OR ((baby[Title/Abstract] OR babies[Title/Abstract]))))) NOT ((animals[mh] NOT humans[mh])))) AND
((pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]))
The above search strategy incorporates the following search line to limit to studies found in PubMed but
not available in Ovid MEDLINE: (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]).
Key
[Mesh] = exploded indexing term (MeSH heading)
[Mesh:noexp] = indexing term (MeSH heading) not exploded
* = truncation
” “ = phrase search
[Title/Abstract]) = terms in either title or abstract fields
Science Citation Index
Via Web of Science, Thomson Reuters
URL: http://thomsonreuters.com/thomson-reuters-web-of-science/.
1900 to 31 January 2017.
Searched on: 1 February 2017.
Records retrieved: 1018.
Search strategy
22 21 AND 9 (1018)
21 20 OR 19 OR 18 OR 17 OR 16 OR 15 OR 14 OR 13 OR 12 OR 11 OR 10 (1,920,782)
20 TS=(baby or babies) (43,069)
19 TS=(lbw or vlbw or elbw) (6578)
18 TS=(low NEAR/3 (birthweight* or “birth weight” or “birth weights”)) (33,946)
17 TS=(prematur* NEAR/3 (birth* or born or deliver*)) (10,333)
16 TS=(preemie* or premie or premies) (127)
15 TS=(preterm or preterms or “pre term” or “pre terms”) (71,557)
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14 TS=(newborn* or “new born” or “new borns” or “newly born”) (128,013)
13 TS=(neonat* or neo-nat*) (217,907)
12 TS=(adoles* or “young people” or “young person” or “young persons” or teen* or youth* or
preteen* or juvenil*) (384,736)
11 TS=(girl or girls or boy or boys or kid or kids) (142,187)
10 TS=(child* or infant* or infancy or pediat* or paediat* or preschool* or pre-school* or schoolchild*
or school-age* or schoolage* or schoolboy* or schoolgirl*) (1,407,704)
9 8 OR 7 OR 6 OR 5 OR 4 OR 3 OR 2 OR 1 (16,789)
8 TS=(catheter* NEAR/2 (injur* or wound*)) (969)
7 TS=(PIV NEAR/2 infiltrat*) (3)
6 TS=(PIV NEAR/2 (injur* or wound*)) (4)
5 TS=(infus* NEAR/2 (injur* or wound*)) (468)
4 TS=((intravenous* or IV or infus*) NEAR/2 leak*) (170)
3 TS=(infiltrat* NEAR/2 (injur* or wound*)) (1492)
2 TS=(infiltrat* NEAR/2 (intravenous* or IV or infus* or catheter* or cannula*)) (306)
1 TS=extravasat* (13,541)
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields
* = truncation
” “ = phrase search
NEAR/2 = terms within two words of each other (any order)
On-going, unpublished or grey literature search strategies
ClinicalTrials.gov
URL: https://clinicaltrials.gov/.
Searched on: 3 February 2017.
Records retrieved: 42.
1. 25 studies found for: extravasation | Child
2. 20 studies found for: infiltration AND (intravenous OR IV OR PIV OR infusion OR catheter OR cannula
OR injury OR wound OR leak) | Child
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3. 2 studies found for: (intravenous OR IV OR infusion) AND leak | Child
Conference Proceedings Citation Index: Science
Via Web of Science, Thomson Reuters.
http://thomsonreuters.com/thomson-reuters-web-of-science/.
1990 to 31st January 2017.
Searched on: 1 February 2017.
Records retrieved: 61.
Search strategy
22 21 AND 9 (61)
21 20 OR 19 OR 18 OR 17 OR 16 OR 15 OR 14 OR 13 OR 12 OR 11 OR 10 (191,435)
20 TS=(baby or babies) (3359)
19 TS=(lbw or vlbw or elbw) (649)
18 TS=(low NEAR/3 (birthweight* or “birth weight” or “birth weights”)) (2670)
17 TS=(prematur* NEAR/3 (birth* or born or deliver*)) (904)
16 TS=(preemie* or premie or premies) (9)
15 TS=(preterm or preterms or “pre term” or “pre terms”) (7407)
14 TS=(newborn* or “new born” or “new borns” or “newly born”) (8707)
13 TS=(neonat* or neo-nat*) (17,826)
12 TS=(adoles* or “young people” or “young person” or “young persons” or teen* or youth* or
preteen* or juvenil*) (34,295)
11 TS=(girl or girls or boy or boys or kid or kids) (8171)
10 TS=(child* or infant* or infancy or pediat* or paediat* or preschool* or pre-school* or schoolchild*
or school-age* or schoolage* or schoolboy* or schoolgirl*) (141,665)
9 8 OR 7 OR 6 OR 5 OR 4 OR 3 OR 2 OR 1 (1222)
8 TS=(catheter* NEAR/2 (injur* or wound*)) (104)
7 TS=(PIV NEAR/2 infiltrat*) (0)
6 TS=(PIV NEAR/2 (injur* or wound*)) (0)
5 TS=(infus* NEAR/2 (injur* or wound*)) (45)
4 TS=((intravenous* or IV or infus*) NEAR/2 leak*) (22)
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3 TS=(infiltrat* NEAR/2 (injur* or wound*)) (117)
2 TS=(infiltrat* NEAR/2 (intravenous* or IV or infus* or catheter* or cannula*)) (27)
1 TS=extravasat* (925)
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields
* = truncation
“ ” = phrase search
NEAR/2 = terms within two words of each other (any order)
EU Clinical Trials Register
www.clinicaltrialsregister.eu/ctr-search/search.
Searched on: 3 February 2017.
Records retrieved: 30.
1. 2 result(s) found for: extravasat* limited to adolescent, children, infant and toddler, newborn, preterm
new born infants, under 18
2. 22 result(s) found for: infiltration AND (intravenous* OR IV OR PIV OR infus* OR catheter* OR cannula*
OR injur* OR wound* OR leak*) limited to adolescent, children, infant and toddler, newborn, preterm
new born infants, under 18
3. 6 result(s) found for: (intravenous* OR IV OR infus*) AND leak* limited to adolescent, children, infant
and toddler, newborn, preterm new born infants, under 18
ProQuest Dissertations & Theses: UK & Ireland
Via ProQuest www.proquest.com/.
Inception to present.
Searched on: 1 February 2017.
Records retrieved: 4.
Search strategy
(TI,AB,SU(extravasat*) OR TI,AB,SU(infiltrat* NEAR/2 (intravenous* OR IV OR infus* OR catheter* OR cannula*)) OR
TI,AB,SU(infiltrat* NEAR/2 (injur* OR wound*)) OR TI,AB,SU((intravenous* OR IV OR infus*) NEAR/2 leak*) OR TI,
AB,SU(infus* NEAR/2 (injur* OR wound*)) OR TI,AB,SU(PIV NEAR/2 (injur* OR wound*)) OR TI,AB,SU(PIV NEAR/2
infiltrat*) OR TI,AB,SU(catheter* NEAR/2 (injur* OR wound*))) AND (TI,AB,SU(child* OR infant* OR infancy
OR pediat* OR paediat* OR preschool* OR pre-school* OR schoolchild* OR school-age* OR schoolage* OR
schoolboy* OR schoolgirl*) OR TI,AB,SU(girl OR girls OR boy OR boys OR kid OR kids) OR TI,AB,SU(adoles* OR
“young people” OR “young person” OR “young persons” OR teen* OR youth* OR preteen* OR juvenil*) OR TI,
AB,SU(neonat* OR neo-nat*) OR TI,AB,SU(newborn* OR “new born” OR “new borns” OR “newly born”) OR
TI,AB,SU(preterm OR preterms OR “pre term” OR “pre terms”) OR TI,AB,SU(preemie* OR premie OR premies) OR
TI,AB,SU(prematur* NEAR/3 (birth* OR born OR deliver*)) OR TI,AB,SU(low NEAR/3 (birthweight* OR “birth
weight” OR “birth weights”)) OR TI,AB,SU(lbw OR vlbw OR elbw) OR TI,AB,SU(baby OR babies))
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Key
TI,AB,SU = terms in the title or abstract or subject heading fields
NEAR/2 = terms within two words of each other (any order)
* = truncation
” “ = phrase search
PROSPERO
Via www.crd.york.ac.uk/PROSPERO/.
Searched on: 1 February 2017.
Records retrieved: 13.
Search strategy
1. MeSH DESCRIPTOR Extravasation of Diagnostic and Therapeutic Materials (1)
2. extravasat* (16)
3. infiltrat* ADJ2 (intravenous* OR IV OR infus* OR catheter* OR cannula*) (2)
4. infiltrat* ADJ2 (injur* OR wound*) (1)
5. (intravenous* OR IV OR infus*) ADJ2 leak* (1)
6. leak* ADJ2 (intravenous* OR IV OR infus*) (0)
7. (intravenous* OR IV OR infus* OR catheter* OR cannula*) ADJ2 infiltrat* (1)
8. (injur* OR wound*) ADJ2 infiltrat* (11)
9. infus* ADJ2 (injur* OR wound*) (2)
10. (injur* OR wound*) ADJ2 infus* (4)
11. PIV ADJ2 (injur* OR wound* OR infiltrat*) (0)
12. (injur* OR wound* OR infiltrat*) ADJ2 PIV (0)
13. catheter* ADJ2 (injur* OR wound*) (1)
14. (injur* OR wound*) ADJ2 catheter* (7)
15. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 (33)
16. MeSH DESCRIPTOR child EXPLODE ALL TREES (1522)
17. MeSH DESCRIPTOR infant EXPLODE ALL TREES (491)
18. MeSH DESCRIPTOR adolescent (609)
19. (child* OR infant* OR infancy OR pediat* OR paediat* OR preschool* OR pre-school* OR schoolchild*
OR school-age* OR schoolage* OR schoolboy* OR schoolgirl*) (6160)
20. girl OR girls OR boy OR boys OR kid OR kids (240)
21. adoles* OR “young people” OR “young person” OR “young persons” OR teen* OR youth* OR
preteen* OR juvenil* (2259)
22. neonat* OR neo-nat* (884)
23. newborn* OR “new born” OR “new borns” OR “newly born” (350)
24. preterm OR preterms OR pre-term or pre-terms (559)
25. preemie* OR premie OR premies (1)
26. prematur* ADJ3 (birth* OR born OR deliver*) (88)
27. (birth* OR born OR deliver*) ADJ3 prematur* (66)
28. low ADJ3 (birthweight* OR “birth weight” OR “birth weights”) (252)
29. (birthweight* OR “birth weight” OR “birth weights”) ADJ3 low (57)
30. lbw OR vlbw OR elbw (50)
31. baby OR babies (330)
32. 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30
OR 31 (7139)
33. 32 AND 15 (13)
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Key
MeSH DESCRIPTOR = indexing term (MeSH heading)
* = truncation
ADJ2 = terms within two words of each other (order specified)
“ ” = phrase search
World Health Organization’s International Clinical Trials Registry Platform
Via www.who.int/ictrp/search/en/.
Searched on: 1 February 2017.
Records retrieved: 62.
Search strategy
All searches below were limited to clinical trials in children.
1. 6 records for 6 trials found for: extravasat*
2. 11 records for 11 trials found for: infiltrat* AND intravenous*
3. 13 records for 13 trials found for: infiltrat* AND IV
4. No results were found for: infiltrat* AND PIV
5. 9 records for 5 trials found for: infiltrat* AND infus*
6. 2 records for 2 trials found for: infiltrat* AND catheter*
7. 1 trial found for: infiltrat* AND cannula*
8. 2 records for 2 trials found for: infiltrat* AND injur*
9. 13 records for 13 trials found for: infiltrat* AND wound*
10. 1 trial found for: infiltrat* AND leak*
11. 1 trial found for: intravenous AND leak*
12. 2 records for 2 trials found for: IV AND leak*
13. 1 trial found for: infus* AND leak*
Guideline searches
The following websites were searched on 3 February 2017.
National Institute for Health and Care Excellence
Via www.nice.org.uk/.
1. Searched the guidance and advice section of the website with terms extravasation or infiltration –
0 results.
2. Searched the website with the terms extravasation (6 results) or infiltration (27 results) – all results
browsed for relevance – no relevant guidelines found.
3. Browsed guidance by topics - infants and neonates, children and young people – no relevant
guidelines found.
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National Guidelines Clearinghouse
Via www.guideline.gov/.
1. extravasat* - 24 results found, browsed for relevance – no relevant guidelines found.
2. infiltrate* AND (intravenous* OR IV OR PIV OR infus* OR catheter* OR cannula* OR injur* OR wound*
OR leak*) – 5 results found, browsed for relevance – no relevant guidelines found.
3. (intravenous* OR IV OR infus*) AND leak* - 40 results found, browsed for relevance – 1 relevant
guideline found.
Trip
Via www.tripdatabase.com/.
1. extravasation OR extravastions OR extravasted OR extravasate OR extravasates, filtered to guidelines –
49 results.
2. (infiltration AND (intravenous* OR IV OR PIV OR infus* OR catheter* OR cannula* OR injur* OR
wound* OR leak*) AND (child* OR infant* or adolescen*)), filtered to guidelines – 139 results.
Results from the above searches were browsed for relevance – three relevant guidelines found.
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Appendix 2 Studies excluded as being about
other extravasations
Seventy studies (63 titles and abstracts and seven full papers) were excluded from the scoping reviewfor being about other types of extravasation. The references of these studies are listed below in
alphabetical order.
Adesanya O, Naqvi M. Term neonate with liver laceration, obstructive uropathy, and ascites-secondary to
extravasation of total parenteral nutrition: a complication of malpositioned umbilical venous catheter.
Glob Pediatr Health 2016;3:2333794X16670494. https://doi.org/10.1177/2333794X16670494
Akar S, Topcuoglu S, Dincer E, Sancak S, Karatekin G, Ovali F. A rare umbilical venous catheter
complication miscible with necrotizing enterocolitis: intraperitoneal extravasation of total parenteral
nutrition. Guncel Pediatri 2015;13:77–80.
Akkan K, Cindil E, Kilic K, Ilgit E, Onal B, Erbas G. Misplaced central venous catheter in the vertebral
artery: endovascular treatment of foreseen hemorrhage during catheter withdrawal. J Vasc Access
2014;15:418–23. https://doi.org/10.5301/jva.5000267
Alia R, Ali H. 2 years follow up of intra-abdominal extravasation of TPN causing liver necrosis in a
preterm infant. Arch Dis Child Fetal Neonatal Ed 2014;99(Suppl 1):A65–6.
Altunhan H, Annagur A, Ertugrul S, Yuksekkaya HA, Örs R. Coexistence of congenital chylous ascites
and congenital hypothyroidism: case report. Turkiye Klinikleri Journal of Medical Sciences
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Appendix 3 Case report study details
Further details of the included case reports are presented in Table 12.
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TABLE 12 Further details and results of case report studies
Authors Design Age Infusate Intervention Outcome
Abraham et al. 201258 Case report 9 years Arginine and 10% glucose Cool compresses and dressings Residual scar but no other
complications
Altan et al. 201359 Case report 23 days Contrast agent Elevation and cold compresses. Volar
fasciotomy for compartmental
syndrome
No functional complications
Altmann et al. 201460 Extractable: only
one case (rest mixed
with adult population)
2 years Unspecified antibiotic Radical debridement
Wound conditioning either by vacuum
assisted closure or temporary wound
coverage by allogeneic donor-tissue
grafts (unclear which)
Full-thickness skin graft
Full restoration of right hand function
Amano et al. 200861 Case report 3 years Arginine monohydrochloride
(10% in sodium chloride)
Conservative therapy with 1% silver
sulphadiazine
One month after the accident
the ulcer healed, leaving a slight
hypertrophic scar
Amaya 201662 Multiple case reports
(four patients)
4–32 weeks old
(three preterm)
NR ALH, debridement and dehydrated
amniotic membrane allograft
Needed skin graft but no untoward
effects seen (healed 21 to 41 days).
Amhaz et al. 201663 Case report 10 days Blood Lipoaspiration cannula to evacuate the
hematoma, elevation and compress
Healed over 2 weeks
Aribit et al. 200064 Multiple case reports
(two patients)
6 and 11 months Glucose 10% (n= 1),
NR (n = 1)
Lipoaspiration, followed by local care
until healed
Full recovery at 4 months other than
postepidermolysis dyschromia, no
other trophic or neurological adverse
event
Baker et al. 199165 Case report 7 years Arginine monohydrochloride
(10%)
Elevate, cold compress. Topical silver
sulphadiazine after twice daily
hydrodebridement. Surgical
debridement and skin graft
Nerve and tendons destroyed. Skin
graft necessary and was 98% viable
fully functional after 5 days. Full
function at 4 weeks
Bassi et al. 200766 Case report 10 months 6 cc arginine
monohydrochloride, 50%
diluted in 12 cc of sodium
chloride 0.9%
Managed conservatively. Enzymatic
debridement by collagenase ointment
(clostridiopeptidase A) together with
local antiseptics
Complete resolution within 2 months
with hypertrophic scar (see Figure 2).
There was no need for skin grafting
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Authors Design Age Infusate Intervention Outcome
Berger et al. 1974162 Multiple case reports
(three patients)
2 days to 1 month
(two preterm)
All calcium gluconate Soaks and mechanical debridement in
two. Antibiotics in two
Took between 3 weeks and 6 months
to heal depending on severity
Beytut et al. 2014163 Case report 7 years NR Oxygenotherapy, heat treatment and
dressings with dextrose
12 days to full recovery
Bhosale et al. 201267 Case report 16 years Dopamine 4 days of antibiotics, and
noradrenaline with dopamine.
Followed by skin debridement and
grafting
Needed skin graft
Borman et al. 199868 Case report 4 years Chloramphenicol and
ampicillin
Dermatofasciotomy, heparin infusion Day 20 gangrene and amputation of
hand
Boyar et al. 201469 Case report 3 weeks (preterm) NR MEDIHONEY® (Derma Sciences,
Plainsboro, NJ, USA) gel and dressing
Healed over 3 weeks with some
scarring
Broom et al. 201670 Multiple case reports
(two patients)
6 months to 1 year NR All underwent fasciotomy for
compartment syndrome
Both had excellent outcome
Chait et al. 197571 Case report 2 years Oncovin dauno rubicin Moist dressings and elevation Healed within 3 months with some
scarring
Chen et al. 201072 Case report 4 days (preterm) Calcium gluconate (10%) Elevation, cold packs. Oxacillin,
ampicillin and gentamicin, fasciotomy
( × 2) for compartment syndrome,
vancomycin and ceftazidime. Wet
dressings
Improved after 3 months
Chiang et al. 200473 Case report 11 days (preterm) Calcium gluconate (10%) Elevation, cold packs, oxacillin and
gentamicin, vancomycin (4 weeks)
Improved after 45 days
Ching et al. 201474 Case report 4 days Calcium gluconate Managed conservatively Improved after 20 weeks
Cho et al. 200775 Multiple case reports
(five patients)
17 to 50 days Parenteral nutrition
(6th case blood transfusion)
Antibacterial (antibiotic) ointment,
sesame oil, anti-inflammatory herbal
mixture, dressings (one debridement,
one escharectomy and oral antibiotic),
Vitamin C
1 month–2 years: no scar and no
functional abnormalities
Cohan et al. 199076 Case report 12 months Iopamidol Elevation and warm compresses 2 days to full recovery
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TABLE 12 Further details and results of case report studies (continued )
Authors Design Age Infusate Intervention Outcome
D’Acunto et al. 201577 Case report 2 months (preterm) Balanced electrolyte solution Elevation, proteolytic cream,
escharectomy as well as autograft skin
Total recovery after 1 year
Davé 199378 Case report 3 years Undefined fluids (no drugs) Wet gauze, hot packs, debridement
and skin graft
No long-term functional complications
Davies et al. 199479 Multiple case reports
(two patients)
26 and 11 days
(both preterm)
Parenteral nutrition Subcutaneous hyaluronidase and
saline flushing
Healed with minimal scarring/no sign
of injury
Denkler et al. 198980 Case report 1 day (preterm –
two sites: hand/
foot)
Dopamine 2% nitroglycerin ointment and
elevation
Full recovery same day
Domizio et al. 200681 Case report 2 days (two sites) Ampicillin (50 mg/kg/day) and
cefotaxime (100 mg/kg/day)
added with 10% calcium
gluconate
7 days later treated topically with an
antibiotic–corticosteroid cream
20 days later, only whitish
subcutaneous nodules from which tiny
white pieces of calcific masses were
eliminated spontaneously without
signs of inflammation
Dunn et al. 198482 Case report 5 months Dextrose and 25% normal
saline
Elevation 2 months later, no movement or
feeling in parts of hand. 9 months
after injury, improvement
Duray et al. 198683 Case report 5 years Doxorubicin Excision of surrounding skin Skin graft needed but healed
Eckersall et al. 199684 Case report 3 years Dextrose saline Elevation (24 hours) 3 days to full recovery
Eroglu et al. 200485 Case report 17 years Mannitol (20%) Fasciotomy for compartment
syndrome
Fully functional, with a scar
Garcia-Alverez et al.
199986
Case report 2 weeks
(administered over
first 3 days of life)
Calcium gluconate Managed conservatively Full recovery 10 weeks later
Gibboney et al. 198687 Multiple case reports
(two patients)
17 days and
4 weeks (both
preterm)
i.v. fluids Surgical debridement and antibiotics,
one received several skin grafts
5.5 to 9 months, healed
Govind et al. 201488 Case report 27 days (preterm) Parenteral nutrition (lipid
infusate)
Incision and drainage, flushing of
central line
18 months, healed naturally
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Grabois et al. 200889 Case report 19 days (preterm) Sodium bicarbonate Clean wound and covered with
Vaseline (Unilever, Surrey, UK;
sterile petrolatum) for 20 days
Recovered after 20 days
Handler 199090 Case report 4 years Dextrose solution (5%),
25% saline, and potassium
chloride
Elevated and warm dressing.
Fasciotomy for compartment
syndrome, skin graft
Needed skin graft
Hankin et al. 198491 Case report 17 years Doxorubicin Cold packs. Wet to dry dressings.
Conservative management.
Debridement after 7 months
Healed with contracture of arm
Harb et al. 201092 Case report 1 year (preterm) Erythromycin Area was irrigated with saline through
small punctures in the skin around
the injury site. Managed initially
conservatively, with regular dressing
changes and delayed surgical
intervention. At 3 weeks –
debridement and skin graft
1 week later – healing well
Hasija et al. 201493 Case report 3 years Phenytoin Fasciotomy for compartment
syndrome
After a few days, normal tissue texture
and the injury was managed
Hey et al. 200594 Case report 12 months Azithomycin Warm compresses, adaptic dressing,
splint, elevation, topical antibiotics
Small area of unusual pigmentation,
but otherwise healthy
Hironaja et al. 198295 Case report 6 days Calcium gluconate (10%) Warm soaks, debridement, soaks of
(2%) ethylenediaminetetraacetic acid
At 4 months, full recovery but does
not mention scarring, etc.
Hirsch et al. 201696 Case report 4 days (preterm) Parenteral nutrition Elevated, antibiotic ointment, slightly
compressive gauze, 13 days
debridement, collagenase, silicone
dressing, splint, silver nitrite, Apligraf®
(Organogenesis, Canton, MA, USA)
Day 16 wound closure, at 2 years,
wrist contracture
Hooke 200597 Case report Adolescent Doxorubicin Aspirated, cold packs DMSO solutions
topically, three debridements, skin graft
Large scar, but full use of area
Kameo et al. 201598 Case report 2 years Vincristine Hyaluronidase for 3 days, warm
compresses
Full recovery
Khan et al. 201499 Case report 29 days (preterm) Parenteral nutrition Hyaluronidase and bacitracin After 9 days, full recovery
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TABLE 12 Further details and results of case report studies (continued )
Authors Design Age Infusate Intervention Outcome
Kishi et al. 2014100 Case report 17 years Hydroxyzine Conservative therapy and 1% silver
sulphadiazine
After 2.5 months, slight scarring
Kuensting 2010101 Case report 6 days 10% dextrose and 0.25%
normal saline solution
administered at 10ml per
hour with the addition of
ampicillin (135 mg every
8 hours) and cefotaxime
(135 mg every 8 hours)
Elevation and warm packs,
hyaluronidase and general wound
care
Recovered within 24 hours,
discharged at 8 days
Kumar et al. 2001102 Multiple case reports
(six patients)
Neonate (preterm)
to 2 years
Flucloxacillin, calcium
gluconate, human
immunoglobulin, sodium
bicarbonate, dextrose
solution, 20% lipid nutrition
Dressings for three. Split skin graft
and debridement for three, elevation
and warm packs
Two excellent (one with scar),
one fair and three moderate scarring
(one contractures treated)
Lee et al. 2013103 Case report 1 month (preterm) Sodium bicarbonate Hyaluronidase, epithelial growth factor
dressings and platelet-rich plasma
dressings
4 days after PRP, completely healed
with no limitation of movement
Lehr et al. 2004104 Multiple case reports
(three patients)
4 to 24 days
(two preterm)
Parenteral nutrition (lipids)
plus antibiotics
Compression, elevation and
hydroactive gel
Healed no complications
Leung et al. 1980105 Case report 6.5 years Contrast medium (sodium
iothalamate 54%)
Repeated incisions, antibiotics,
excision of necrotic skin and skin
grafts
At 6 months, scarring, no limits on
movement
Llinares et al. 2005106 Case report 4 years Anthracycline (idarubicin) Topical DMSO and cooling, antiseptic
and moisturiser
Pain from application but recovered.
At 4 weeks, loss pigmentation and
focal induration
Martin et al. 1994107 Case report 4 months 8.4% bicarbonate 20 ml,
10% calcium gluconate
10 ml, 50% glucose 5 ml,
1 : 1000 adrenaline 3 ml
and 4.5% human albumin
solution 50ml
Hyaluronidase, liposuction and saline
wash-out
2 weeks later, no signs of soft tissue
damage
Meszes et al. 2017108 Multiple case reports
(six patients)
Neonates
(1 to 23 days)
Fatty acid, lipid and amino
acid infusion (n= 4), glucose
(n= 1) and dobutamine
(n= 1)
Epithelising ointment (n= 3),
hydrogels (n= 2), surgical necrectomy
(n= 1) and observation (n= 1)
Transfer to NICU (n= 4), home (n= 1),
surgery (n= 1)
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Authors Design Age Infusate Intervention Outcome
Mohr et al. 2014109 Multiple case reports
(two patients)
3 weeks (preterm),
19 days (preterm)
Antibiotics, NR Hyaluronidase, ALH hydrogel, ALH
calcium alginate, silver/collagen
dressings
No negative side effects
Morrison et al. 1999110 Multiple case reports
(four patients)
Neonates (preterm) Calcium gluconate Skin grafts 3 years later, visible scarring
Mukherjee et al.
1977111
Multiple case reports
(two patients)
5 years, and NR Dextrose solution; NR
(rehydration)
Skin grafts; debridement Gangrene, disfigured, and
incapacitated
Nissim et al. 2008112 Case report 1 day NR Conservative treatment Interval shrinkage and dissolution of
the mass
Onesti et al. 2012113 Case report 2 days (preterm) Parenteral nutrition Elevation, topical silver sulphadiazine,
some debridement, acellular dermal
substitute, autologous keratinocytes
9 months, scars and deformed foot
(surgical correction); 14 months, fully
healed
O’Reilly et al. 1988114 Case report Neonate Parenteral nutrition Glyceryl trinitrate patch Healed without scarring (small area
not covered, skin lost)
Ozcan et al. 2015115 Case report 14 years Adrenalin Elevation, local antibiotic ointment
and pentoxyphilline
Patient died due to septic shock
Pantelides et al. 2013116 Case report 1 day (preterm) Dextrose solution (12.5%) Elevation No scarring or functional deficit
Park et al. 2015117 Case report 7 months Parenteral nutrition Fasciotomy for compartment
syndrome. Irrigation with saline
solution. Debridement, after 4 months
skin graft
Needed rehabilitation for contracture,
healed with scar
Phillips et al. 2009118 Case report 3 months Dopamine Conservative treatment, topical
antibiotics, debridement, physical
therapy
Needed 12 months of physical
therapy. May need secondary surgery
Raffaella et al. 2009119 Case report (two
extravasations)
5 years Calcium gluconate Treated conservatively (limb elevation,
daily wound care, and warm
compresses), antibiotics, disinfection,
and physiotherapy, daily hyperbaric
oxygen therapy, weekly surgical
debridement and escharectomy,
sodium thiosulphate for calcification
8 months to fully healed
continued
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TABLE 12 Further details and results of case report studies (continued )
Authors Design Age Infusate Intervention Outcome
Ravenel 1983120 Case report 6 days Calcium gluconate Antibiotics, nafcillin sodium 6 weeks, swelling subsided
Reilly et al. 1977121 Multiple case reports
(three patients)
13, 15 and
17 years
Adriamycin Cold compress (n= 1), antibiotics
(n= 1) and hydrocortisone (n= 1)
Two lost functional use; less serious,
one healed
Reynolds 2007122 Case report 2 days (preterm) Intralipid and parenteral
nutrition
Elevation 12 hours to heal completely
Roberts 1977123 Multiple case reports
(five patients)
Neonates (range
1 day–1 year)
Calcium gluconate Conservative treatment (none or
warm soaks)
Resolved spontaneously
Rosales et al. 2004124 Case report 75 days (preterm) Parenteral nutrition and
intralipid
Antibiotics, drained Died of sepsis
Roth et al. 2006125 Case report 31 days Propofol and lidocaine Saline, debridement, skin graft Satisfactory functional healing
Rustogi et al. 2005126 Case report 4 days (preterm) Sodium bicarbonate ACTICOAT™ dressing 57 days to heal
Salameh et al. 2004127 Case report 3.5 years Arginine Compressive dressing, debridement,
skin grafts
Functional result
Samiee-Zafarghandy
et al. 2014128
Case report 1 day (preterm) Packed red blood cells Conservative management, topical
nitroglycerin
Loss of two toes
Sanpera et al. 1994129 Multiple case reports
(two patients)
3 days and
neonate (preterm)
Calcium solution and NR Eusol and debridements, dressings Limb shortening and deformity
Santoshi et al. 2008130 Case report Neonate (preterm)
(seen at 5 years)
Blood, fluids and antibiotics NR – claw deformity at 5 years –
fibrous sheet was excised, the
extensor tendons were tenolysed and
full correction was obtained
Some scarring but functional
Schäfer et al. 2005131 Case report 2 weeks Phenobarbital Topical antibiotics, debridement and
skin graft
Fully recovered
Schie et al. 2013132 Case report 33 weeks
(preterm)
NR Non-contact low-frequency ultrasound
(19 sessions), debridement,
amorphous hydrogel and covered with
a thin film or hydrocolloid, silicone
sheet
32 days, healed without complication
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Authors Design Age Infusate Intervention Outcome
Schumacher et al.
1987133
Case report 7 years Calcium disodium edetate
(EDTA)
Warm soaks and splints Calcification needed surgery
(1.75 years later)
Sharief et al. 1994134 Case report (two
extravasations)
1 day (and 3 days) Phenytoin NR 1 week, complete resolution
Shenaq et al. 1996135 Case report 10 years Adriamycin (doxorubicin) Left for 4 months, debridement,
physical therapy, dressings, skin graft,
capsulotomies
Not fully functional
Sindal et al. 2015136 Case report Neonate (preterm) NR Debridement and topical antibiotic
ointment
2 weeks, healed completely
Siu et al. 2007137 Case report 2 days (preterm) Parenteral nutrition (dextrose,
calcium, potassium, etc)
Hyaluronidase and saline flushes,
dressings
Healed within 5 days
Siwy et al. 1987138 Case report 2 days Dopamine Infusion of phentolamine (Regitine®,
Novartis Pharmaceuticals Corporation,
NJ, USA) in saline solution, kept at
heart level
Healed after 9 days
Sokol et al. 1998139 Case report 14 months
(preterm)
Phenytoin Hyaluronidase Barely visible scar
Sonohata et al. 2006141 Case report 14 years Phenytoin (diazepam before) Hydrocortisone injections, elevation,
warm packs
5 weeks to fully recovered
Sonohata et al. 2008140 Case report 3 days Calcium gluconate No treatment 5 months, fully recovered
Soon et al. 2001142 Case report 38 weeks Calcium gluconate Local skin care and topical antibiotic 3 months, recovered
Spenny et al. 2004144 Case report 3 years Ceftriaxone sodium Cold pack, diphenhydramine
hydrochloride and adrenaline,
clindamycin and morphine, fasciotomies
3 months, healed with complete
function
Stahl et al. 2000143 Case report 10 years Mannitol Fasciotomies 1 year, no neurological or vascular
damage
Subedi et al. 2011145 Case report 16 years Dextrose Analgesics and antibiotics followed by
local incision and drainage. Managed
conservatively for almost 5 months.
Oral medications (gabapentin,
amitriptyline, tramadol), a series
of stellate ganglion blocks with
bupivacaine, and limb physiotherapy
6 months, pain and swelling subsided
drastically with marked functional
recovery
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TABLE 12 Further details and results of case report studies (continued )
Authors Design Age Infusate Intervention Outcome
Subhani et al. 2001146 Case report 1 day Dopamine Phentolamine Within the next few hours, there
was complete resolution of the
discoloration
Talbot et al. 2011147 Multiple case reports
(three patients)
7 to 10 months Two NR, one hydration Fasciotomies for compartment
syndrome, vacuum-assisted closure
(n= 2) or moist dressings (n= 1)
Full functional recovery
Tilden et al. 1980148 Multiple case reports
(four patients)
15 days to
4 months
Nafcillin sodium Saline dressing and sulphadiazine
silver (n= 2), debridement and skin
graft (n= 1), bacitracin ointment
(n= 1)
Healing well (n= 3), bacitacin not
improved, died
Tiras et al. 2005149 Case report 2 days Calcium gluconate Debridement using collagenase
clostridipeptidase A and bacitracin
ointment mixture in gauze after
wetting the wound with sterile saline
Healed without surgery
Tobin 2007150 Case report 1 day (preterm) Parenteral nutrition Oral antibiotics, ActiFormCool®
(Activa Healthcare, Burton upon Trent,
UK) dressings
6 weeks, the wound had healed,
with scarring
Tuncer et al. 2006151 Case report 6 years Calcium solution Surgery for calcinosis (4 years later) Full recovery
Vanwijck and Lengele
1994152
Case Report 9 years Meglumine ioxitalamate Lipoaspiration with saline wash,
followed by liposuction, under LA
(n= 8) or GA (n = 1). Redon’s drain
kept under aspiration for 24 hours.
Perioperative and postoperative i.v.
antibiotics, NSAIDS, elevated arm
with light compress for 48 hours.
Lymphatic drainage for persistent
oedema at 1 week follow-up
Absent pulse in one child reappeared
immediately after liposuction.
Moderate reduction in extension (20 °)
of two fingers extension in one
patient. No other adverse events.
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Authors Design Age Infusate Intervention Outcome
von Muhlendahl
2012153
Multiple case reports
(six patients)
14 days (preterm)
to 14 months
Fluids or electrolyte solution
(n= 5; one plus
erythromycin), phenytoin
(n= 1)
Immediate/early stage: within
24 hours of extravasation injury,
complete removal of the aggravating
substance via pressure-relieving
incisions and flushing with Ringer’s
solution or removal by aspiration
(whichever is more appropriate); or
Later than 24 hours: debridement and
defect coverage (e.g., grafts)
Standard care (n= 6), skin grafts
(n= 2)
Scars (n= 3), loss of fingers due to
sepsis (n = 1), successful grafts (n= 2)
Wada et al. 2003154 Case report Neonate Calcium solution Conservative treatment, debridement,
skin graft
6 years, surgery for physeal arrest and
short leg; further surgeries up until
12 years; 16 years, deformity remained
Wiegand et al. 2010155 Case report 17 years Dextrose Elevation, cold compresses,
hyaluronidase
Full recovery
Wolfe et al. 1983156 Case report 2 days Calcium solution Antibiotics, immobilisation, and
dressings
6 months, full recovery
Wong et al. 1992157 Multiple case reports
(two patients)
4 and 15 days
(both preterm)
Dopamine Nitroglycerin ointment, phentolamine
(n= 1), elevation (n= 1)
24 hours, full recovery
Wong et al. 2015158 Case report 4 days Calcium gluconate Managed conservatively 20 weeks, healed
Yamamoto et al.
1994159
Multiple case reports
(two patients)
1 and 4 years Dopamine and tromethamine Debridement and skin grafts (n= 2),
scar surgery (n= 1)
Functional recovery
Yosowitz et al. 1975160 Multiple case reports
(seven patients)
2 days to 10 years
(two preterm)
Dextrose (10%) or calcium
solutions
Debridement (n = 7) and skin grafts
(n= 4)
Functional (n= 3), NR (n= 1), healed
(n = 2), leg amputated (n= 1)
Zenk et al. 1981161 Multiple case reports
(three patients)
3 days to
4 months
Nafcillin sodium Hyaluronidase (n= 2); warm
compresses and elevation, and
2 months skin graft (n= 1)
Healed (n= 3; two given
hyaluronidase healed within a day)
ALH, active Leptospermum honey; EDTA, ethylenediaminetetraacetic acid; GA, general anesthetic; LA, local anesthetic; NSAIDs, non-steroidal anti-inflammatory drugs; NR, not reported;
PRP, platelet-rich plasma.
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Appendix 4 Survey questionnaire content
The full questionnaire is detailed in Table 13.
TABLE 13 Questionnaire content
Question Answers and format
What is your position? (e.g. consultant paediatrician): Free text
What is the name and location of your unit? Free text
Which of the following best describes your clinical setting: Neonatal unit
Paediatric intensive care unit
Principal oncology/haematology unit
Shared care oncology/haematology unit
Other (please state)
Does your unit have a written protocol or guideline for treating extravasation
injuries?
If yes, ask:
Yes
No
Does the protocol or guideline contain a staging system for grading severity of
extravasation injury?
Yes
No
Does your unit have a list of treatments/interventions which may cause serious
problems when extravasated?
Yes
No
Please consider the list below of possible treatments for extravasation injuries.
How frequently is each of them used in your unit?
Elevation of affected area
Warm compress
Cold compress
Analgesia
Specific topical cream or ointment (please state)
Occlusive dressing
Saline irrigation without hyaluronidase
Saline irrigation with hyaluronidase
Antidotes to specific infusates
For each, choose one of:
Always
Usually
Sometimes
Rarely
Never
Do not know
Apart from plastic surgery, are there any other interventions you would use for
extravasation injuries which were not listed in the previous question?
Yes
No
continued
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TABLE 13 Questionnaire content (continued )
Question Answers and format
If yes please list the other intervention(s) and indicate frequency of use.
Please note that our study does not cover preventative interventions Free text along with one of:
Always
Usually
Sometimes
Rarely
Please select the type of access site most associated with extravastion injuries
in your unit’s patients:
Peripheral line (hands, feet)
Peripheral central line
Central line
Other (please state)
Do not know
Please select the type of infusate which causes the largest proportion of all the
extravastion injuries in your unit’s patients
More than one option may be selected if
the proportion of injuries is around the
same for two or more types of infusate:
Parenteral nutrition
Contrast agents
Calcium
Blood
Vesicant chemotherapies
Non-vesicant chemotherapies
Inotropes or pressors
Other (please state)
Do not know
What proportion of the extravasation injuries in your unit would you estimate
is caused by extravasation of infused (insert above response)
75–100%
50–74%
25–49%
11–24%
1–10%
Not sure, but > 50%
Not sure, but < 50%
Approximately what proportion of extravasations injuries that you have actively
treated have resulted in a need for plastic surgery at any stage?
More than 50%
25–50%
5–24%
< 5%
Do not know
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 13 Questionnaire content (continued )
Question Answers and format
In the last 10 years did any of the extravasation injuries which occured in your
unit result in litigation?
If yes, please state how many cases resulted in litigation:
Yes
No
1
2
3
4
5
≥ 6
Do not know
Regarding a future research study in this area, do you think a randomised trial
design can be successfully undertaken to compare different treatments for
extravasation injuries in babies and young children?
If yes:
Please tell us which treatment(s) you would most like to see studied in a
randomised trial (state one or two treatments):
If no:
It would be helpful if you could say why a randomised trial design might not
be viable. If you have any thoughts on alternative study designs, which you
think might be more appropriate, please also state them here.
Yes
No
Free text
Free text
Are you aware of any summary data on the effectiveness or safety of
treatments for extravasation injury which we are unlikely to have identified in
our searches of literature databases (e.g. unpublished data)?
If yes display: ‘We would be very grateful if you could e-mail details on the
summary data to mark.corbett@york.ac.uk within the next three weeks.’
Yes
No
If you have any comments or suggestions about our study which have not
been covered in this survey please add them here
Free text
Would you like to receive an e-mail notification when our final report is
published online (it will be open-access)?
Yes
No thanks
If yes display: ‘Please tell us the e-mail address you would like the link sending
to:’
Free text
End message: Thank you very much for completing the survey
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Appendix 5 Further questionnaire results
Graphs summarising responses to the question ‘What proportion of the extravasation injuries in yourunit would you estimate is caused by extravasation of infused calcium/blood/vesicant chemotherapies?’
(asked of those responders selecting calcium/blood or vesicant chemotherapies for the previous question)
are summarised in Figures 4–6.
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FIGURE 4 Percentage of neonatal unit extravasation injuries caused by calcium in units, indicating calcium as the
main cause of injuries.
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FIGURE 5 Percentage of neonatal unit extravasation injuries caused by blood in units, indicating blood as the main
cause of injuries.
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FIGURE 6 Percentage of principal oncology/haematology unit extravasation injuries caused by vesicant
chemotherapies in units, indicating vesicant chemotherapies as the main cause of injuries.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
